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Abstract	  
 
 
 
 
Protein quality control is a well-organized cellular process in which potentially toxic 
misfolded proteins are either refolded back to their native state, degraded or 
deposited into special deposition sites. Sequestration of misfolded protein species 
into specific deposition sites occurs in all kingdoms of life and serves as a second 
line of defense when refolding or degradation machineries that normally deal with 
these misfolded proteins are overwhelmed. In Saccharomyces cerevisae, three major 
subcellular sequestration sites have been described for deposition of different protein 
aggregates: INQ (intranuclear quality control compartment)/JUNQ (juxtanuclear 
quality control compartment), IPOD (insoluble protein deposit) and CytoQ. 
Amorphously aggregating proteins are targeted either to the INQ/JUNQ by the 
nuclear sorting factor Btn2, or they are targeted to a peripheral deposition site termed 
as Cyto Q with the aid of the cytosolic small heat shock protein Hsp42.   
Amyloidogenic aggregates including yeast prions are predominantly sequestered at 
the IPOD, a perivacuolar deposition site. The perivacuolar IPOD is located in close 
proximity to the PAS (Phagophore Assembly Site) where the cells initiate formation of 
autophagosomes and CVT (Cytoplasm-to-Vacuole Targeting) vesicles. The cellular 
machinery, however, by which amyloid aggregates are recognized and deposited at 
the IPOD is still unknown.  
Using a fishing approach with immobilized prion fibers formed by the prion domain of 
Sup35 (PrD), I identified components of actin cable-based and SNARE-mediated 
vesicular transport machinery to bind to PrD fibers. Using an auxin-based depletion 
system, I show that proper recruitment of the model prion amyloid PrD-GFP to the 
IPOD and the CVT substrate preApe1 to the PAS is disrupted upon depletion of 
essential components of the actin-based transport machinery, Myo2, Cmd1 and 
Tpm1/2, as well as Sec18-mediated SNARE function. Interestingly, the IPOD 
substrate PrD-GFP and the two PAS markers preApe1 and Atg8 accumulate 
reversibly in the cytosol in these mutants. Using fluorescence microscopy, I observed 
that PrD-GFP aggregates are associated with Atg9 transport vesicles similar to 
preApe1 and are targeted to the IPOD through these vesicles along actin cables. In 
addition, these PrD-GFP aggregates are shown to interact with Myo2 in vivo upon 
disruption of Sec18 SNARE function. 
 
	  
	  
ii	  
In a next approach, I investigated the possible fate of PrD-GFP aggregates deposited 
at the IPOD, that is located adjacent to the site in the cell where 
autophagosomes/CVT vesicles are formed. I demonstrate that PrD-GFP aggregates 
are not turned over in bulk via autophagy, but can be degraded by proteasomal and 
other unknown cellular degradation pathway(s) only after their slow and progressive 
extraction by the disaggregase Hsp104 from the IPOD. Thus accumulation of PrD-
GFP amyloids at the IPOD might serve a temporary storage function when 
downstream cellular degradation systems are overwhelmed. Based on the above 
findings, a model was proposed where PrD-GFP and preApe1 use an Atg9-vesicular 
transport machinery and Myo2 as a linking factor to be deposited at their recruitment 
sites IPOD and PAS, respectively, along tropomyosin-coated actin cables. 
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Proteinqualitätskontrolle ist ein gut organisierter zellulärer Prozess, bei dem potentiell 
toxische, fehlgefaltete Proteine entweder rückgefaltet oder abgebaut werden oder zu 
speziellen Ablagerungsstellen transportiert werden. Die Ablagerung falsch gefalteter 
Proteine an spezifische intrazelluläre Ablagerungsstellen kommt in allen Lebewesen 
vor und dient als alternativer Mechanismus, falls Rückfaltungs- und Abbauprozesse 
ausgelastet sind. In Saccharomyces cerevisiae wurden bislang drei unterschiedliche 
subzelluläre Strukturen identifiziert, an denen verschiedene Proteinaggregate 
abgelagert werden: INQ (intranuclear quality control compartment)/JUNQ 
(juxtanuclear quality control compartment), IPOD (insoluble protein deposit) und 
CytoQ. Fehlgefaltete Proteine werden entweder mittels dem nuclear sorting factor 
Btn2 an das INQ/JUNQ Kompartiment transportiert oder mit Hilfe des zytosolischen 
kleinen Hitzeschockproteins Hsp42 an das peripher lokalisierte CytoQ geleitet. 
Amyloidartige Aggregate einschließlich Prionen werden in der Hefe hauptsächlich 
zum IPOD transportiert, welches perivakuolär lokalisiert ist. Bislang ist unklar, wie 
genau die Amyloid-Aggregate erkannt und dann an das IPOD gebracht werden. Das 
IPOD liegt in unmittelbarer Nähe des PAS (Phagophore Assembly Site), wo die Zelle 
die Bildung von Autophagosomen und CVT (Cytoplasm-to-Vacuole Targeting) 
Vesikeln initiiert.  
Mit Hilfe eines sogenannten „Fishing Approaches“ durch immobilisierte Sup35-PrD 
Fibrillen konnte ich Komponenten der Aktin- und SNARE-vermittelten vesikulären 
Transportmaschinerie identifizieren, welche das IPOD ansteuern. Ein Auxin-basiertes 
Depletionssystem wurde benutzt um zu zeigen, dass die Rekrutierung des Modell-
Prions PrD-GFP an das IPOD und des CVT-Substrats preAPE-1 an das PAS durch 
den Verlust essentieller Komponenten des Aktin-basierenden Transports gestört ist. 
Zu diesen Komponenten zählen Myo2, Cmd1 und Tpm1/2 sowie Sec18, welches 
SNARE-Funktionen reguliert. Interessanterweise akkumulierten die IPOD-Substrate 
PrD-GFP und die PAS-Marker pre-Ape1 und Atg8 reversibel im Zytosol dieser 
Mutanten. Mittels Fluoreszenzmikroskopie konnte ich nachweisen, dass die PrD-GFP 
Aggregate ähnlich wie preApe1 mit Atg9 Transportvesikeln assoziiert sind und so 
entlang von Aktinkabeln zum IPOD gebracht werden. Darüber hinaus interagierten 
diese PrD-GFP Aggregate bei Verlust der SNARE-Funktion durch Depletion von 
Sec18 mit Myo2 in vivo. 
	  
Zusammenfassung	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Im nächsten Schritt untersuchte ich das weitere Schicksal der PrD-GFP Aggregate, 
die am IPOD abgelgert wurden. Das IPOD liegt in unmittelbarer Nachbarschaft zur 
Phagophore-Assemby Site (PAS). Ich konnte zeigen, dass PrD-GFP Aggregate nicht 
als Ganzes durch Autophagie abgebaut werden, sondern dass diese erst nach 
langsamer und progressiver Extraktion durch Hsp104 vom IPOD durch das 
Proteasom und andere unbekannte Abbausysteme degradiert werden. Demnach 
könnte die Akkumulierung von PrD-GFP Amyloiden am IPOD eine befristete 
Lagerfunktion haben, wenn zelluläre Abbausystem überlastet sind. Basierend auf 
den oben genannten Ergebnissen wurde ein Model vorgeschlagen, in dem PrD-GFP 
und preApe1 die Machinerie der Atg9-Transportvesikel und Myo2 als Bindungsfaktor 
nutzen, um entlang von Tropomyosin-gebundenen Aktinkabeln an das IPOD bzw. 
PAS zu gelangen. 
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Introduction	  
 
 
	  
 
Proteins perform the vast majority of cellular processes in all kingdoms of life such as 
enzymatic activity, regulatory function, transport of biomolecules, and structural 
component of subcellular organelles. For proper function of proteins, they have to 
fold into the correct three-dimensional structure and may additionally require other 
co-factors for proper folding. Inside the crowded cellular environment, protein folding 
to the native state is not an easy task to accomplish. Only one out of the many 
possible conformations that each protein can adopt, is the functional 3-D native fold 
[1]. In addition to the crowded cellular environment, endogenous errors (mutations, 
translational errors) or environmental stress (heat/metabolic/oxidative stress) can 
cause protein misfolding during and after synthesis. To cope with these challenges, 
cells evolved a complex protein quality control machinery to ensure either proper de 
novo folding, refolding of misfolded proteins to the native state or their degradation by 
different cellular proteolysis systems to prevent the accumulation of misfolded 
proteins.   
Increased protein misfolding and failure of removal of these potentially toxic protein 
species leads to coalescence of excess misfolded species into aggregates and is 
associated with several pathological conditions. Furthermore, a decline/failure in the 
capacity of the protein quality control machinery is associated with aging. Thus 
understanding the underlying molecular and cellular mechanism of protein 
homeostasis or proteostasis is of great interest for basic and applied research [2]. 
 
In general, mechanisms and principles that govern protein aggregation have gained 
attention at the foreground of research. Several age-related neurodegenerative 
diseases, including Alzheimer's disease (AD), Parkinson's disease (PD) and 
polyglutamine expansion diseases are associated with the accumulation of misfolded 
proteins into aggregates in the brain. However, mounting evidence suggests that 
protein aggregation is not only the result of a failure of the protein quality control 
network, but it is also a well-controlled, non-random process serving as another line 
of defense to deal with protein folding stress and to protect the cellular environment 
from potentially toxic misfolded species. 
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1.1.   Protein aggregation 
 
 
1.1.1.  Protein misfolding and aggregation 
During in vivo protein folding of a polypeptide chain, there is a kinetic competition 
between aggregation and the productive folding process due to non-native 
interactions. Several local energy minima exist within the funnel-shaped energy 
landscape of a folding polypeptide chain. Therefore, no specific folding route is pre-
determined, but many different routes are possible [3]. Along these protein folding 
routes, polypeptide chains are often at continuous risk to be trapped in nonnative, 
aggregation-prone conformers which subsequently assemble into protein 
aggregates. Even if the protein has reached its native state, it is still at continuous 
risk of misfolding due to several stresses. Partially unfolded or misfolded polypeptide 
chains are more prone to aggregation due to non-polar interactions of exposed 
hydrophobic residues that would normally be buried in the interior of the native 
protein [4]. 
During the aggregation process, “sticky” hydrophobic patches of the polypeptide 
chains, which are usually buried inside the core of the protein, undergo a 
hydrophobic collapse into unstructured/ disordered amorphous aggregates [5]. In 
addition to that, a small subset of proteins termed amyloidogenic proteins can 
undergo conformational changes to form stable, insoluble and highly ordered β-
sheet-rich amyloid aggregates [6] (Fig 1).  The protein quality control network has 
evolved such that under normal growth conditions, protein aggregation is prevented 
or rapidly reversed in the cytoplasm. Within the protein quality control network, 
molecular chaperones work in both co- and post-translational quality control systems 
to reverse erroneous conformations as well as to resolubilize protein aggregates to 
allow folding of single polypeptide chains back to the native state [7]. Instead of 
recognizing a specific amino-acid sequence, molecular chaperones bind to exposed 
hydrophobic stretches of client unfolded/misfolded proteins and can handle a large 
number of different protein substrates [8]. In case disordered aggregates and 
misfolded intermediates are unable to refold into their native conformation, 
chaperone activity guides them for degradation by ubiquitin-proteasome system 
(UPS) and autophagy to keep the cytoplasm free from potentially toxic 
misfolded/aggregated species [2]. Many components of the protein quality control 
network are under control of stress response pathways, and their expression is 
upregulated during several proteotoxic stresses. The basic principles of the protein 
quality control network are well conserved throughout evolution. However, the 
complexity of this network increases with the complexity of multicellular organisms 
and organismal stress signaling [9]. In eukaryotic cells, each cellular compartment, 
for example the cytosol, the endoplasmic reticulum and mitochondria have a unique 
protein-folding environment to cope with different stresses. Therefore specific stress 
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response pathways are linked with these subcellular compartments. The main 
objective of this thesis is to investigate the recruitment machinery for amyloid 
aggregates to a specific deposition site termed “Insoluble Protein Deposition (IPOD)” 
(see section 1.4.3) localized in a perivacuolar site in the cytoplasm. Therefore, the 
focus of this thesis is on cytosolic processes. 
 
 
 
FIGURE 1: Protein misfolding and aggregation – Nascent polypeptide chains, after being translated 
on ribosomes, have to adopt their functional 3-D native state to exert their specific cellular functions. 
This complex folding process is threatened by multiple stresses such as mutations, translational errors 
or environmental stress conditions that lead to the formation of misfolded protein species. These 
misfolded proteins are either refolded back to their native states with the action of chaperones, are 
directly degraded by the ubiquitin-proteasome system (UPS) or accumulate into amorphous aggregate 
structures. A subset of amyloidogenic proteins undergoes conformational changes under physiological 
conditions and forms stable and insoluble amyloid fibers. Amorphous aggregates are refolded 
efficiently by disaggregation machinery. In eukaryotes, aggregates can be degraded directly through 
autophagic pathways. Arrows indicate a process of major significance; dashed arrows indicate a 
process where the physiological significance is unclear.    
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1.1.2.  Conditions causing protein misfolding and aggregation 
Protein aggregation is driven by hydrophobic interactions, by which exposed 
hydrophobic portions of one polypeptide chain interact non-covalently with the 
exposed hydrophobic regions of other polypeptides that are normally buried inside 
the protein core in the native state [10]. Partially folded intermediates during the 
folding process are often prone to form amorphous aggregates [11, 12]. Different 
internal and external/environmental factors influence protein folding and can cause 
aggregation by either destabilizing the native fold or preventing the proper folding. 
Usually, the protein quality control system effectively handles these erroneous, 
misfolded or unfolded species by supporting either their proper refolding or 
degradation. However, the capacity of this system is restricted, and formation of 
aggregates is a result of the overwhelmed protein quality control network. 
Remarkably, not only very harsh condition can cause protein aggregation, but also a 
combination of multiple harmless conditions which act at once, can cause 
aggregation [13].  
 
Genetic factors 
Genetic mutations can cause an altered amino acid sequence, thereby changing the 
biophysical properties of a protein and consequently influencing its intrinsic 
aggregation propensity. For instance, trinucleotide repeat expansions such as 
repetitive [CAG]n result in polyglutamine (polyQ) stretches that cause aggregation of 
the protein carrying it [14, 15]. These variations for example in the huntingtin gene 
are associated with neurodegenerative disease such as Huntington’s disease. The 
length of the CAG repeat (polyQ-stretch) correlates with the aggregation propensity 
of the translated poly(Gln) chain [16] and age of disease onset [17].  
Small point mutations at critical positions/domains also can cause protein 
aggregation by altering the protein conformation. It was for example shown that a 
mutant of superoxide dismutase 1 (SOD1) is associated with familial amyotrophic 
lateral sclerosis (FALS) and forms protein inclusions [18]. These mutations not only 
affect the stability and aggregation propensity of native proteins but also affect 
assembly of oligomers into large complexes by promoting hydrophobic interactions. 
In addition, point mutations in components of the protein quality-control system can 
also initiate protein aggregation. For example, a point mutation in a gene encoding 
the small HSP (sHSP) α-crystallin causes congenital cataract [19] and mutation in the 
PARKIN/PARK2 gene that encodes E3 ubiquitin ligase Parkin results in young-onset 
Parkinson's disease (YOPD) [20].  
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Translational errors 
Alterations in the polypeptide sequence are not only caused by genetic mutations but 
can also result from the error-prone translation of mRNAs at the ribosome, amino 
acid misincorporation, frameshift mutation or stop codon readthrough [21]. 
Translation errors are also caused by misassembly of ribosomal subunits, tRNA 
synthesis errors and mRNA sequence modifications. Nascent polypeptide chains are 
particularly prone to misfolding and aggregation in a crowded cellular environment 
[22]. Therefore, they are prevented from aggregation by the action of ribosome-
associated chaperones which specially promote the native conformation and avoid 
non-native interactions even in non-stressed situations [22].  
In addition, in eukaryotes, truncated mRNAs cause ribosome stalling in which the 
stalled/aberrant nascent chain is ubiquitinated by the E3 ubiquitin ligase, Listerin/Ltn1 
and co-translationally degraded by proteasomes. These processes are termed 
ribosome quality control (RQC). In line with this, it was shown that mutations in the 
E3 ligase Listerin cause protein aggregation and neurodegeneration in mice [23]. In 
the cell, translation errors are avoided by several ways. Firstly, monitoring ribosome 
biosynthesis and assembly faithfully, proof reading of tRNA amino acetylation for 
correct amino acid incorporation into the growing polypeptide chain and degradation 
of defective mRNAs to prevent aberrant protein synthesis [24]. Secondly, a 
sophisticated ribosome-associated chaperone network facilitates correct folding of 
nascent polypeptides upon emerging from the ribosomal exit tunnel [25, 26]. In 
human cells, 12-15% of nascent polypeptides are ubiquitinated co-translationally for 
their degradation to prevent the formation of defective ribosomal products [27]. In 
yeast, 2%–5% of nascent polypeptides are co-translationally ubiquitinated for 
degradation [28].  
	  
Environmental stresses 
Besides genetic mutations and translational errors, various environmental stress 
conditions such as heat and oxidative stress can cause proteins to lose their native 
structures and promote the formation of protein aggregates by influencing directly the 
protein folding landscape. An increase in ambient temperature than normal growth 
temperature leads to massive unfolding of cellular proteins and can overwhelm the 
capacity of the cellular protein quality control system. This leads to protein 
aggregation. Yet, this heat-induced unfolding/ aggregation is a reversible process 
[29]. Oxidative stress can generate reactive oxygen species (ROS), which can modify 
proteins irreversibly through either direct fragmentation of the polypeptide chain or 
irreversible modification of specific amino acids. These irreversible chemical 
modifications can cause proteins to misfold and aggregate. Since oxidative 
modifications often alter the primary amino acid sequence, those proteins can usually 
not fold back to the native state, but have to be removed from the system [30-32].  
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Ageing 
During ageing, the cellular protein quality control (proteostasis) capacity is declined. 
This increases accumulation of misfolded/damaged proteins and protein aggregation 
in different organisms. For example, a misfolding-prone mutant of human superoxide 
dismutase 1 (SOD1) in mice and an extension of polyQ protein in C. elegans 
accumulates in aggregates only during ageing [33, 34]. Oxidatively damaged and 
carbonylated proteins also accumulate in aged yeast cells [35]. In human, ageing 
cells can accumulate misfolded species that lead to several age- associated 
neurodegenerative disease such as Parkinson’s , Alzheimer’s, and Huntingtin’s 
Disease or Type II Diabetes [36, 37].  	  
1.1.3.  Structural features of protein aggregates 
Protein aggregates are insoluble in aqueous solutions, and some are even detergent-
insoluble. These aggregates are made up of non-native proteins and are found in the 
intracellular or in the extracellular space [12]. These aggregates are classified 
structurally into two categories as: (I) disordered aggregates (amorphous aggregates, 
folding aggregates and inclusion bodies) and (II) highly ordered cross- β-sheet-rich 
fibrils (amyloids) [12].  
Amorphous aggregates are generally formed under stress conditions. 
Overexpression of recombinant proteins in bacteria can also cause the formation of 
amorphous aggregates such as inclusion bodies in E. coli [12]. However, compelling 
evidence shows that bacterial inclusion bodies can also contain highly ordered 
amyloid aggregates during recombinant proteins expression [38, 39]. For example, it 
was shown that Aβ42-GFP aggregates inside the prokaryotic inclusion bodies show 
amyloid-like properties [38]. 
Deposition of amyloid aggregates is a pathological hallmark of many 
neurodegenerative diseases [40]. Amyloids are protease resistant, often SDS-
insoluble and form even in the absence of stress. PolyQ amyloid aggregates, formed 
by polyglutamine (polyQ) stretches, were shown to cause cellular toxicity, yet the 
source of toxicity is under debate [41]. “Prions” are self-propagating proteinaceous 
infectious particles that cause several prion-based neurodegenerative diseases in 
mammals. These prions also show characteristics of amyloid aggregates i.e. cross-β 
fibrillar structures [42]. Mammalian prions are infectious (amyloidogenic) proteins that 
spread a disease/trait via horizontal transmission without any nucleic acid. 
Mammalian prion proteins are denoted as Prion Protein (PrP) that exist in two 
conformations: (I) PrPC, the normal cellular and non-toxic form and (II) PrPSc, the 
pathogenic form which is a conformationally altered isoform of the PrPc. The PrPSc 
form was initially found in sheep suffering from Scrapie [43]. PrPSc generates cross-β 
fibrillar structures (amyloids) that accumulate in the brains of humans and animals. 
Prion fiber assembly is a two-step process: (I) A soluble prion protein (PrP) 
undergoes conformational conversion and forms small oligomers (transient 
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intermediates) that act as seed/nucleus (II) The seed polymerizes conformational 
conversion of other soluble protein of the same type into mature amyloid fibers [44]. 
The most common prion diseases in humans and animals are: Transmissible 
Spongiform Encephalopathy (TSE) or Scrapie, Bovine Spongiform Encephalopathy 
(BSE), Kuru and Creutzfeld-Jakob-Disease [45]. Prions are also present in yeast, 
where they act as protein-based epigenetic elements and are inherited via the 
cytoplasm in a non-Mendelian fashion [46] (see section 1.2). Yeast prions are 
involved in epigenetic, transcriptional and translational regulatory processes and can 
be beneficial [47]. For example, it was shown that prion formation is induced in 
variable environmental stress conditions and, depending on the yeast strain 
background, sometimes had a beneficial effect on cell viability under these conditions 
[48, 49].  
	  
1.2.  Yeast Prions 
Yeast prions are self-propagating amyloid-like conformations. Yeast has different 
proteins that can adopt a prion conformation. The first discovered yeast prions were 
[PSI+] and [URE3], that are prion forms of Sup35 and Ure2 proteins, respectively [50, 
51]. These prions can be formed spontaneously at low rates. During prion 
conversion, Ure2 or Sup35 proteins undergo conformational changes, becoming 
protease resistant and insoluble and form amyloid fibers [52]. Prion-states often lose 
the normal cellular functions of the protein that is responsible for the prion. However, 
the [RNQ+]/[PIN+] prion, caused by the Rnq1 protein can have a gain-of-function 
phenotype, which is to enhance the de novo formation of [PSI+] prions via a prion 
cross-seeding mechanism [51-54]. Generally, yeast prions are not toxic to yeast cells 
[55, 56]. The biological significance of yeast prions is still under debate, but it was 
suggested that they can act as protein-based genetic elements (i.e. non-
chromosomal) that are inherited to the progeny without following Mendel's laws of 
inheritance [57, 58]. The prion state is associated with several phenotypic changes 
that can be beneficial under certain environmental conditions [48, 49]. In line with 
this, it was shown that stress can induce prion formation [49]. It was hypothesized 
that this stress-induced prion formation creates a larger variety of phenotypes, some 
of which might help to cope better with the stress conditions such as high salt 
concentrations, oxidative stress (H2O2), and high temperature [49].  
 
1.2.1.  Formation of Yeast Prions 
 
Yeast prions often contain a glutamine (Q) and asparagine (N) rich prion domain that 
is responsible for the prion-like properties of the respective protein due to its self-
propagating propensity [59, 60]. These Q/N-rich domains are present either at the N-
terminus (in Sup35 and Ure2) or at the C-terminus (in Rnq1) of the proteins [60]. 
Transient overexpression of a full-length prion protein or its prion domain can induce 
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the de novo formation of yeast prions [61]. These prion proteins can form amyloids 
either spontaneously on their own, or their initial appearance can be promoted by the 
presence of other prions. For example, the [RNQ+] prion acts as a template for cross-
seeding and enhances the de novo formation of the [PSI+] prion. Hence [RNQ+] is 
also termed as [PIN+] ([PSI+]-inducible) [62, 63].  
The protein-remodeling factor Hsp104 (AAA+ ATPase chaperone) is involved in the 
faithful propagation of most known yeast prions including the [PSI+] prion [64]. 
Hsp104 works in combination with Hsp70 and Hsp40 for remolding of misfolded 
proteins as well as for maintaining prions. Elimination of Hsp104 function, either by 
deletion of the HSP104 gene or by inhibition of its ATPase activity by GdnHCl 
(termed curing) induces a slow loss of [PSI+] over several generations, and the cells 
become [psi-] [61, 65, 66]. This process is reversible. Fragmentation of prion fibrils by 
Hsp104 threading activity results in the generation of smaller units (termed 
propagons) that are inherited to the progeny [67, 68]. These propagons also act as 
seeds to form long prion fibrils. Therefore, loss of Hsp104 function abolishes prion 
fiber fragmentation and hence, no smaller units are generated that can be passed to 
the progeny. This causes a loss of the prion state in the progeny over multiple 
generations due to failure in the formation of new propagon/seed [68].  
 
1.2.2.  The yeast [PSI+] prion 
The [PSI+] prion is the best-characterized yeast prion. It is the amyloid isoform of the 
translation termination factor Sup35p [69]. The non-prion form is indicated as [psi-] 
where the Sup35p protein remains in the soluble, functional conformation. Formation 
of the prion isoform is associated with a phenotypic switch. In case of the [PSI+] 
prion, the phenotypic switch is caused by a reduction of the translation termination 
function of Sup35p, because the aggregated/prion form of Sup35 is unable to 
terminate the translation properly. The result is translational readthrough of some 
STOP codons in the [PSI+] form.   
This feature facilitates to differentiate these two isoforms of Sup35 based on the 
red/white colony assay. Both isogenic strains carry a premature stop codon (UGA) in 
the ADE1 gene (ade1-14) [70, 71]. In [psi-] cells, translation of the ade1-14 allele is 
terminated prematurely due to the translation termination activity of soluble Sup35p. 
The truncated Ade1 protein is not functional in the adenine biosynthesis pathway. 
Consequently, the cells are auxotroph for adenine and accumulate a red adenine 
synthesis byproduct (Fig 2). The colonies of these [psi-] cells appear red on YPD [70, 
71]. On the contrary, in [PSI+] cells a large portion of the Sup35p protein forms 
insoluble amyloid fibrils and cannot perform its normal translation termination 
function. Consequently, functional full-length Ade1 protein is synthesized by stop-
codon readthrough, the [PSI+] cells are prototroph for adenine and accumulate much 
less of the red synthesis byproduct and hence appear white to light pink on YPD 
plates  [70, 71]. 
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FIGURE 2: The [PSI+] prion and [psi-] non-prion states in S. cerevisae – Both isogenic strains 
harbor a premature UGA stop codon in their ADE1 gene (termed ade1-14 mutation). In [psi-] cells, the 
Sup35p terminates the translation together with Sup45p and releases the truncated Ade1 protein, 
which is not functional in adenine biosynthesis. Therefore, [psi-] cannot grow on media lacking adenine 
(−Ade) and corresponding colonies are red on YPD due to the accumulation of a side product of 
adenine biosynthesis. In [PSI+], since most of the Sup35p forms amyloid fibrils and cannot perform its 
normal translation termination activity, full-length Ade1 is produced by stop-codon read through of 
ribosomes. Thus, [PSI+] cells are white on YPD and can grow on −Ade plates.  
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PrD-GFP as a model substrate for amyloid 
The Sup35p is made up of three domains: Q/N-rich N-terminal domain (N) required 
for [PSI+] formation, highly charged middle domain (M) and the C-terminal domain (C) 
necessary for translation termination [72] (Fig 3). The N-terminal domain (N) is 1-114 
residues long but to study the prions, many researchers use 1-253 long sequence 
including the highly charged middle domain (M) which makes this peptide more 
soluble and easy to handle [60]. The combined sequence of N and M domain of 
Sup35p is called as “NM” or “PrD”. A GFP fusion protein of Sup35p prion domain 
(PrD-GFP) provides a visually tractable prion model to study the amyloid-like 
properties of [PSI+] in yeast [65]. 
During de novo prion induction and maturation, the PrD-GFP fusion is deposited in 
three different stages of prions termed as Diffuse, Rings/Ribbon and Dot [65] [65]. 
Initially, during prion induction, PrD-GFP is expressed as a soluble form which shows 
diffuse fluorescence (Diffuse state). The soluble PrD-GFP can be converted to prion 
state in the presence of [PSI+] prion inducer, called [PIN+/RNQ+]. In this stage, PrD-
GFP amyloid aggregates appear as bundles of long fibrils at the cell periphery, often 
intersecting with the IPOD (Ring state). The molecular chaperone Hsp104 cleaves 
these long fibrils, and bundles of short fibrils become visible at the IPOD. This 
indicates the final mature state of PrD-GFP (Dot state) [65, 73]. Thus PrD-GFP can 
be used as a model amyloid substrate to study amyloid biology in yeast. 
	  
	  
FIGURE 3: Protein domain organization of Sup35p– (A) The Sup35p has three domains: Q/N-rich 
N-terminal domain (N), highly charged middle domain (M) and the C-terminal domain (C). The NM or 
PrD domain is sufficient for [PSI+] formation while the C-terminal domain is necessary and sufficient for 
translation termination. (B) A GFP fusion protein of Sup35p prion domain (PrD-GFP) serves as a 
model amyloid substrate to study the amyloid-like properties of [PSI+] in yeast [65].  
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1.3.  Components of the protein quality control network  
 
Inside the cell, proteins often get misfolded due to several proteotoxic stresses, 
mutations or translational errors [55, 74]. These misfolded proteins normally have a 
tendency to aggregate which might have a toxic ‘gain-of-function’ to the cells [75]. In 
order to eliminate protein aggregates, cells have evolved a highly sophisticated 
cellular protein quality control machinery that maintains the proteome integrity and 
cell viability [74]. Several components of this protein quality control network work 
collaboratively to promote native folding of nascent polypeptides, degradation of 
misfolded proteins prior to aggregation or removal or deposition/sequestration of 
aggregates once they have formed [55, 74]. Molecular chaperones are the key 
players of this quality control network that determine the fate of misfolded/aggregated 
proteins in various ways.  
 
1.3.1.  Molecular chaperones involved in protein disaggregation 
Molecular chaperones are an essential group of proteins that facilitate the proper 
folding, refolding and macromolecular assembly/disassembly of client proteins either 
through substrate binding and release cycles in an ATP-dependent manner or an 
ATP-independent ‘holdase’ mode [76, 77]. Although chaperones are very abundant 
cellular proteins, their intracellular levels are further increased during many stress 
conditions. The chaperones are classified into five major families based on their 
molecular weights: Hsp60, Hsp70, Hsp90, Hsp100 and the small heat shock proteins 
(sHSPs) [4, 78, 79]. Among them, some chaperones such as Hsp100, Hsp90, Hsp70 
and Hsp60 proteins are ATP-dependent chaperones while sHSPs are ATP-
independent chaperones  [77]. The small heat shock proteins (sHSPs), the Hsp70 
system and Hsp100 disaggregases are the major families of chaperones involved in 
aggregate handling in the cell. Therefore, the focus of this thesis is on those families 
of chaperones.  
 
The Hsp70 chaperone family 
The Hsp70 family of chaperones recognizes exposed hydrophobic amino acid side-
chains of unfolded/partially folded proteins and promote de novo folding and refolding 
through substrate release cycles in an ATP-dependent manner [80-82]. The 
Hsp70/DnaK system is composed of Hsp70 (in yeast) or DnaK (in bacteria) with its 
two co-chaperones, a J-domain protein (Hsp40 in yeast and DnaJ in bacteria) and a 
nucleotide exchange factor (NEF) [55, 77, 83, 84]. Hsp70 is the most ubiquitous and 
conserved chaperone that exists in different cellular compartments. It drives various 
cellular functions including folding, assembly, and translocation of newly synthesized 
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proteins across organelle membranes and disaggregation of aggregated proteins [78, 
85]. Hsp70 contains two domains: (I) a substrate-binding domain and (II) an ATPase 
domain. Hsp70 chaperone activity depends on dynamic interactions of these 
domains with its co-chaperones such as J-domain protein/Hsp40 (which delivers 
substrates to ATP-bound Hsp70 and accelerates ATPase activity of Hsp70) and 
nucleotide exchange factor (NEF) [78, 85].The ATP-bound Hsp70 (low substrate 
affinity state), binds with the exposed hydrophobic patches of unfolded/partially 
folded proteins via its substrate-binding domain [7, 85]. After ATP hydrolysis, the 
substrate is released by nucleotide exchange factors (NEFs) that trigger the 
exchange of ADP by ATP during the Hsp70 cycle. Hsp70 also works together with 
Hsp104 disaggregases, as described below for the disaggregation of large 
aggregates [67, 78].   
 
The Hsp100 chaperone family 
Hsp100 chaperones extract single polypeptides from aggregated species through its 
ATP-driven threading activity to either degrade them in cooperation with an 
associated protease or to refold them together with Hsp70. The Hsp100 
disaggregase (ClpB in bacteria and Hsp104 in yeast) belongs to the Clp/Hsp100 
family of the AAA+ (ATPases associated with various cellular activities) chaperones 
[86]. The Hsp100 disaggregases were initially identified as essential factors for cell 
survival when cells are exposed to extreme temperatures. This phenomenon is  also 
referred to as heat-induced thermotolerance [87]. Later it was shown that such a 
thermotolerance is a consequence of the reactivation of aggregated proteins by a 
system called as Hsp100/Hsp70 bi-chaperone system [67, 88, 89]. This 
Hsp100/Hsp70 bi-chaperone system is composed of hexameric Hsp100 
disaggregase and the Hsp70 system that facilitates in re-solubilization of the 
aggregated proteins in an ATP-dependent manner. Remarkably, cooperative action 
of both chaperone systems is necessary for proper protein disaggregation. Either 
system alone is unable to rescue the aggregated proteins.  
The mechanism of protein disaggregation by this bi-chaperone system (Fig 4) 
involves several steps. Initially, the Hsp70 system recognizes misfolded protein 
aggregates and later recruits the hexameric Hsp100 disaggregase (ClpB/Hsp104). 
Fueled by ATP hydrolysis, ClpB/Hsp104 extracts polypeptides from aggregates by a 
threading activity through its central pore [55, 90]. A puling force generated by ATP 
hydrolysis promotes the translocation of the unfolded protein through the central pore 
of ClpB/Hsp104 hexamer [55]. Finally, the extracted unfolded polypeptide is 
subjected to the protein quality control network for either refolding or degradation. 
Besides the action of Hsp100/Hsp70 bi-chaperone system on disaggregation of heat-
induced amorphous aggregates, this bi-chaperone system is also involved in prion 
(amyloids) fragmentation and propagation [77]. 
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FIGURE 4: Mechanism of protein disaggregation by the ClpB/Hsp104-Hsp70 bi-chaperone 
system–The Hsp70 system (Hsp70 plus its co-chaperone Hsp40) initially recognizes the misfolded 
protein aggregates and later transfers them to the Hsp100 disaggregase (ClpB in bacteria and Hsp104 
in yeast). The ClpB or Hsp104 hexamer extracts polypeptides from the aggregates by a threading 
activity, driven by ATP hydrolysis. The ATP hydrolysis generates a puling force to promote the 
translocation of single polypeptide chains from the aggregates through the central pore of the 
ClpB/Hsp104 hexamer. The unfolded protein is then refolded back to its native state by the Hsp70 
system. The figure was adapted from [55]. 
 
The sHSP family 
sHSPs are low molecular weight (15-42 kDa) ATP-independent chaperones which 
modulate the architecture of protein aggregates and facilitate their disaggregation. 
sHSPs generally function as ‘holdase’. Yeast harbors 2 known sHSP’s, namely 
Hsp26 and Hsp42 are known sHSPs. During stress conditions, these sHSPs (the 
high substrate affinity state) directly interact with misfolded/aggregated proteins and 
form a stable sHSP–substrate complex [55, 91]. This complex does not allow to 
release bound misfolded proteins spontaneously. Therefore, it creates a temporary 
reservoir of aggregated proteins inside the cytosol. The sHSPs-misfolded protein 
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complex then recruits either Hsp100/Hsp70 bi-chaperone system or Hsp70 system 
for the disaggregation of aggregated proteins [55].   
 
 
1.3.2.  Degradation and clearance of misfolded protein aggregates  
 
Removal of damaged or misfolded proteins is an important task within the cellular 
quality control network and is mediated by different degradation machineries. 
Specialized recognition of damaged proteins for their degradation is ensured in 
organisms from all kingdoms of life, although it is accomplished by different ways in 
different organisms. Aggregated proteins can be degraded in two ways: (I) either as 
soluble single polypeptide chain extracted from an aggregate or (II) as entire protein 
aggregate. In the first case, single misfolded polypeptide chains have to be extracted 
first by specialized disaggregases such as Hsp104 (see section 1.3.1) before they 
can be turned over for example by the proteasome as described below. 
  
The ubiquitin-proteasome system (UPS)  
In eukaryotic cells, the ubiquitin-proteasome system (UPS) (Fig 5) confers a major 
cytosolic proteolytic activity by which mostly the short-lived proteins are first 
ubiquitinated and then targeted to the proteasome for their degradation. The protein 
ubiquitination is catalyzed by a cascade of three enzymatic reactions that conjugate 
the ubiquitin moiety (8.5 kDa) to lysine residues of the substrate. First, ubiquitin is 
activated by the ubiquitin-activating enzyme (E1). Subsequently, the activated 
ubiquitin is handed over to the ubiquitin-conjugating enzyme (E2). In the last step, the 
ubiquitin ligase (E3) binds both the substrate protein and E2~Ub and catalyzes the 
Ub transfer from E2~Ub onto the amino group of a lysine reside of the target protein 
[92, 93]. The E3 ligases recognize one or several specific proteins from the cytosolic 
proteome. Therefore, E3’s provide the substrate selectivity for the UPS. Additional Ub 
moieties can be attached to the first Ub moiety to polyubiquitinated substrates. The 
polyubiquitinated proteins are then turned over by the 26S proteasome. 
The 26S proteasome is composed of one 20S core particle and two 19S regulatory 
particle/cap subunits. The 20S core particle (made up of two times two heptameric 
rings, α1-7 and β1-7) is a proteolytic chamber that harbors three different proteolytic 
activities (chymotrypsin-like, trypsin-like, and peptidyl glutamyl-like) [94, 95]. The 19S 
regulatory particle recognizes polyubiquitinated proteins, removes the ubiquitin chain 
by 19S-cap associated deubiquitinases (DUBs) [96] and unfolds the substrate to 
translocate it into the interior of the 20S proteolytic core [92, 97]. Finally, the 
substrate is cleaved into oligopeptides. Targeting of cellular proteins for effective 
degradation needs to be controlled, independently of the nature of the substrates. 
Polyubiquitination is considered as a key degradation mark for substantial 
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proteasomal substrates, although ubiquitin-independent proteasomal degradation is 
also known for a few substrates [98]. Degradation of misfolded proteins via the UPS 
system uses specific E3 ligases. In yeast, the most prominent ones are: Ubr1 [99] 
and Ubr2 [100] in the cytosol and San1 in the nucleus [101]. Nuclear San1 was 
shown to degrade cytosolic misfolded proteins (∆ssCPY*-­‐GFP substrate) with a 
parallel action of cytosolic Ubr1 [102]. Both Ubr1 and San1 can compensate for each 
other’s function. Therefore, cytosolic misfolded substrates (tGnd1-­‐GFP, 
∆ssCPY*-­‐GFP) are not ubiquitinated/degraded in the absence of these E3 ligases 
[102, 103]. Remarkably, some preferred E2 enzymes such as Ubc4 and Ubc5 also 
involve in proteasome-mediated degradation of aberrantly folded cytosolic proteins. 
[104].  
 
FIGURE 5: The ubiquitin–proteasome system (UPS) of protein degradation–The UPS is initiated 
by tagging the substrate protein with a highly conserved 76 amino-acid residue polypeptide, ubiquitin 
(Ub). This conjugation is an ATP-dependent process and is achieved by three enzymatic cascade 
reactions (E1–E3). The ubiquitin-activating enzymes (E1) first bind ubiquitin under ATP hydrolysis. 
Afterwards, the ubiquitin moiety is handed over to the ubiquitin-conjugating enzyme (E2). 
Subsequently, the ubiquitin ligase (E3) is attached with the substrate protein together with E2~Ub and 
catalyzes the transfer of Ub chain from E2~Ub onto an amino group of lysine residues of the target 
substrate protein. Multiple ubiquitin moieties are attached to the substrate protein destined for 
proteolytic turnover, resulting in polyubiquitin chains. The polyubiquitinated proteins are afterwards 
recognized by the 19S regulatory subunit (19S cap) of the 26S proteasome complex. Deubiquitinating 
enzymes (DUBs) that are associated with the 19S cap remove the ubiquitin chain before the substrate 
is unfolded and transferred into the interior core of the 20S cylindrical subunit (20S core) of the of the 
26S proteasome complex. Finally, the substrate is cleaved into short peptides by the proteolytic 
activity of the 20S proteolytic core. 
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Autophagy  
Autophagy ('self-eating') is a self-degradation system that efficiently removes 
nonfunctional cytoplasmic components under certain circumstances. Autophagy can 
also be involved in the turnover of aggregates and recycling of basic building blocks 
(i.e., amino acids) in response to nutrient starvation [105]. It is an evolutionary highly 
conserved cellular process that eliminates long-lived misfolded/aggregated proteins, 
damaged organelles (mitochondria, endoplasmic reticulum and peroxisomes) and 
intracellular pathogens [106-109]. The lysosomal (vacuolar) autophagy is the second 
major proteolytic degradation machinery in eukaryotes in addition to the UPS. This 
process mediates the bulk degradation of cytoplasmic components which are 
enwrapped into double-membrane vesicles termed autophagosomes. The 
autophagosome delivers these components into specific lytic compartments such as 
lysosomes in mammals and vacuoles in fungi and plants, for their proteolytic 
degradation. Thus, autophagy is an important cellular process that promotes cell 
viability by keeping the cellular environment free of aberrant proteins/organelles 
[110].   
Based on cargo selection, two types of autophagy are described: non-selective (bulk) 
autophagy and selective autophagy [108, 111, 112] (Fig 6). The non-selective (bulk) 
autophagy degrades bulk cytoplasmic contents. [112]. The bulk autophagy is a 
nonspecific (non-selective) process that normally operates at a basal level, but can 
be induced upon starvation [111-114]. Thus, it is also termed starvation-induced 
autophagy [112, 115] that sequesters bulk cytoplasmic components to the growing 
autophagosomes. These autophagosomes further fuse with vacuole and release the 
bulk cytosolic contents into the vacuolar lumen for their degradation by resident acid 
hydrolases [112, 115]. In contrast, selective autophagy is a receptor-mediated 
process which degrades only specific cargoes (damaged mitochondria/peroxisomes, 
stress-induced ER, nucleus, proteasomes, pathogens and ribosomal/damaged 
proteins) by binding to specific autophagy receptors [112, 116-120].  
In mammalian cells, ubiquitinated protein aggregates are internalized into lysosomes 
via selective autophagy (aggrephagy) that is mediated by specific autophagy 
receptors such as for example p62 and NBR1 [107, 121-124]. P62 or NBR1 directly 
bind to the autophagy marker protein LC3 (Atg8 in yeast) [121, 123] and recruits 
deposits of ubiquitinated protein aggregates to the lysosome. LC3 is a component of 
autophagic membranes, which enwrap these aggregates to form autophagosomes 
that subsequently fuse with the lysosome to release the aggregates into the 
lysosomal lumen for degradation by resident lysosomal proteases [107].  
In yeast, vacuolar degradation of aggregated proteins has also been shown recently 
for some aggregates such as α-synuclein and polyQ-aggregates [125]. α-synuclein 
aggregates, formed upon overexpression, were found to be more stable in certain 
autophagy mutants than after proteasome inhibition [125]. This suggested that α-
synuclein aggregates are efficiently degraded by an autophagic pathway in yeast 
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[125]. However, it did not become clear how these α-synuclein aggregates are 
recognized, transported and sequestered into the autophagosomes. Moreover, the 
Atg8 (LC3) adaptor protein CUE5 (human Tollip homolog) binds to ubiquitinylated 
PolyQ aggregates and links them to Atg8-phosphatidylethanolamine (Atg8–PE), 
present at the autophagosomes [126]. Deletion of the CUE5 adaptor protein leads to 
accumulation of PolyQ aggregates in the cytosol [126], suggesting PolyQ aggregates 
are removed by Cue5-mediated autophagy in yeast. In yeast, several autophagy-
related (ATG) genes (33 ATG genes) are involved in the core machinery of both 
selective (CVT) and non-selective autophagy [127]. 
 
 
 
FIGURE 6: The non-selective (bulk) autophagy and selective autophagy in yeast – During non-
selective (bulk) autophagy, bulk cytoplasm and other cytosolic constituents are randomly/non-
selectively sequestered into the autophagosomes. The autophagosomes fuse with vacuole and 
release these cargos into the vacuolar lumen for their degradation by resident acid hydrolases. In 
contrast, selective autophagy is a receptor-mediated process which either degrades only specific 
cargoes (for example damaged mitochondria or peroxisomes) or delivers resident hydrolases 
aminopeptidase I (preApe1) and α-mannosidase (Ams1) into the vacuolar lumen for their maturation 
via the CVT (cytoplasm-to-vacuole targeting) pathway [112, 116-118]. 
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The CVT pathway: a selective autophagy pathway in yeast 
Selective autophagy is an important cellular quality control process that operates at a 
basal level under normal growth conditions and contributes to maintain cellular 
homeostasis. This process has the capacity to distinguish and recognize their 
substrates from the cytosolic pool by specific receptors. In yeast, the CVT 
(cytoplasm-to-vacuole targeting) pathway is a biosynthetic selective autophagy 
pathway that usually operates under non-starvation/nutrient-rich conditions [113, 
116]. The CVT pathway delivers the resident precursor hydrolases aminopeptidase I 
(preApe1) and α-mannosidase (Ams1) from the cytosol into the vacuolar lumen for 
their maturation [112, 116-118]. Since it employs the core machinery of 
macroautophagy, it is also considered as a selective autophagy pathway in yeast.  
The precursor aminopeptidase 1 (preApe1) is the primary cargo protein of this 
pathway. It oligomerizes in the cytosol to form dodecamers and higher order 
complexes of multiple dodecamers and is bound by the Atg19 receptor to form the 
CVT complex [113] [112, 114, 116, 127, 128]. The smaller oligomers of α-
mannosidase (Ams1) also associate with this CVT complex [117, 118, 127]. This 
complex subsequently binds to the Atg11 adaptor, which links the complex to 
vesicles that contain the transmembrane protein Atg9 and are termed Atg9-vesicles. 
These Atg9 vesicles (containing preApe1, Atg19, Atg11 and Atg9) then associate 
with actin cables via unknown factors and are recruited to the Phagophore Assembly 
Site (PAS) adjacent to the vacuole [114] [115]. The PAS is a cellular site where cells 
initiate formation of double-membrane autophagosomes during autophagy and CVT 
vesicles during the CVT pathway (Fig 7). At the PAS, Atg8-phosphatidylethanolamine 
(Atg8–PE) conjugates bind to the Atg19 receptor and stay on the inner and outer 
membrane of the forming CVT vesicles [108, 109, 111, 129]. After fusion of these 
CVT vesicles with the vacuole, preApe1 is released into the vacuolar lumen and 
converted to its active mature form by proteolytic cleavage of the propeptide [113, 
114]. Those Atg19 and Atg8–PE molecules that are located at the inner membrane of 
the CVT vesicles, are also degraded after this fusion event [109]. Although the CVT 
substrates preApe1 and Ams1 are delivered into the vacuole by their incorporation 
into CVT vesicles under normal growth conditions, CVT substrates can also be 
incorporated into autophagosomes under starvation conditions for their transport into 
the vacuole [115]. In yeast, the CVT pathway is studied extensively and serves as a 
model for selective types of autophagy. Its maturation kinetics can easily measure 
the degree of selective autophagy in vivo.   
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FIGURE 7: The CVT (cytoplasm-to-vacuole targeting) pathway is an example of a 
selective/specific autophagy in yeast – After synthesis, the precursor aminopeptidase 1 (preApe1) 
forms cytoplasmic oligomers that bind to its receptor Atg19 and forms the CVT complex. This complex 
further binds to Atg9-containing vesicles via the adaptor Atg11. These Atg9 vesicles (containing 
preApe1, Atg19 and Atg11) then associate with actin cables via an unknown linking factor and move 
to the phagophore assembly site (PAS), adjacent to the vacuole. At the PAS, preApe1 is enwrapped 
into double-membrane CVT vesicles which subsequently fuse with the vacuolar membrane and deliver 
preApe1 into the vacuolar lumen for its maturation. The figure was adapted and slightly modified from 
[114]. 
 
1.4.  Spatial protein quality control network 
Various stress conditions can cause proteins to misfold. Those misfolded proteins 
can accumulate in spatially distinct inclusions from bacteria to humans when 
refolding and degradation systems, dealing with the misfolded substrates, get 
overwhelmed [55]. It is assumed that such organized spatial quality control 
compartmentalization serves many favorable cellular purposes such as: (I) efficient 
protection of the cellular environment from the accumulation of potentially toxic 
aggregated species, (II) possible organization of protein quality control 
factors/chaperones acting on these aggregates, (III) supporting the triage process of 
refolding versus degradation of a misfolded protein and (IV) allow for asymmetric 
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inheritance of damaged/aggregation-prone species as a means to generate 
aggregate free progeny [74].  
 
 
1.4.1.  Aggregate deposition in bacteria 
In bacteria, endogenous proteins can aggregate upon heat or oxidative stress. 
Overexpression of certain heterologous proteins in bacteria can cause stress. 
Consequently, these proteins form amorphous aggregates which are spatially 
compartmentalized into inclusion bodies (IBs) that are formed predominantly at the 
cell poles. Therefore, IBs are considered as temporary storages to deal with the 
overload of misfolded/aggregated species [130]. These protein aggregates recruit the 
disaggregation system ClpB/DnaK/DnaJ, also termed the bi-chaperone system 
(compare section 1.3.1). However, the actual mechanism by which aggregated and 
misfolded proteins are transported into peripheral inclusions, is still under debate. 
The polar localization of inclusions is not an active process but could be explained by 
a passive mechanism due to large nucleoid occlusion, which forces 
aggregates/inclusions to move towards the poles [55].  This polar localization allows 
for asymmetric inheritance of protein aggregates and rejuvenation of daughter cells 
without inclusions [131, 132]. This asymmetric inheritance of aggregates is lost when 
cytosolic aggregation is artificially targeted to the inner membrane [132], 
demonstrating that such spatial compartmentalization facilitates asymmetric 
inheritance of inclusion bodies.  
 
1.4.2.  Aggregate deposition in mammals 
In the mammalian cytoplasm, specialized inclusion bodies, termed “aggresomes” are 
formed which deposit misfolded cytosolic proteins upon expression of heterologous 
proteins, various disease conditions or impairment of proteasomes [133]. These 
aggresomes are formed temporally at a perinuclear site termed microtubule-
organizing center (MTOC). Aggresomes are surrounded by a cage of the 
intermediate filament vimentin [133]. The histone deacetylase HDAC6 functions as 
an adaptor that binds to Lys63-linked polyubiquitin chains on misfolded proteins on 
the one hand and the minus-end microtubule motor protein dynein on the other hand, 
which drives the active transport of aggregates along microtubules towards the 
MTOC [134]. Therefore, ubiquitination mediated by Parkin/CHIP or other related E3 
ubiquitin ligases [135, 136], seems to serve as a recognition signal to target 
misfolded proteins to the aggresome, though it was not shown for all aggresome 
substrates [137]. Disruption of microtubules or dynein motor function and inhibition of 
HDAC6 prevents aggresome formation and can lead the accumulation of misfolded 
protein aggregates as dispersed foci in the cytoplasm [133, 134]. Thus aggresomes 
protect the cell from the accumulation of potentially toxic aggregation-prone proteins 
in the cytoplasm. Furthermore, it facilitates the selective autophagic clearance of 
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these proteins. For autophagic degradation, protein aggregates bind to autophagic 
receptors p62 or NBR1 via their ubiquitin chains. These receptors also bind to the 
light chain 3 (LC3), a mammalian homologue of yeast Atg8 [123, 138]. This complex 
is enwrapped into double-membrane autophagosome which subsequently fuses with 
the lysosome and releases ubiquitylated substrates into the lysosomal lumen for 
degradation by hydrolytic enzymes (Fig 8).  
 
 
 
  
FIGURE 8: The aggresome–autophagy pathway (aggrephagy) in mammalian cells - In 
mammalian cells, misfolded proteins are initially ubiquitinated and degraded by the ubiquitin-26S 
proteasome system (UPS). When this UPS system failed or is overwhelmed, misfolded proteins form 
oligomers and small aggregates that can cause cytotoxicity. Under conditions of proteasomal 
impairment, these polyubiquitinated aggregates are recognized by the adaptor protein histone 
deacetylase HDAC6 which subsequently links these protein aggregates to the dynein motor protein. 
Aggregated proteins are transported by dynein motor protein complexes in a microtubule dependent 
manner towards the microtubule-organizing center (MTOC), adjacent to the nucleus. At the MTOC, 
these small aggregates coalesce to form large aggregates termed “aggresomes”, which are 
surrounded by a vimentin-cage of intermediate filaments. Ubiquitinated aggregates at the aggresomes 
are recognized by autophagic receptors p62 or NBR1 which facilitate the recruitment of autophagic 
membranes to the aggresome for autophagosome formation. Subsequently, the autophagosome 
fuses with the lysosome to form autolysosomes that allow the degradation of aggregated proteins by 
lysosomal hydrolases.  
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1.4.3.  Deposition of Aggregates in Saccharomyces cerevisae 
 
When components of the protein quality control system such as molecular 
chaperones and the ubiquitin–proteasome system (UPS)/autophagy degradation 
systems are overwhelmed or declined, protein aggregation is increased [74]. To deal 
with the overload of aggregated/damaged proteins, cells evolved additional spatial 
quality control strategies by which aggregated species are sequestered into 
specialized subcellular compartments, and such sequestration also facilitates 
asymmetric distribution of aggregates from mother to daughter cells [55, 74, 103, 
139].  
 
Asymmetric inheritance of protein aggregates 
In S. cerevisiae, protein aggregates, particularly oxidatively damaged proteins, are 
retained in the mother cells during cell division. In the absence of the histone 
deacetylase Sir2, this process is compromised and accelerates the ageing processes 
and damage inheritance of protein aggregates by daughter cells [35, 139]. In 
addition, the disaggregase Hsp104 is also directly involved in the asymmetric 
segregation process [35, 140]. The mechanism of how Hsp104 works in the 
asymmetric segregation of damaged protein is still controversial. One study [141] 
showed that Hsp104 binds to aggregated proteins and tethers them to actin cables. 
Due to actin cable flow from the buds to the mother cells, aggregates are retrogradely 
transported and retained in the mother cell. The other study  [140] showed that 
Hsp104 modulates the polarity of the actin cytoskeleton by binding with the 
components of the actin cytoskeleton or the septin machinery. Since the actin 
cytoskeleton facilitates asymmetric segregation of damaged proteins, deletion of 
HSP104 may have an indirect effect on aggregate segregation.  
The cellular rejuvenation effect during asymmetric aggregate segregation was also 
observed in S. pombe and E. coli, suggesting that asymmetric inheritance is an 
evolutionarily conserved mechanism [142]. Different mechanistic perspectives were 
controversially discussed for asymmetric aggregate distribution: On the one hand, 
Sir2 and Hsp104 dependent actin-based active retrograde transport along cables 
clear the buds of damaged proteins [141] while on the other hand, the formation of 
aggregate-free buds was explained via passive diffusion of aggregates due to cell 
geometry and solubilization/disaggregation of aggregates in the buds by Hsp104 
[143].  A passive asymmetric segregation was also observed in S. pombe, where 
heat-induced small Hsp104-GFP aggregates fuse into a large entity, which is 
asymmetrically inherited during budding through one of the daughter cells while 
leaving the other daughter cell free of aggregates. This fusion event is mediated by 
the small heat shock protein Hsp16 during the asymmetric segregation process [144]. 
In S. cerevisiae, the formation of specialized deposition sites for different types of 
	  
	  
23	  
aggregates, INQ/JUNQ and IPOD (described in more detail in the next section), was 
suggested to facilitate asymmetric aggregate segregation [145, 146].  In human 
HEK293 cells, aggresome-like inclusions formed by an EYFP-tagged expanded 
polyglutamine segment (HDQ119-EYFP) were retained in only one of the daughter 
cells during their asymmetric inheritance [147]. In addition, such asymmetric 
inheritance of misfolded/aggregated proteins was also observed in mammalian cells 
where JUNQ-inclusion bodies (VHL substrate) were inherited asymmetrically while 
inheritance of IPOD like inclusions (HttQ97 substrate) was less stringently 
asymmetric [148]. 
 
Distinct aggregate deposition sites in yeast  
In Saccharomyces cerevisae, misfolded/aggregated proteins are deposited at three 
major subcellular sequestration sites as described: INQ (intranuclear quality control 
compartment) [earlier JUNQ (juxtanuclear quality control compartment)], IPOD 
(insoluble protein deposit) and CytoQ [56, 103] (Fig 9). Aggregated proteins require 
the nuclear factor Btn2 for deposition at the INQ [103, 149, 150]. Alternatively, they 
can be targeted to a newly discovered peripheral deposit termed as Cyto Q with the 
aid of the cytosolic small heat shock protein Hsp42 [151-154]. The IPOD, a 
perivacuolar deposition site, predominantly sequesters amyloidogenic protein 
aggregates [56, 65], terminally aggregated proteins [56] including carbonylation-
sensitive proteins [65] and inactive 26S proteasomes [155], suggesting IPOD 
sequesters the high-molecular-weight aggregates/protein complexes before they are 
processed. 
It was proposed that formation of INQ requires an intact actin cytoskeleton [153] but it 
was not clear if IPOD formation requires an intact actin cytoskeleton as well. For 
studying these deposition sites, different misfolded model substrates, degraded via 
the UPS, are commonly used. Those are a thermosensitive variant of the SUMO E2 
enzyme Ubc9, Ubc9ts [156] and the human von Hippel-Lindau tumor suppressor 
protein (VHL), which is an E3 ligase that only properly folds when its cofactors 
Elongin B and C are present. In the absence of these co-factors, VHL is constantly 
misfolded and targeted for proteasomal degradation [157]. To study the IPOD, next 
to Ubc9ts and VHL, amyloidogenic substrates such as yeast prion Rnq1 [158] and 
the polyQ-rich protein Htt, amongst others, were used [56]. 
 
 
INQ (intranuclear quality control compartment)/ JUNQ (juxtanuclear quality 
control compartment) 
	  
JUNQ was originally suggested as a juxtanuclear cytosolic deposition site since it 
was adjacent to DAPI staining [56]. However, DAPI stains only the chromatin, not the 
entire nucleus. Therefore missing co-localization of JUNQ and DAPI could not 
exclude a nuclear localization of JUNQ. Recently, Miller and coworkers showed that 
under the standard published protocol (heat shock at 37°C + proteasome inhibition 
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by MG132) [56, 153], JUNQ substrates, Ubc9ts and VHL are localized inside the 
nucleus when nucleus was visualized by the nuclear envelope/ring markers, Nup49 
and Nsp1 [103]. A similar observation was made when VHL-GFP was co-expressed 
with Nup49-RFP. In this situation, misfolded VHL foci after heat shock were localized 
inside the Nup49 nuclear ring [150]. Taken together, JUNQ resides inside the 
nucleus, and it was subsequently renamed as INQ (intranuclear quality control 
compartment) [103]. The INQ/JUNQ also holds proteasomal subunits and the protein 
disaggregase Hsp104. The conditions leading to the formation of the INQ/JUNQ are 
similar to the mammalian aggresome. However, INQ/JUNQ was not found in the 
vicinity of the spindle pole body (SPB) that is equivalent to the mammalian 
microtubule-organizing center (MTOC) where aggresomes are formed. FLIP 
(Fluorescence Loss in Photobleaching) experiments show that INQ/JUNQ exchanges 
substrate proteins constantly with the surrounding pool [56, 153]. Initially, 
ubiquitination was proposed as a sorting signal for deposition of misfolded proteins at 
the INQ/JUNQ. Since the INQ/JUNQ also comprises proteasomes, it was recognized 
at first as deposition site for degradation of misfolded proteins [56]. In line with this, it 
was shown that either overexpressing a deubiquitinating enzyme (DUBs) or knocking 
out the two quality control E2 enzymes Ubc4 and Ubc5, which both results in less 
ubiquitination of misfolded proteins, sequester a JUNQ substrate at the IPOD instead 
of the JUNQ [56]. However, recent studies show that sorting of misfolded protein 
substrates to the INQ/JUNQ does not require ubiquitination [103].  
 
CytoQ 
 
Yeast has an additional subcellular aggregate deposition site termed as CytoQ 
(former Q body/peripheral aggregates/foci) that sequesters amorphous aggregates 
during heat stress [103, 152, 153]. Dissolution of CytoQ’s requires the Hsp104-
dependent disaggregation machinery [153]. Upon heat stress, initially, multiple 
peripheral foci/CytoQs are formed that coalesce into few larger inclusions over time 
[103]. Interestingly, these peripheral aggregates/CytoQs do not randomly diffuse in 
the cytoplasm, but formed in a coordinated manner along an intact cortical 
endoplasmic reticulum (ER) [152]. Formation of CytoQs is not required for 
degradation but seems to maintain the cellular fitness by sequestering misfolded 
species.  
 	  
IPOD (insoluble protein deposit) 
 
Another subcellular deposition site identified in yeast is the IPOD. At the IPOD, 
insoluble aggregates such as terminally misfolded proteins, potentially oxidatively 
damaged proteins and amyloid aggregates (Htt103Q), the yeast prions [RNQ] and 
[URE3] [55, 56] and inactive proteasomes [155] accumulate. More recently, the IPOD 
was shown to serve as an intermediate sorting center for the damaged proteasomes 
before they are degraded by autophagy [155]. The IPOD exists adjacent to the 
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vacuole and is associated with the Hsp104 disaggregase. It is, however, striking that 
upon impairment of the ubiquitin-proteasome system (UPS) by deleting both E2 
ubiquitin-conjugating enzymes Ubc4–Ubc5 (causes loss of ubiquitination of misfolded 
proteins), INQ/JUNQ substrates can be targeted to the IPOD, whereas introduction of 
a ubiquitin moiety to the bona fide IPOD substrate (Rnq1) allows for partial 
redistribution of the protein to the INQ/JUNQ [56]. In contrast to INQ/JUNQ, IPOD is 
quite stable and does not exchange substrate with the cytosol [56, 153]. The IPOD 
compartment also co-localizes with a bona fide autophagy marker, Atg8/LC3, but the 
possible physiological role for this is still unclear [56]. It is also unclear what the 
possible fate of substrates of IPOD is.  
 
 
 
 	  
FIGURE 9: S. cerevisae sorts misfolded proteins into three distinct quality control 
compartments - Upon stress, misfolded proteins are either targeted for degradation or refolding with 
the aid of different molecular chaperones. Soluble protein aggregates are targeted either to the INQ 
with the nuclear sorting factor Btn2, or they are targeted to a peripheral deposition site termed as Cyto 
Q with the aid of cytosolic small heat shock protein Hsp42. Amyloidogenic aggregates (shown as an 
array of β-sheets) predominantly accumulate at the IPOD, a perivacuolar deposition site. 	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Factors determining deposition of misfolded proteins 
The presence of three different aggregate deposition sites in yeast asks for cellular 
factors that specifically guide a misfolded/aggregated protein to the respective site. In 
Saccharomyces cerevisae, different substrate-independent sorting factors were 
identified that sequester amorphously misfolding proteins into spatial deposition sites. 
The first aggregate-sorting factor is the cytosolic small heat shock protein Hsp42 
which is required for deposition of these aggregates at the Cyto Q [151-154]. 
Deletion of HSP42 results loss of Cyto Q but does not affect the formation of 
INQ/JUNQ upon cellular stress conditions [153]. Remarkably, an intact actin 
cytoskeleton is required for INQ/JUNQ formation since disruption of the actin 
cytoskeleton by latrunculin A (LatA) leads to increased foci of mCherry-VHL 
aggregates in both WT and hsp42∆ cells [153]. 
A second aggregate sorting factor is Btn2, which was originally identified as a factor 
acting in an unrelated biological process, which is late endosome to Golgi transport of 
specific proteins [159]. Btn2 is a short-lived nuclear protein which is rapidly degraded 
under standard growth conditions [149]. It interacts with v-SNAREs (vesicle -SNAP 
(Soluble NSF Attachment Protein) REceptor) and transports proteins via late 
endosome-Golgi trafficking [149, 159]. Btn2 is closely associated with another 
protein-sorting factor termed Cur1. Both factors are stress-inducible and interfere with 
each other during prion propagation. However, in contrast to Cur1, Btn2 directly 
regulates spatial protein quality control. Cells lacking Btn2 form peripheral protein 
aggregates (now CytoQ) upon stress, but not the INQ/JUNQ [149]. Btn2 interacts 
with Hsp40 chaperone Sis1 [149]. Therefore, it was suggested that Sis1 may 
promote sorting of misfolded cytosolic proteins to the INQ/JUNQ. However, since 
depletion of Sis1 does not entirely block the sequestration of misfolded proteins at 
the INQ/JUNQ, other factors were hypothesized to act together with Sis1 [103]. 
Alternatively, Sis1 was also suggested to have an indirect effect on the INQ/JUNQ 
formation as its depletion can reduce the capacity of the protein quality control 
system which then would lead to more aggregation.  
The amyloidogenic substrates (Htt103Q, Rnq1 or the NM (PrD) domain of Sup35) are 
deposited at the perivacuolar deposition site IPOD under all conditions [56, 65]. 
However, the molecular mechanism underlying this deposition process is still 
unknown. No targeting factor till now had been identified which is required for 
deposition of amyloids at this site. A model of misfolded protein deposition in S. 
cerevisiae is shown in Fig 9. 
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The protein quality control system is an important cellular strategy that maintains 
proteome integrity by removing or sequestering misfolded proteins at specific 
deposition sites. Such sequestration strategy protects the cellular environment from 
potentially toxic misfolded species. In Saccharomyces cerevisae, three distinct 
deposition sites have been identified: INQ/JUNQ, Q body/CytoQ and the IPOD. 
Misfolded proteins are deposited at the INQ/JUNQ with the nuclear sorting factor 
Btn2 [103, 149, 150] or they are deposited to a peripheral site termed as Q 
body/CytoQ with the aid of the cytosolic small heat shock protein Hsp42 [151-154]. 
Amyloidogenic protein aggregates such as prions are deposited at the IPOD, a 
perivacuolar deposition site, but the mechanism by which amyloid aggregates are 
recognized and deposited at this site is unknown. The IPOD is located adjacent to 
the Phagophore Assembly Site (PAS) [56, 65] where the cell initiates autophagy and 
the Cytoplasm-to-Vacuole Targeting (CVT) pathway. Formation of the IPOD is 
independent of Hsp42, suggesting that both amyloidogenic substrates and misfolded 
protein substrates are handled differently [153]. Earlier, it was hypothesized that 
formation of INQ requires an intact actin cytoskeleton [153] but it was not clear if 
IPOD formation requires an intact actin cytoskeleton.  
Within my PhD thesis, I focused on understanding the molecular mechanism that is 
involved in the recruitment of prion amyloid aggregates to the IPOD and investigated 
the fate of amyloid depositions in the vicinity of the PAS. I addressed the following 
key questions: 
 
1. Which are the factors that are involved in recognition and targeting of amyloid 
substrates to the IPOD? 
2. What is the molecular mechanism of recruitment of amyloid substrates to the 
IPOD? 
3. What is the fate of amyloids deposited at the IPOD?  
 
I approached this task by employing a fishing approach for amyloid binding factors 
using immobilized prion amyloid fibers and microscopy of fluorescently tagged 
amyloid fibers. For studying the fate of amyloid depositions at the IPOD, I employed 
pulse-chase type of experiments.  
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3.1.      Identification of PrD-GFP amyloid binding partners 
 
In 2008, two distinct types of aggregate deposition sites have been described in S. 
cerevisiae: JUNQ and IPOD [56]. IPOD is a perivacuolar compartment and mainly 
sequesters amyloidogenic protein aggregates such as Ure2, Rnq1 and HttQ103 [56]. 
In addition, a GFP fusion protein of Sup35p prion domain (PrD-GFP) was also shown 
to co-localize with the Rnq1 prion and deposit at the IPOD, suggesting that PrD-GFP 
can serve as a model amyloidogenic substrate to study amyloid deposition at the 
IPOD in yeast [65]. However, the molecular machinery underlying the recognition and 
recruitment of these amyloidogenic substrates to the IPOD is not known.  
Therefore, I employed the prion domain (PrD) of Sup35 [160-162] for identifying 
amyloid binding factors from yeast cell lysates that are involved in recognition and 
recruitment of amyloid aggregates to the IPOD. To do so, I used a fishing approach 
with yeast cell lysates and in vitro assembled recombinant biotin-labeled PrD amyloid 
fibrils immobilized to streptavidin coated magnetic beads.  
 
3.1.1. Purification of recombinant PrD proteins from E. coli  
To use PrD-fibers as amyloid bait, 10xHis-Sumo-PrD-AviTag and 10xHis-Sumo-PrD-
STOP constructs were used. The two constructs were available in the Tyedmers Lab 
(Fig 10A and 10B). The construct that allows for biotinylation of the PrD domain was 
pHis10-Sumo-PrD-TEV-Avi. The AviTag is a biotinylation tag that efficiently 
biotinylates any protein by a co-expressed biotin ligase in vivo and in vitro. To 
synthesize non-biotinylated PrD, the pHis10-Sumo-PrD-STOP construct was used. In 
both constructs, a Ulp1 protease cleavage site was included between pHis10-Sumo 
and PrD to be able to remove the 10xHis-sumo tag by Ulp1 digestion. To make PrD-
fibers, I did not use only 10xHis-Sumo-PrD-AviTag since it could bind very tightly to 
Results	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streptavidin beads and may then disturb the interaction of PrD-binding partners. 
Therefore, I also included the non-biotinylated (10xHis-Sumo-PrD-STOP) construct to 
produce mixed PrD fibers with a few molecules of biotinylated PrD and excess 
molecules of non-biotinylated PrD (1:50 ratio).  
I expressed these constructs in E. coli BL21 (DE3) harboring a biotin ligase from an 
IPTG-inducible pBirAcm plasmid. I purified biotin-labeled 10xHis-Sumo-PrD-AviTag 
and unlabeled 10xHis-Sumo-PrD-STOP recombinant PrD proteins from E. coli using 
a Ni-NTA resin (Fig 10C-D). Finally, PrD-Avitag and PrD-STOP were obtained after 
removal of the 10xHis-Sumo tag with Ulp1 digestion (Fig 10E, lane 3 and lane 6). 
The cleaved His-sumo tag was removed by a second incubation with Ni-NTA resin 
(see section 5.2.8 for detail). I prepared biotin labeled PrD heterofibers by mixing 
purified PrD-Avitag to PrD-STOP at a ratio of 1:50 and incubating overnight at room 
temperature with a slow rotation (Fig 11A, lane1). The PrD heterofibers were then 
sonicated for 5 min in order to gain short fibers which were found in the pellet after 
centrifugation (Fig 11A, lane3). I confirmed the formation of amyloid fibers by electron 
microscopy (EM) after negative staining with 2 % aqueous uranyl acetate on 100 
mesh carbon-coated copper TEM grids (Fig 11B). The average length of sonicated 
PrD heterofibers was ~300 nm (Fig 11C).  
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FIGURE 10: Purification of 10xHis-Sumo-PrD-Avitag and 10xHis-Sumo-PrD-STOP by Ni2+-
affinity chromatography and removal of 10xHis-Sumo by UlpI digestion – (A, B) Cartoon of 
10xHis-Sumo-PrD-Avitag (A) or 10xHis-Sumo-PrD-STOP (B) constructs used to generate the amyloid 
bait. Both constructs contain an UlpI protease cleavage site to remove the His-sumo tag after 
purification. PrD-Avitag/Biotin generates biotin labeled PrD whereas PrD-STOP is used to generate 
unlabeled PrD. (C) 10xHis-Sumo-PrD-Avitag was expressed in E. coli BL21 (DE3) and purified with a 
Ni-NTA column and 250 mM of imidazole for elution. (D) Same as (C) but with the 10xHis-Sumo-PrD-
STOP construct. (E) Removal of the 10xHis-Sumo tag from the purified 10xHis-Sumo-PrD-Avitag and 
10xHis-Sumo-PrD-STOP proteins after cleavage by an UlpI protease. PrD-Avitag (biotinylated) or PrD-
STOP (non-biotinylated) were collected in the flow through (FT) after incubating UlpI digested 10xHis-
Sumo-PrD-Avitag/STOP with Ni-NTA beads. The PrD-Avitag/STOP proteins were further used to form 
the biotin-labeled PrD heterofibers.  
 
 
 
FIGURE 11: Analysis of biotin-labeled PrD heterofibers – (A) SDS-PAGE with biotin-labeled PrD 
heterofibers after sonication for 5 min. Sonicated fibers were centrifuged at 14000 rpm for 30 min. The 
supernatant and pellet was loaded onto an SDS-PAGE to check if the fibers are still in the pellet 
fraction after sonication. (B) Electron Microscopy (EM) of PrD amyloid fibers prepared from biotin-
labeled and unlabeled recombinant PrD at a ratio of 1:50 after negative staining with uranyl acetate at 
50000X magnification. (C) Same as (B) but after 5 min of sonication. Scale bar, 250 nm. 
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3.1.2. Binding of biotin-labeled PrD heterofibers to streptavidin 
beads  
I immobilized the sonicated PrD heterofibers with streptavidin beads for ~ 1-2 h at 
4°C. The beads with immobilized PrD fibers were further  incubated with [PSI+] yeast 
cell lysates at 4°C over night under gentle agitation (Fig 12A). Streptavidin beads 
without any immobilized PrD were taken as negative control. After overnight 
incubation, potential PrD amyloid binding partners were eluted by boiling the beads in 
2X Laemmli sample buffer at 95°C and separated by SDS-PAGE (Fig 12B) prior to 
mass spectrometry (MS) analysis at the Core Facility for Mass Spectrometry & 
Proteomics/ZMBH, Heidelberg. In brief, In-gel tryptic digestion and LC-MS/MS 
analysis was used. Samples on the Coomassie stained gel were first reduced and 
alkylated before the trypsin digestion. Single lane containing proteins was excised 
and cut into two slices from the entire lane with a fresh scalpel. Subsequently, 
peptides were extracted, concentrated in a vacuum centrifuge concentrator and 
diluted to 30 µl with 0.1% TFA. 25 µl of peptides were injected into a nanoHPLC 
system (nanoAcquity, Waters) coupled to an ESI LTQ Orbitrap mass spectrometer 
(Thermo Fisher). The uninterrupted MS/MS spectra were searched against “The 
Swissprot_2014_04 Saccharomyces Cerevisiae Database” (for details please refer 
the paper [163]).  
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FIGURE 12: Fishing of prion amyloid binding proteins from yeast cell lysates – (A) A cartoon of 
the fishing approach with [PSI+] yeast cell lysates and in vitro assembled recombinant biotin-labeled 
PrD amyloid fibers immobilized to streptavidin coated magnetic beads. Proteins bound to the resin 
were eluted by boiling in 2X SDS sample buffer and separated by SDS-PAGE followed by Coomassie 
staining prior to mass spectrometry (MS) analysis. (B) SDS-PAGE with eluate from a resin 
immobilized with PrD fibers (left lane) and a negative control where just beads without immobilized 
PrD fibers were incubated with yeast lysates (right lane).   
 
From my fishing approach, 64 proteins were ≥2-fold enriched in the column with PrD 
fibers as compared to the control (without fibers). These proteins were considered as 
potential	  as PrD interactors. They belong to various functional groups such as actin 
cytoskeleton-modulating proteins (Tpm1 and Tpm2), proteins involved in the 
endocytic secretory pathway/autophagy (Sec4, Sec14, Sec21 and Ykt6 and Ypt1), 
chaperones (Sis1, Saa1/2, Sec18 and Sgt2) and stress granule-associated RNA 
binding proteins (Pub1 and Pab1). Among them, I found several proteins that were 
previously shown to interact with Sup35 or its PrD [164-169]. These proteins were: 
The Hsp40 chaperones Sis1 and Ydj1, the Hsp70 chaperones Saa1/2, the amyloid 
sensor Sgt2, the mRNA binding proteins Pub1 and Pab1 and the actin binding and 
organizing protein Sla2. The identification of these known interaction partners of 
Sup35 or its PrD, highlighted in green in Fig 13, indicated that my fishing approach 
worked. I note that I did not find all known [PSI+] aggregate interactors in my fishing 
approach, which demonstrates that the method is not quantitative. Interestingly, 
however, I found proteins that were not previously described as PrD binding partners, 
such as tropomyosin1/2 and several SEC genes (Fig 13).   
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FIGURE 13: Functional grouping of hits identified in fishing of PrD binding proteins from yeast 
cell lysates – The strongest hits (see also Appendix Table 1) which were bound to PrD fibers on 
column and were ≥2-fold enriched compared to the control (without fibers) in the fishing approach, 
were grouped according to their role in biological processes. The hits are categorized based on the 
corresponding descriptions in the SGD database (http://www.yeastgenome.org/). 
 
3.1.3. Co-localization of identified binding partners with PrD-GFP  
In yeast, tropomyosin has two isoforms Tpm1 and Tpm2, which bind and stabilize 
actin cables/filaments, thereby influencing several transport processes such as 
organelle segregation and cell polarization along tropomyosin-decorated actin cables 
[170]. Earlier, it was shown that INQ formation requires an intact actin cytoskeleton 
[153], but it was unclear if amyloid substrate recruitment to the IPOD also requires an 
intact actin cytoskeleton. To test a possible role of Tpm1/2 in IPOD biogenesis, I 
	  
	  
35	  
tested first whether the protein was bound to the column only in traces or in 
significant amounts. For testing this, I repeated the fishing experiment with PrD as 
amyloid bait as described before, but with a lysate from a yeast strain that carried 
Tpm2 with an HA-tag. This tag allowed me to ask whether the protein bound to the 
immobilized PrD was present in amounts detectable by Western Blotting.  I found that 
Tpm2 was bound to PrD fibers in vitro in detectable amounts (Fig 14A). Next, I asked 
whether an interaction between Tpm1/2 and PrD may also occur in vivo? To do so, I 
designed a co-localization experiment for investigating if Tpm1/2-mCherry interacts 
with PrD-GFP in vivo. As a positive control, I also included mCherry fusions of known 
PrD interactors such as Ssa1 [167, 168], Pub1 [166] and Pab1 [164]. The latter three 
indeed co-localized with PrD-GFP at the IPOD, however Tpm1/2-mCherry did not 
accumulate with PrD-GFP at the IPOD (Fig 14B). This left the possibility that such a 
putative interaction could be more transient, for example during the recruitment of 
PrD-GFP aggregates to the IPOD.  
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FIGURE 14: Test for binding of Tpm1/2 with PrD in vitro and in vivo – (A) Fishing experiment as 
in Fig 12A, but with yeast cell lysates from a strain that carried a deletion in TPM1 and an aid-degron 
tagged Tpm2. The aid-degron-tag contained additionally an HA-tag. After elution of the bound fraction, 
the samples were subjected to SDS-PAGE followed by Western Blotting with an antibody against the 
HA-tag to detect Tpm2-aid-HA in the eluate. (B) Logarithmic growth phase culture of 74D-694-ΔPrD 
(SUP35) [PrD-GFP+] that contained C-terminal mCherry fusions of different genes identified as PrD-
fiber binding proteins in the fishing experiment described in Fig 13.  Cells were subsequently fixed with 
4% of formaldehyde (PFA) and analyzed by fluorescence microscopy as described in methods. After 
deconvolution, a merged image of the z-stacks taken in the GFP- and the mCherry channels, 
respectively, were overlaid. Scale bar, 2 µm. 
 
 
3.2. Characterization of the molecular mechanism of 
recruitment of prion amyloids to the IPOD 
 
3.2.1. Tropomyosin, Myo2 and Calmodulin functions are required 
for proper recruitment of PrD-GFP to the IPOD  
Since both Tpm1/2 were found to interact with PrD-GFP in vitro, but did not co-
localize at the IPOD in vivo, I wondered if tropomyosins may interact transiently with 
PrD-GFP aggregates, for example during a recruitment step to the IPOD deposition 
site. If that was the case and was a crucial step in the recruitment, depletion of these 
proteins should interfere with proper targeting of PrD-GFP aggregates to the IPOD. 
For testing this, I used a [PSI+] strain expressing PrD-GFP under control of a 
galactose inducible promoter. Since both Tpm1 and Tpm2 have overlapping 
functions and the double deletion of both tropomyosins is lethal [171], I conditionally 
depleted Tpm2 in a tpm1-knock out strain (tpm1∆) employing the well-established 
“Auxin Inducible Degron (aid)” tag system  [172]. For this, Tpm2 was tagged with a 
degron-tag (aid) and the plant E3 ligase SCF-TIR1 was co-expressed. Upon addition 
of the plant hormone auxin, auxin binds to E3 ligase SCF-TIR1 that promotes the 
interaction between SCF-TIR1 and the “aid” tagged protein. The target protein is then 
polyubiquitinated and efficiently degraded by the 26S proteasome. I induced the PrD-
GFP in galactose-based media for 6 hours in the absence and presence of auxin. 
After PrD-GFP induction and Tpm2 depletion, I withdrew an aliquot, fixed the cells 
with PFA and visualized the aggregation pattern of PrD-GFP under the fluorescence 
microscope. In the control, more than 95% of the cells showed one single large PrD-
GFP dot/IPOD (Fig 15A and 15B) as formerly described [65]. In contrast, 61 % (Fig 
15D) of the cells showed multiple PrD-GFP foci upon depletion of tpm1/2 (Fig 15C, 
right panel). The wild-type (wt) strain that lacks an aid-tag showed only one single 
large PrD-GFP dot/IPOD per cell even in the presence of auxin (Fig 15A and 15B ), 
suggesting that the multiple PrD-GFP foci phenotype was due to the conditional 
depletion of the tropomyosin function and not due to a side effect of auxin. Depletion 
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of Tpm2 in [PSI+] tpm1∆ strain was confirmed by Western Blot analysis with an 
antibody against an HA tag attached to the “aid” degron tag (Fig 15I). Short-term 
depletion of Tpm2 for 6 hrs was not lethal for the cells (Fig 15J). 
It was recently shown that tropomyosins decorate actin filaments for efficient 
interaction and movement of class-V myosins such as Myo2 along actin filaments 
[173, 174]. In addition, Myo2 was shown to interact genetically with another actin-
binding protein termed calmodulin (Cmd1), which is involved in proper organization of 
actin cables and polarized growth [175]. Furthermore, it has been shown that 
tropomyosin along with Myo2 and Cmd1 are required for retaining Htt103Q- and 
heat-induced protein aggregates asymmetrically in the mother cells during cell 
division [139, 141, 176]. Thus, I extended my studies to Myo2 and Cmd1 due to this 
functional association. Since these two actin-binding proteins are essential, I applied 
the same “aid system” to greatly deplete their levels temporarily. Similar to Tpm2, I 
fused both proteins with a degron-tag (aid) [172] and performed the experiment in the 
same way as for Tpm2 depletion. I observed a similar multiple PrD-GFP foci 
phenotype upon depletion of Myo2 and Cmd1 (Fig 15E and Fig 15G) as for Tpm1/2 
depletion, suggesting that these proteins are also involved in the recruitment of PrD-
GFP aggregates to the IPOD. Depletion of Myo2 and Cmd1 was confirmed by 
Western Blot analysis with an antibody against an HA tag attached to the “aid” 
degron tag (Fig 15I). Short-term depletion of these proteins for 6 hrs did not have a 
negative effect on cell viability (Fig 15J). 
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FIGURE 15: Tropomyosin, Myo2 and calmodulin are essential for proper accumulation of PrD-
GFP at the IPOD – (A, C) PrD-GFP was induced with galactose for 6 hours in a [PSI+] wild-type strain 
(A) or in a strain containing a deletion of Tpm1 and a C-terminal aid tag in Tpm2 (C), in the absence or 
presence of 20 mM of auxin as indicated. Cells were fixed with PFA and analyzed by fluorescence 
microscopy. (B, D, F, H) Quantification of PrD-GFP foci in the wild-type strain (B) and upon depletion 
of Tpm1/2 (D) or Myo2 (F) or Cmd1 (H) is shown. Frequencies of cells with 1 single focus or more 
than 1 foci are given in %. (E, G) Same experiment as in (C), but in a [PSI+] strain with C-terminal aid-
tag in MYO2 (E) or CMD1 (G). (I) Western blot of the tpm1Δ Tpm2-aid, Myo2-aid and Cmd1-aid 
strains after auxin treatment as in (C, E, and G) with an antibody against an HA-tag present in the aid-
tag. An anti-actin antibody served as loading control. (J) Wild-type (wt), tpm1Δ Tpm2-aid, Myo2-aid 
and Cmd1-aid strains were treated as in (A) prior to serial dilution and a spotting test for cell viability. 
Cells were grown on YPD plates for 2-3 days. Scale bar, 2 µm. 
 
3.2.2. Myo2 and Calmodulin functions are required for the formation 
of ring- and ribbon-shaped aggregates of PrD-GFP 
While PrD-GFP is present at the IPOD in the mature [PrD-GFP+] prion state, the 
protein was found in ring- and ribbon-shaped aggregates during de novo induction of 
the prion state when PrD-GFP was overexpressed in [psi-] cells [65, 167, 177]. 
Therefore, I also tested if auxin-induced depletion of Myo2 and Cmd1 would impair 
the formation of these ring- and ribbon-shaped aggregates. Rings/ribbon-shaped 
PrD-GFP aggregates were induced with galactose for 24 hours in a [psi-] strain [65] 
carrying either an aid tag in Myo2 or Cmd1, in the absence or presence of 20 mM of 
auxin. Upon auxin addition, these mutants did not form proper rings/ribbon-shaped 
aggregates but formed multiple punctate aggregates (Fig 16A top middle and bottom 
right panels). A wild-type (wt) strain (without any aid tag) displaying rings/ribbon-
shaped aggregates of PrD-GFP in [psi-] cells did not show any auxin effect (Fig 16A 
top right panel). The viability was not yet affected by this prolonged presence of auxin 
for 24 hrs (Fig 16B). Together, these data demonstrate that essential components of 
the actin cable -based transport machinery, Myo2, Cmd1 and Tpm1/2, are crucial for 
the formation of ring- and ribbon-shaped aggregates of PrD-GFP.  
 
 
 
 
 
 
 
 
	  
	  
41	  
FIGURE 16: Myo2 and calmodulin are essential for formation of ring- and ribbon-shaped 
aggregates – (A) PrD-GFP was induced with galactose for 24 hours in a 74D-694 [psi-] strain that 
either carried a C-terminal aid-tag in MYO2 and in CMD1 or was wild-type (wt). While one culture was 
left untreated (control, top and bottom left panel), 20 mM of auxin was added for 24 hours during PrD-
GFP induction (top middle, top right and bottom right panel) to the other one. Cells were subsequently 
fixed with PFA and analyzed by fluorescence microscopy as described in the methods. (B) Wild-type 
(wt), Myo2-aid and Cmd1-aid strains were treated as described in (A) before subjecting them to serial 
dilutions followed by a spotting test for cell viability after the auxin treatment. Cells were subsequently 
grown on YPD plates for 2 days at 30 °C. Scale bar, 2 µm. 
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3.2.3.  Washout of auxin restores Myo2 function and causes re-
localization of PrD-GFP aggregates to the IPOD	  
Loss of tropomyosin, Myo2 and Cmd1 function led to formation of multiple PrD-GFP 
foci in the cytoplasm rather than recruiting these aggregates to one single IPOD site. 
If these proteins are involved in the coalescence and recruitment of PrD-GFP 
aggregates to the central IPOD deposition site, washout of auxin should readily 
restore the targeting defect. Since auxin-induced depletion of these functionally 
linked proteins caused a similar multiple PrD-GFP foci phenotype, I focused on Myo2 
in the following experiments. To test if the defect in PrD-GFP localization could be 
restored, I washed out auxin from Myo2-depletd cells that expressed PrD-GFP under 
control of a galactose-inducible promoter and incubated the cells in glucose-based 
media without auxin to monitor the pre-existing multiple PrD-GFP foci. Already after 1 
hour of auxin removal, 93% of the cells had one single PrD-GFP IPOD again (Fig 
17A, right panel and 17B). In addition, for further confirmation that all multiple 
fluorescence foci really refused again to one central IPOD rather than being 
degraded, I performed a time-lapse microscopy experiment. In brief, after induction of 
PrD-GFP with galactose and auxin addition, cells were pelleted and placed on an 
agarose pad on a microscope slide without auxin, but with glucose instead of 
galactose. Z-stack images were acquired every 2-5 min over a period of 1 hr. Within 
1 hour of auxin removal in glucose-based media, pre-existing multiple PrD-GFP foci 
directly refused to one central IPOD deposition site (Fig 17C and Fig 17D). This 
suggests that PrD-GFP foci represent transport intermediates that are trapped on the 
way to the IPOD deposition site if the actin–tropomyosin–myosin-based transport 
machinery is impaired.  
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FIGURE 17: Washout of auxin restores Myo2 function and localization of PrD-GFP at the IPOD – 
(A) PrD-GFP was induced with galactose for 6 hours in the presence of 20 mM auxin in a [PSI+] strain 
with a C-terminal aid-tag in MYO2 (left panel). Subsequently, cells were pelleted, resuspended in YPD 
without auxin to rescue Myo2 function and further incubated for 60 min prior to fixation and 
fluorescence microscopy (right panel). (B) Quantification of PrD-GFP localization in either 1 or more 
than 1 foci in % in the absence or presence of 20 mM auxin or after auxin washout (1 hr recovery). (C) 
Microscopy images from a time-lapse microscopy experiment as in A, but after removal of auxin. In 
brief, after induction of PrD-GFP and auxin addition for 6 hours, cells were pelleted and placed onto an 
agarose pad containing glucose instead of galactose on a microscope slide for time-lapse microscopy. 
A z-stack with a step width of 0.3 µm was taken every 2-5 min (D) A single cell from an experiment as 
in C to highlight direct refusion events of PrD-GFP foci. Scale bar, 2 µm.  	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3.2.4.  Myo2 depletion impairs proper recruitment of PrD-GFP to the 
IPOD rather than IPOD integrity 
Myo2 and tropomyosins were shown to deliver different cargoes along actin cables 
during many cellular transport processes [178]. Therefore, the most likely explanation 
for the multiple foci phenotype upon Myo2 depletion was an impaired recruitment of 
PrD-GFP to the central IPOD site. However, at this point of time, I could not exclude 
the possibility that Myo2 and tropomyosins are involved in maintaining the IPOD 
integrity instead recruiting PrD-GFP aggregates to this single IPOD site. In such a 
case, Myo2 depletion would lead to a loss of the integrity of the IPOD and the 
deposition site would fall apart (fragment) into multiple smaller aggregates, which 
would also give the multiple PrD-GFP foci phenotype I observed upon Myo2 and 
Tpm1/2 depletion (see Fig 17A, left panel). Therefore, to differentiate these two 
possibilities, I first pre-formed the PrD-GFP IPOD with galactose induction for 6 hours 
without depleting Myo2, then removed the galactose media and incubated the cells 
with the preformed IPODs in glucose-based media in the presence of auxin to 
deplete Myo2 for 6 more hrs and subsequently monitored the pre-existing single 
IPODs over time for 6 hours. Aliquots were withdrawn every 2 hours (0, 2, 4 and 6 
hours) for fluorescence microscopy (Fig 18A) and cells with one PrD-GFP or multiple 
foci were quantified (Fig 18B). I did not observe any fragmentation/disruption of pre-
existing single PrD-GFP IPOD upon Myo2 depletion, suggesting that Myo2 is 
involved in the recruitment of the PrD-GFP at the IPOD rather than maintaining the 
IPOD integrity. However, I observed that the pre-existing PrD-GFP dot was slowly 
and progressively decaying over time, which is followed up upon and explained in 
more detail in Fig 29A.  
In second set of experiments, I further ruled out the possibility that Myo2 is involved 
in maintaining the IPOD integrity by looking if Moy2 depletion causes immediate 
appearance of multiple PrD-GFP foci or one single and transient IPOD before 
multiple PrD-GFP foci would appear. For testing this idea, I induced PrD-GFP with 
galactose in the presence of auxin for 6 hours.  After 2, 4 and 6 hours, I withdrew 
aliquots for fluorescence microscopy (Fig 18C) and quantified the cells with one or 
multiple PrD-GFP foci (Fig 18D). A great majority of cells showed multiple PrD-GFP 
foci (68% - 78%) at all time points (Fig 18D), strongly favoring the hypothesis that 
Myo2 is involved in the recruitment of the PrD-GFP aggregates to the IPOD rather 
than maintaining IPOD integrity.  
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FIGURE 18: Myo2 depletion impairs proper recruitment of PrD-GFP to the IPOD rather than 
IPOD integrity – (A) PrD-GFP was induced with galactose for 6 hours without auxin in a [PSI+] Myo2-
aid strain to allow for IPOD formation. Subsequently, cells were pelleted and resuspended in YPD 
media with 20 mM auxin and incubated further. Aliquots were withdrawn every 2 hours, fixed and 
analyzed by fluorescence microscopy. (B) Quantification of PrD-GFP localization from experiment A. 
PrD-GFP localization in either 1 or more than 1 foci was determined from cells that still carried PrD-
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GFP aggregates and plotted as %. (C) PrD-GFP was induced with galactose in the presence of 20 
mM auxin in a [PSI+] Myo2-aid strain. After the indicated times, aliquots were withdrawn, fixed and 
analyzed by fluorescence microscopy. (D) Quantification of PrD-GFP localization from experiment C. 
PrD-GFP localization in either 1 or more than 1 foci was determined and plotted as %. Scale bar, 2 
µm.  
 
3.2.5.  Myo2 depletion results in co-accumulation of Atg8 together 
with PrD-GFP foci  
 
Depletion of the Tpm1/2 and Myo2 resulted in a reversible defect in deposition of 
multiple PrD-GFP foci at one single IPOD deposition site near the vacuole. The IPOD 
is known to be in close proximity to the PAS [56, 65] where the cells initiate formation 
of autophagosomes and CVT vesicles [113, 128]. Atg8 was shown to co-localize with 
the IPOD [56]  and was also found to co-localize with PrD-GFP at the IPOD [65]. At 
the same time, it is the most commonly used PAS marker. Atg8 was suggested to be 
recruited to the PAS via the actin cytoskeleton, as disruption of actin filaments by 
Latrunculin A (LatA) blocked Atg8 sorting to the PAS [179]. To understand a possible 
correlation between the IPOD, it’s vicinity to the PAS and the involvement of Myo2 in 
PrD-GFP recruitment to the IPOD, I introduced the PAS marker RFP-Atg8 into a 
Myo2-aid [PSI+] strain with the Gal-inducible PrD-GFP construct and tested if the 
recruitment of Atg8 to the PAS and its co-localization with PrD-GFP aggregates is 
affected upon Myo2 depletion. In short, PrD-GFP was induced with galactose for 6 
hours with or without auxin in the [PSI+] Myo2-aid strain that carried a plasmid coding 
for RFP-Atg8. Cells were fixed with PFA and analyzed by fluorescence microscopy in 
the GFP and mCherry channels. In the absence of auxin, 79 % of the single PrD-
GFP IPODs showed a co-localization with Atg8 PAS marker, as expected [56, 65] 
(Fig 19A, upper panel). Remarkably, I observed that upon Myo2 depletion, RFP-Atg8 
formed multiple foci, which co-localized with the multiple PrD-GFP foci in 89 % of the 
case (Fig 19A, lower panel). This result left two possibilities: First, PrD-GFP 
aggregates could have attracted/co-aggregated the PAS marker proteins, as 
amyloids tend to be sticky [180], and due to the multiple PrD-GFP foci phenotype, I 
observed multiple PAS marker foci. Secondly, recruitment of Atg8 to the PAS also 
depends on Myo2 based transport along actin cables and both, PrD-GFP and RFP-
Atg8, use a similar recruitment machinery (track) to accumulate at the neighboring 
IPOD and PAS respective sites. Consequently, the PAS marker would co-accumulate 
with the multiple PrD-GFP foci. To differentiate between these two possibilities, I 
applied two independent approaches. In the first approach, I incubated the PrD-GFP 
and RFP-Atg8 expressing Myo2-aid strain with 5 mM GdnHCl, which abolishes the 
prion state (termed curing) and leads to diffuse PrD-­‐GFP fluorescence throughout the 
cytoplasm [65, 66]. The cured cells still formed one RFP-Atg8 focus in the absence of 
auxin (Fig 19B, upper panel), whereas Myo2-depleted cured cells showed multiple 
RFP-Atg8 foci (Fig 19B, lower panel), suggesting that PrD-GFP and RFP-Atg8 foci 
can be formed independently. In the second approach, I introduced a galactose-
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inducible genomic N-terminal GFP fusion to endogenous Atg8 in a Myo2-aid [PSI+] 
strain that did not express any PrD-GFP. Multiple GFP-Atg8 fluorescent foci (Fig 
19C, middle panel) were observed upon Myo2 depletion for 6 hours with auxin in this 
strain, which were subsequently refused to one PAS focus after auxin washout (Fig 
19C, right panel and Fig 19D). In addition, a clear and direct re-fusion event of pre-
existing multiple GFP-Atg8 foci was monitored by time-lapse microscopy immediately 
after removal of auxin (Fig 19E), suggesting that the PAS marker RFP-Atg8 forms 
multiple foci upon Myo2 depletion independently of the IPOD or the PrD-GFP 
substrate.  
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FIGURE 19: Myo2 depletion results in co-accumulation of RFP-Atg8 together with PrD-GFP foci 
– (A) PrD-GFP was induced with galactose for 6 hours in the absence or presence of 20 mM auxin in 
a [PSI+] Myo2-aid strain that carried a plasmid coding for RFP-Atg8. Cells were fixed with PFA and 
analyzed by fluorescence microscopy in the GFP and mCherry channels. Co-localization: –auxin: 79 
%, n=114 foci; +auxin: 89 %, n=96 foci. (B) Same experiment as in (A) in the same strain after curing 
of the [PSI+] prion with GdnHCl. (C) Same experiment as in (A), but in a [PSI+] Myo2-aid strain that did 
not express PrD-GFP, but GFP-Atg8 as a genomic fusion under control of the Gal1 promoter. In brief, 
GFP-Atg8 was induced with galactose for 6 hours in the absence or presence of 20 mM auxin. 
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Subsequently, cells were pelleted, resuspended in YPD without auxin to restore Myo2 function and 
incubated further for 60 min (auxin washout, right panel) prior to fixation and fluorescence microscopy. 
(D) Quantification of GFP-Atg8 foci in the absence or presence of auxin or after auxin washout (1 hr 
recovery). Frequencies of cells with 1 single focus or more than 1 foci are given in %. (E) Microscopy 
images from a time-lapse microscopy experiment as in C, but after removal of auxin. In brief, after 
induction of GFP-Atg8 and auxin addition for 6 hours, cells were pelleted, resuspended in YPD in the 
absence of auxin to restore Myo2 function and placed onto a microscope slide with an agarose pad for 
time-lapse microscopy. Z-stacks with a step width of 0.2 µm were acquired every 4 min. Scale bar, 2 
µm.   	  
 
3.2.6 Myo2 depletion results in co-accumulation of preApe1 
together with PrD-GFP foci  
 
After my observation that Myo2 depletion impairs the sorting of Atg8 to the PAS site, I 
wondered how preApe1, a substrate of the CVT pathway, is affected by Myo2 
depletion. Precursor preApe1 is sorted to the PAS along actin cables [114]. At the 
PAS, preApe1 accumulates as multimeric complex and is enwrapped into the double-
membrane CVT vesicles that subsequently fuse with the vacuolar membrane and 
deliver preApe1 into the lumen for its maturation (See the Fig 7). Therefore, for 
testing the effect of Myo2 depletion on this CVT substrate, I introduced a preApeI-
mCherry fusion into Myo2-aid [PSI+] cells expressing galactose-inducible PrD-GFP 
and performed a similar experiment as described in Fig19A. For this, PrD-GFP was 
induced with galactose for 6 hours with or without auxin in this strain. Fixed cells 
were analyzed by fluorescence microscopy in the GFP and mCherry channels. In the 
absence of auxin, 60 % of single PrD-GFP IPODs showed a co-localization with 
preApe1 PAS marker (Fig 20A, upper panel) while upon Myo2 depletion, 65 % of 
multiple PrD-GFP foci co-localized with multiple preApe1-mCherry foci (Fig 20A, 
lower panel). Here, I expected co-localization of almost all PrD-GFP IPODs with a 
preApe1 PAS marker focus [56, 65] just as with with RFP-Atg8 (compare Fig 19A). 
The lower degree of co-localization (only 60 %) compared to RFP-Atg8 was perhaps 
due to the following reasons: (I) interference of the mCherry tag with the preApe1 
structure/conformation that led to failure of targeting to the PAS (II) the preApre1-
mCherry fusion was present in low amounts such that the accumulation of preApe1 
at the PAS could be detected technically in every cell.  
Next, I further validated that preApe1 is mistargeted upon Myo2 depletion in the 
absence of any potentially sticky PrD-GFP amyloid aggregates. For testing this, I 
generated a galactose-inducible genomic N-terminal GFP-preApe1 fusion in a Myo2-
aid [PSI+] strain that did not express any PrD-GFP. 49 % of the cells (Fig 20C) 
showed multiple GFP-preApe1 fluorescent foci (Fig 20B, right panel) after Myo2 
depletion compared to the control cells without auxin (Fig 20B, left panel), suggesting 
that Myo2 is required for sorting the CVT substrate preApe1 to the PAS.  
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FIGURE 20: Myo2 depletion results in co-accumulation of preApe1-mCherry together with PrD-
GFP foci – (A) PrD-GFP was induced with galactose for 6 hours in the absence or presence of 20 mM 
auxin in a [PSI+] Myo2-aid strain with a genomic C-terminal mCherry fusion to preApe1. Cells were 
fixed with PFA and analyzed by fluorescence microscopy in the GFP and mCherry channels. Co-
localization of existing PrD-GFP foci with at least 1 preApe1-mChery focus: –auxin: 60 %, n=98 foci; 
+auxin: 65 %, n=234 foci.  (B) Same experiment as in (A), but in a [PSI+] Myo2-aid strain that did not 
express PrD-GFP, but a genomic N-terminal GFP fusion to preApe1 controlled by a Gal promoter. (C) 
Quantification of GFP-preApe1 foci upon depletion of Myo2 is shown in the right panel. Frequencies of 
cells with 1 single focus or more than 1 foci are given in %. Scale bar, 2 µm.     
	  
	  
3.2.7.   Myo2 is also essential for proper accumulation of different 
amyloid substrates (Rnq1, Ure2 and Htt103Q) at the IPOD 
Since Myo2 is involved in sorting of both, the IPOD substrate PrD-GFP to the IPOD- 
and the CVT pathway substrate preApe1 to the adjacent PAS destination site, I 
wondered whether Myo2 is also required for targeting of additional bona fide IPOD 
substrates such as Ure2, Rnq1 and HttQ103 [56] to the IPOD? For exploring this, I 
repeated a similar experiment as compared to PrD-GFP (compare Fig 15) by 
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introducing galactose-inducible Rnq1-GFP, Ure2-YFP and Htt103Q-CFP constructs 
into Myo2-aid mutants in [PSI+] cells instead of PrD-GFP. In brief, I induced the 
corresponding IPOD substrates with galactose for 6 hours in a [PSI+] Myo2-aid strain 
or a wild-type (wt) strain, in the absence or presence of auxin and withdrew aliquots 
for fluorescence microscopy. Subsequently, cells were resuspended in YPD (glucose 
chase) without auxin and incubated further for 60 min (auxin washout) prior to PFA 
fixation and fluorescence microscopy. All corresponding Myo2-aid strains expressing 
these IPOD substrates displayed one single IPOD in the absence of auxin (no Myo2 
depletion), but a multiple foci phenotype upon auxin-based depletion of Myo2, just 
like PrD-GFP did auxin (Fig 21A, E, and I, middle panels). The control strains without 
the Myo2-aid tag did not show any multiple foci phenotypes, confirming again that the 
observed effect was due to the depletion of Myo2 (Fig 21C,D, G, H, K and L). These 
pre-existing multiple foci of different IPOD substrates were again refused to one 
central IPOD after removal of auxin (Fig 21A, E, and I, auxin washout panels), 
suggesting that Moy2 is involved in general in the recruitment of different IPOD 
substrates to the IPOD.  
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FIGURE 21: Myo2 is also essential for proper accumulation of different amyloid substrates 
(Rnq1, Ure2 and Htt103Q) at the IPOD – (A, C) Rnq1-GFP (integrated into genome) was induced 
with galactose for 6 hours in a [PSI+] strain with a C-terminal aid-tag in MYO2 (left and middle panel) 
(A) or a wild-type (wt) strain (C), in the absence or presence of 20 mM of auxin as indicated. 
Subsequently, cells were pelleted, resuspended in YPD (glucose chase) without auxin to restore Myo2 
function and incubated further for 60 min [auxin washout, right panel, (A)] prior to fixation and 
fluorescence microscopy. (B, D) Quantification of Rnq1-GFP foci upon depletion of Myo2 (B) or in the 
wild-type (wt) (D) is shown. Frequencies of cells with 1 single focus or more than 1 foci are given in %. 
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(E, G) Same experiment as in (A), but in a [PSI+] Myo2-aid strain (E) or a wild-type strain (G) with a 
Ure2-YFP construct integrated into the genome under control of the Gal1 promoter. (F, H) 
Quantification of Ure2-YFP foci upon depletion of Myo2 (F) or in the wild-type (H) is shown. 
Frequencies of cells with 1 single focus or more than 1 foci are given in %. (I, K) Same experiment as 
in (A), but in a [PSI+] Myo2-aid strain (I) or a wild-type strain (K) with a Htt103Q-CFP construct 
integrated into the genome under control of the Gal1 promoter. (J, L) Quantification of Htt103Q-CFP 
foci upon depletion of Myo2 (J) or in the wild-type (L) is shown. Frequencies of cells with 1 single focus 
or more than 1 foci are given in %. Scale bar, 2 µm.  	  
	  
3.2.8.  Depletion of Myo2 impairs proper recruitment of IPOD 
substrates (Rnq1, Ure2 and Htt103Q) to the IPOD rather than the 
integrity of the IPOD 
In Fig 21, I showed that Moy2 is required in general for sorting of different IPOD 
substrates to the IPOD. To confirm that Moy2 is required for recruitment of these 
different substrates to the IPOD rather than being required for maintaining IPOD 
integrity (compare Fig 18), I performed a similar experiment with galactose-inducible 
Rnq1-GFP in a [PSI+] Myo2-aid strain as shown for PrD-GFP in Fig 18A. In brief, I 
first pre-formed the single Rnq1-GFP IPOD with galactose without Myo2 depletion 
and subsequently monitored this pre-existing single IPOD for 6 hours in glucose-
based media containing auxin to deplete Myo2. I withdrew aliquots every 2 hours for 
fluorescence microscopy (Fig 22A) and quantified the cells with one or multiple Rnq1-
GFP foci (Fig 22B). Again, I did not observe any fragmentation of pre-existing single 
Rnq1-GFP IPODs upon Myo2 depletion, suggesting that Myo2 is involved in sorting 
the Rnq1-GFP aggregates to the IPOD rather than in maintaining IPOD integrity.  
Next, I asked whether two different IPOD markers expressed in the same cell are 
recruited simultaneously to the same IPOD site. For this, I used a [PSI+] Myo2-aid 
strain expressing galactose-inducible Ure2-YFP and Htt103Q-CFP. I induced both 
substrates with galactose for 6 hours in the absence or presence of 20 mM auxin. 
After auxin-based Myo2 depletion, I observed multiple foci of both Ure2-YFP and 
Htt103Q-CFP markers (Fig 22C, middle panel) that co-localized with each other, 
while without auxin, the cells showed one IPOD with both substrates as expected [56, 
65] (Fig 22C, upper panel). Interestingly, these pre-existing multiple foci of the two 
IPOD substrates Ure2 and Htt103Q sorted back to one central IPOD after restoration 
of Myo2 function by auxin washout (Fig 22C, lower panel). From these data, it is 
concluded that Myo2-based transport along actin cables is crucial for sorting different 
amyloids substrates to the IPOD instead of maintaining the IPOD morphology.  
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FIGURE 22: Depletion of Myo2 impairs proper recruitment of IPOD substrates (Rnq1, Ure2 and 
Htt103Q) to the IPOD rather than interfering with maintenance of the IPOD integrity – (A) Rnq1-
GFP was induced with galactose for 6 hours in the absence of auxin in a [PSI+] Myo2-aid strain. 
Subsequently, cells were pelleted and resuspended in YPD media in the presence of 20 mM auxin 
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and incubated further. Aliquots were withdrawn every 2 hours, fixed and analyzed by fluorescence 
microscopy. (B) Quantification of Rnq1-GFP foci from experiment A. Rnq1-GFP localization in either 1 
or more than 1 foci was determined from cells that still carried Rnq1-GFP aggregates and plotted as 
%. (C) Co-localization of Ure2-YFP with Htt103Q-CFP. Both Ure2-YFP and Htt103Q-CFP in the same 
strain were induced with galactose for 6 hours in the absence or presence of 20 mM auxin in a [PSI+] 
Myo2-aid strain (upper and middle panel). Subsequently, cells were pelleted, resuspended in YPD 
without auxin to restore Myo2 function and incubated further for 60 min (auxin washout, bottom panel) 
prior to fixation and fluorescence microscopy. Co-localization: –auxin, +auxin and auxin washout: 100 
%, n=100-150 foci. Scale bar, 2 µm.      
	  
3.2.9.  Myo2 depletion results in co-accumulation of Atg9 with PrD-
GFP foci	  
Recruitment of preApe1, a substrate of the CVT pathway, involves formation of the 
so called CVT complex. The CVT complex consists of preAp1 and its receptor Atg19 
[114]. It is loaded onto Atg9 transport vesicles and moves to the PAS along actin 
cables [114] in normal growth conditions. Atg9 is a multispanning transmembrane 
protein which exists in small cytoplasmic membrane vesicles termed as Atg9 vesicles 
[181] (see Fig7). Thus, disruption of actin filaments blocks the transport of both 
preApe1 and Atg9 vesicles to the PAS [179]. However, the linkage between these 
transport vesicles and actin cytoskeleton is unknown. At the PAS, preApe1 is 
enwrapped into the double-membrane CVT vesicles that subsequently deliver 
preApe1 into the lumen of the vacuole for its maturation (see Fig 7 for detail). Since 
PrD-GFP and preApe1 both use a similar targeting route for their sorting to the IPOD 
and PAS respectively, I wondered if PrD-GFP aggregates may also be associated 
with such Atg9 vesicles during recruitment to the IPOD deposition site. For testing 
this hypothesis, I labeled Atg9 with 3X-mCherry and introduced it into the previously 
used [PSI+] Myo2-aid strain expressing galactose-inducible PrD-GFP and performed 
a co-localization experiment. In the autophagy field, it is known that there is a large 
pool of Atg9 vesicles in the cytoplasm, but only a subfraction of this pool co-localizes 
with the preApe1 PAS marker [182].  Atg9 vesicles also co-localize with Atg8 during 
the PAS formation [183]. PrD-GFP was induced with galactose for 6 hours in the 
absence or presence of 20 mM auxin in a [PSI+] Myo2-aid strain that carried a C-
terminal 3xmCherry-tag in the endogenous ATG9. Cells were fixed with PFA and 
analyzed by fluorescence microscopy in the GFP and mCherry channels. In the 
absence of auxin, 78 % of the single PrD-GFP IPODs showed co-localization with at 
least one of the multiple foci representing the pool of Atg9- 3X-mCherry (Fig 23, 
upper panel). Upon Myo2 depletion, I observed many more Atg9- 3X-mCherry foci. 
Nevertheless, 77 % of the multiple PrD-GFP foci observed under these conditions 
had at least one Atg9- 3X-mCherry focus co-localizing to them (Fig 23, lower panel). 
These above data suggest that PrD-GFP aggregates are associated with Atg9 
transport vesicles, just like preApe1 is [182]. Thus these transport vesicles likely 
deliver both cargos to their destination sites, IPOD and PAS respectively, using the 
same targeting route, i.e. actin cables.  	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FIGURE 23: Myo2 depletion results in co-accumulation of Atg9 with PrD-GFP foci – PrD-GFP 
was induced with galactose for 6 hours in the absence or presence of 20 mM auxin in a [PSI+] Myo2-
aid strain with a C-terminal 3xmCherry-tag in the endogenous ATG9. Cells were fixed with PFA and 
analyzed by fluorescence microscopy in the GFP and mCherry channels. Co-localization of existing 
PrD-GFP foci with at least 1 Atg9-3xmCherry focus: –auxin: 78 %, n=116 foci; +auxin: 77 %, n=205 
foci. Scale bar, 2 µm.      
 
3.2.10.   Depletion of Sec14, Sec18 and Sec21 also impairs the 
recruitment of PrD-GFP to the IPOD 
Recently, it was shown that Sec proteins (Sec18 and Sec53) are required for 
asymmetric inheritance of Htt103Q and heat-induced protein aggregates together 
with Myo2/Cmd1/actin [139]. Since I also fished with immobilized PrD several Sec 
proteins (Sec4, Sec14, Sec18, Sec21, and Sec53) from yeast cell lysates (compare 
Fig 13), I decided to also investigate their possible role in the recruitment of the PrD-
GFP aggregates to the IPOD. Sec4 is Rab family GTPase which associates with 
secretory vesicles and is involved in their polarized transport towards the site of cell 
growth  in a Myo2-dependent manner along actin cables [184]. Sec4 is also involved 
in the transport of Atg9 vesicles to the PAS during autophagy/CVT pathway [185]. 
Sec14 is a phosphatidylcholine/phosphatidylinositol (PI/PC) transfer protein that is 
required for the transport of trans-Golgi-derived vesicles as well as for autophagy 
[186]. Sec18, a SNARE [SNAP (Soluble NSF (N-ethylmaleimide-sensitive factor) 
Attachment Protein REceptor] disassembly chaperone is required for several 
vesicular fusion events such as homotypic vacuole fusion and translocation of 
preApe1 into the vacuole [182, 187]. Sec18 has also been shown to be involved in 
the trafficking of Atg9 vesicles from peripheral sites to the PAS along with several 
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SNARE proteins such as Sso1/2, Sec9, Tlg2, Ykt6 and Sec22 [182]. Sec21, a COPI 
coatomer protein was found to associate with Vid (vacuole import and degradation) 
vesicles to deliver inactive fructose-1,6-bisphosphatase (FBPase) into the vacuolar 
lumen for its degradation [188].  
Since all these Sec proteins (Sec4, Sec14, Sec18, Sec21 and Sec53) are essential, I 
applied the same auxin-based depletion system [172] to greatly deplete their levels 
temporally and monitored the distribution of PrD-GFP aggregates. I tested all Sec 
proteins except for Sec4, whose auxin-based depletion did not work due to technical 
reasons. However, I was able to observe the depletion effect of Sec14, Sec18, 
Sec21 and Sec53 proteins on PrD-GFP sorting to the IPOD. In short, I induced PrD-
GFP with galactose for 6 hours in the absence and presence of auxin in [PSI+] 
Sec14/18/21/53-aid strains. In response to auxin, I observed a similar reversible 
multiple PrD-GFP foci phenotype as observed with Myo2 depletion in most of the 
cells (70 % in the Sec14-aid strain, 83% in the Sec18-aid strain and 74 % in the 
Sec21-aid strain) (Fig 24 A-F). Since these proteins are known to be involved in 
vesicular transport processes, these results suggested that efficient recruitment of 
PrD-GFP to the IPOD involves vesicular transport. This would be consistent with a 
function of Myo2 in vesicle transport along actin cables, that has been described for 
other vesicular transport processes already [189]. Restoration of Sec14, Sec18 and 
Sec21 functions by auxin washout led to refusion of all pre-existing multiple foci to 
one central IPOD (Fig 24A, Fig 24C and Fig 24E, right panels). Depletion of Sec14, 
Sec18 and Sec21 was confirmed by Western Blot analysis with an antibody against 
an HA tag attached to the “aid” degron tag (Fig 24I). Short-term depletion of these 
proteins, such as Sec14 and Sec18 for 6 hrs had no effect on cell viability (Fig 24J). 
Taken together, above data suggest that Sec14, Sec18 and Sec21 are involved in 
proper targeting of PrD-GFP amyloids to the IPOD site. In case of the Sec53-aid 
strain, I did not observe any sorting defect for PrD-GFP aggregates (Fig 24G, right 
panel). I note, however, that the degree of depletion for this protein was very low (Fig 
24 I). This suggests that Sec53 is either not involved in sorting of PrD-GFP 
aggregates to the IPOD or that its depletion was just not sufficient to display a 
phenotype (Fig 24I). 
 
 
 
 
 
 
 
 
	  
	  
58	  
 
 
FIGURE 24: Depletion of Sec14, Sec18 and Sec21, but not Sec53, impairs the recruitment of 
PrD-GFP to the IPOD – (A, C, E) PrD-GFP was induced with galactose for 6 hours in the absence or 
presence of 20 mM auxin (left and middle panels) in a [PSI+] strain with a C-terminal aid-tag in SEC14 
(A) or SEC18 (C) or SEC21 (E) and aliquots were withdrawn for fluorescence microscopy analysis. 
Subsequently, cells were pelleted, resuspended in YPD (glucose chase) without auxin and incubated 
further for 60 min to restore Sec14, Sec18 and Sec21 functions (auxin washout, right panels) prior to 
PFA fixation and fluorescence microscopy. (B, D, F, H) Quantification of PrD-GFP foci upon depletion 
of Sec14 (B), Sec18 (D), Sec21 (F) or Sec53 (H) is shown. Frequencies of cells with 1 single focus or 
more than 1 foci are given in %. (G) Same experiment as in (A), but in a [PSI+] strain with a C-terminal 
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aid-tag in SEC53. The experiment was performed without auxin washout. (I) Western blot analysis of 
the [PSI+] Sec14-aid, Sec18-aid, Sec21-aid and Sec53-aid strains without (-Aux) or after depletion of 
Sec14, Sec18, Sec21 and Sec53 (+Aux) with an antibody against an HA-tag present in the aid-tag. An 
anti-actin antibody served as loading control. (J) A [PSI+] wild-type (wt), Sec14-aid and Sec18-aid 
strains were treated as described in (A, C) before serial dilution and spotting onto YPD plates and 
growth for 2 days to test for viability. Scale bar, 2 µm.   
	  
3.2.11.   Sec18 depletion results in co-accumulation of multiple 
mCherry-Atg8 foci together with PrD-GFP foci 
Trafficking of Atg9 vesicles from peripheral sites to the PAS requires several SNARE 
proteins such as Sso1/2, Sec9, Tlg2, Ykt6 and Sec22 including Sec18 SNARE 
chaperone [182]. From my fishing approach, Sec18, a SNARE disassembly 
chaperone was found to bind PrD fibers in vitro (see Fig13). Sec18 is involved in 
several cellular processes such as: (I) ER to Golgi trafficking (secretory pathway) 
[190]; (II) endocytic pathway [191]; (III) homotypic vacuole fusion and vesicular fusion 
events [192]; (IV) autophagy [182]. I found evidence that PrD-GFP aggregates are 
associated with such Atg9 vesicles during their recruitment to the IPOD (see Fig 23). 
Interestingly, I found that Sec18 SNARE-mediated vesicular transport is required for 
reversible accumulation of PrD-GFP aggregates at the IPOD (see Fig 24C). Since I 
observed that PrD-GFP and PAS proteins use a similar machinery for their 
recruitment to the IPOD and PAS, respectively, I wondered whether Sec18 also 
mediates sorting of PAS markers to the PAS.  
To investigate this, I transformed the mCherry-Atg8 PAS marker into [PSI+] Sec18-
aid strain expressing galactose-inducible PrD-GFP and asked if Atg8 sorting to the 
PAS and its co-localization with PrD-GFP aggregates is impaired upon Sec18 
depletion. In the absence of auxin, 76 % of single PrD-GFP IPODs showed a co-
localization with the Atg8 PAS marker, as expected [56, 65] (Fig 25A, upper panel). 
More interestingly, auxin-based depletion of Sec18 also caused multiple mCherry-
Atg8 foci which were further co-localized with 79 % of the multiple PrD-GFP foci (Fig 
25A, lower panel). However, to further rule out the possibility that multiple mCherry-
Atg8 foci phenotype was a consequence of co-aggregation of the PAS marker with 
potentially sticky PrD-GFP aggregates, I cured this strain with 5 mM GdnHCl to 
abolish the prion state in PrD-GFP and repeated the same experiment (compare Fig 
19B). After curing, these cells still formed one mCherry-Atg8 focus in the absence of 
auxin (Fig 25B, upper panel), whereas Sec18-depleted, cured cells showed multiple 
mCherry-Atg8 foci (Fig 25B, lower panel), suggesting that PrD-GFP and mCherry-
Atg8 do not co-aggregate, but form multiple foci independently of each other. 
Furthermore, auxin-based Sec18 depletion also caused reversible multiple GFP-Atg8 
fluorescent foci in 76 % of the cells (Fig 25C, middle panel and Fig 25D) when a 
galactose-inducible genomic N-terminal GFP-Atg8 fusion was used in a Sec18-aid 
[PSI+] strain without any PrD-GFP. These GFP-Atg8 foci were re-localized to one 
PAS focus after auxin removal (Fig 25C, right panel).  
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FIGURE 25: Sec18 depletion results in co-accumulation of multiple mCherry-Atg8 foci together 
with PrD-GFP foci – (A) PrD-GFP was induced with galactose for 6 hours in the absence or presence 
of 20 mM auxin in a [PSI+] Sec18-aid strain with a plasmid carrying an N-terminal mCherry-Atg8 fusion 
under control of the Atg8 promoter prior to fixation and fluorescence microscopy in the GFP and 
mCherry channels. Co-localization of PrD-GFP foci with mCherry-Atg8 foci: –auxin: 76 %, n=105 foci; 
+auxin: 79 %, n=108 foci. (B) Same experiment as in (A) in the same strain after curing of the [PSI+] 
prion with GdnHCl. V=vacuole (C) Same experiment as in (A), but in a [PSI+] Sec18-aid strain that did 
not express PrD-GFP, but GFP-Atg8 as a genomic fusion under control of the Gal1 promoter. In brief, 
GFP-Atg8 was induced with galactose for 6 hours in the absence or presence of 20 mM auxin. 
Subsequently, cells were pelleted, resuspended in YPD without auxin and incubated further for 60 min 
to restore Sec18 function (auxin washout, right panel) prior to fixation and fluorescence microscopy. 
(D) Quantification of GFP-Atg8 foci in the absence or presence of auxin or after auxin washout (1 hr 
recovery). Frequencies of cells with 1 single focus or more than 1 foci are given in %. Scale bar, 2 µm.    
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3.2.12.   Sec18 depletion leads to co-localization of Myo2 with PrD-
GFP foci 
Impairment of the actin-based transport machinery by depleting Myo2 and Tpm1/2 
blocked proper recruitment of PrD-GFP and the PAS markers Atg8 and preApe1 to 
their adjacent destination sites, IPOD and PAS, respectively (see Fig 19 and 20). 
Furthermore, I found evidence that PrD-GFP and the PAS markers are loaded onto 
Atg9 vesicles (compare Fig 23). It is known that vacuolar vesicles/lobes are moved 
and inherited from the mother to daughter cells with the aid of Myo2 motor protein 
and specific adaptors/receptors along actin cables [193]. Therefore, I hypothesized 
that Myo2 might be the linking factor between the vesicular transport machinery and 
the actin cytoskeleton. Therefore, I tested whether Myo2 is present in PrD-GFP 
transport intermediates after Sec18 depletion. For that, I tagged the genomic copy of 
Myo2 with 3xmCherry in a [PSI+] Sec18-aid strain expressing galactose-inducible 
PrD-GFP. Then, I induced PrD-GFP with galactose for 6 hours in the absence or 
presence of 20 mM auxin. After induction, I fixed the cells with and analyzed by 
fluorescence microscopy in the GFP and mCherry channels. The control cells without 
auxin showed a diffuse fluorescence of Myo2-3xmCherry (Fig 26A, upper panel), 
while after Sec18 depletion, Myo2-3xmCherry formed foci-like structures that co-
localized in 74 % of the cases with the multiple PrD-GFP aggregates (Fig 26A, lower 
panel). From this, I concluded that Myo2 links the Atg9-vesicle based transport 
machinery to tropomyosin-coated actin cables to deliver PrD-GFP and preApe1 
substrates to their recruitment sites IPOD and PAS, respectively.  
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FIGURE 26: Sec18 depletion leads to co-localization of Myo2 structures with PrD-GFP foci – 
PrD-GFP was induced with galactose for 6 hours in the absence or presence of 20 mM auxin in a 
[PSI+] Sec18-aid strain with a C-terminal 3xmCherry-tag in the endogenous MYO2. Cells were fixed 
with and analyzed by fluorescence microscopy in the GFP and mCherry channels. Co-localization of 
existing PrD-GFP foci with Myo2-mCherry structures: +auxin: 74 %, n=238 foci. Scale bar, 2 µm.      
 
 
3.3.    Investigating the fate of amyloid aggregates at the 
IPOD 
 
3.3.1.   PrD-GFP is not turned over via bulk autophagy  
I observed that PrD-GFP aggregates are recruited to the IPOD using a similar 
vesicular transport machinery as preApe1 employs for its transport to the PAS. Not 
surprisingly then, both IPOD and PAS exist in close proximity to each other, because 
they seem to use the same tracks. At the PAS, preApe1 is enwrapped by a double-
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membrane vesicle to form the CVT vesicle which subsequently delivers preApe1 into 
the vacuolar lumen for its maturation [127]. Therefore, I wondered if PrD-GFP 
amyloid aggregates are recruited in close proximity to the PAS for their enwrapping 
into double-membrane autophagosomes and possible autophagy-mediated turnover. 
This would resemble the situation in mammalian cells where aggresomes are 
degraded by autophagy [122]. For testing this idea, I used a strain that constitutively 
expresses PrD-GFP and accumulates PrD-GFP aggregates at the IPOD i.e. [PrD-
GFP+] and tested whether the protein levels of PrD-GFP would change when 
autophagy was either inhibited or induced [65]. I also included a strain expressing 
PrD-GFP in the non-prion (soluble) conformation i.e. [prd-gfp-], where PrD-­‐GFP 
shows diffuse fluorescence throughout the cytoplasm. This served as a positive 
internal control for successful induction of autophagy for the following reason: 
Induction of bulk autophagy results in enwrapping of random parts the cytoplasm into 
autophagosomes and degradation in the vacuole [113, 194]. In the strain with soluble 
PrD-GFP dispersed throughout the cytoplasm, some of the PrD-GFP should also be 
incorporated into autophagosomes along with the random parts of the cytoplasm and 
degraded in the vacuole. Since GFP that is released from GFP fusion proteins is 
quite stable in the vacuolar lumen [126, 195, 196], this should result in emergence of 
free GFP and reduced levels of PrD-GFP. After autophagy induction with 4 mM 
spermidine [197], I observed indeed a slight decrease in the PrD-GFP levels and the 
release of free GFP moiety in the [prd-gfp-] strain (Fig 27A, lane 4) compared to the 
untreated wild-type cells (Fig 27A, lane 2), confirming that autophagy was induced 
successfully. If PrD-GFP aggregates were also turned over via autophagy, then the 
steady state levels of PrD-GFP should also decrease in the strain where the protein 
is aggregated and deposited at the IPOD, and a band of free GFP should emerge. 
However, upon autophagy induction, I could not observe such an appearance of the 
free GFP moiety or a change in the PrD-GFP levels (Fig 27A, lane 3). Thus PrD-GFP 
aggregates are not turned over in the vacuole to a detectable degree. When, I 
inhibited autophagy by adding 1 mM of PMSF in pep4 mutant background [119] of 
both strains, I did not see any increased PrD-GFP level in [PrD-GFP+] (Fig 27A, lane 
5) and [prd-gfp-] strain (Fig 27A, lane 6), again arguing that there is no significant 
turnover of PrD-GFP aggregates in the vacuole under steady state conditions. In 
second experiment, I deleted essential components of the autophagy machinery 
[119], and looked whether these mutants show a difference in the steady-state level 
of PrD-GFP compared to wild-type (wt). In these mutants, I observed neither a 
significant difference in the levels of PrD-GFP compared to the wild-type cells (Fig 
27B) nor in the morphology/intensity of PrD-GFP IPOD (Fig 27C). These above data 
suggest that PrD-GFP IPOD is not turned over via bulk autophagy in yeast. 
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FIGURE 27:PrD-GFP is not turned over by bulk pathway – (A) Strains expressing PrD-GFP 
constitutively under control of the GPD promoter with a deletion in the endogenous prion domain in 
SUP35 were either in the prion state [PrD-GFP+] or in the non-prion state [prd-gfp-]. The PEP4 gene 
was deleted as indicated. Strains were grown to saturation, diluted to an OD600 of 0.15 and were 
further incubated untreated or in the presence of 4 mM spermidine (autophagy induction) or 1 mM 
PMSF (inhibition of vacuolar peptidases, no autophagic turnover of proteins) as indicated. After ~4 
hours, cells were harvested, adjusted to identical cell numbers and subjected to Western Blot analysis 
using an anti-GFP antibody. Turnover of PrD-GFP is monitored by release of free GFP moiety. An 
antibody against actin was used as loading control. (B) Yeast strains as in (A) that propagated PrD-
GFP in the prion state ([PrD-GFP+]) but carried a different deletion in autophagy-related genes as 
indicated, were grown to logarithmic growth phase, adjusted to identical cell numbers and analyzed by 
Western Blotting with an anti-GFP antibody and an anti-actin antibody as loading control. (C) Same as 
(B) where logarithmic growth phase cells were fixed and subjected to fluorescence microscopy. Scale 
bar, 2 µm.     
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Role of substrates of the CVT pathway (preApe1 and Ams1) and different CVT 
pathway components (Atg9, Atg11 or Atg19) on PrD-GFP sorting to the IPOD  
Both preApe1 and PrD-GFP aggregates use a similar actin-mediated Atg9 vesicle-
based transport machinery for their recruitment at the IPOD and PAS, respectively. 
Loading of the CVT substrate preApe1 to the Atg9 vesicles is mediated by a specific 
receptor termed Atg19, and the adaptor Atg11 [114, 116, 127]. It was shown that 
another vacuolar hydrolase, α-mannosidase (Ams1) also employs the same CVT 
pathway as preApe1 to enter into the vacuole [127]. Therefore, I also tested whether 
any substrate of the CVT pathway or its receptor/adaptor is required for targeting of 
PrD-GFP aggregates to the IPOD. For testing these components of the CVT 
pathway, I deleted these genes in a [PSI+] strain expressing galactose-inducible PrD-
GFP. Then, I induced PrD-GFP with galactose for 6 hours in a [PSI+] wild-type (wt) 
strain and deletion mutants of the components of the CVT pathway. However, these 
mutants did not show any difference in the morphology/intensity of PrD-GFP IPOD 
compared to the wild-type cells (Fig 28). These above data show that no CVT 
pathway components are required for recruitment of PrD-GFP to the IPOD. 
 
FIGURE 28: Neither the substrates of the CVT pathway (preApe1 and Ams1) nor different CVT 
pathway components (Atg9, Atg11 or Atg19) are crucial for PrD-GFP sorting to the IPOD – PrD-
GFP was induced with galactose for 6 hours in a [PSI+] wild-type (wt) strain or an identical strain, but 
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with the indicated deletions in CVT pathway substrates/components. Cells were fixed with PFA and 
analyzed by fluorescence microscopy. Scale bar, 2 µm. 
 
3.3.2.   PrD-GFP is slowly extracted from the IPOD by Hsp104 and 
progressively decays over time 
 
Although I did not find any evidence for autophagic turnover of PrD-GFP aggregates, 
PrD-GFP IPODs slowly and progressively decayed over time (see Fig 18A) in a 
[PSI+] Myo2-aid strain. To investigate how this decay is mediated, I performed such a 
decay experiment in the wild-type [PSI+] strain expressing galactose-inducible PrD-
GFP. First, I induced formation of the PrD-GFP IPOD with galactose for 6 hours. 
Subsequently, I chased the cells with this pre-existing single IPOD in glucose-based 
media for 8 hours and monitored the fate of the IPOD over time. I observed that the 
IPOD decayed and progressively became smaller and smaller over time (Fig 29A and 
29B). This observation gave a hint that PrD-GFP aggregates are processed from the 
IPOD. In yeast, a well-known amyloid remodeling factor is Hsp104 [198-202], which 
was shown to interact in vivo with different IPOD substrates [167, 203]. To test if PrD-
GFP aggregates at the IPOD are subjected to Hsp104-dependent processing, I 
induced the PrD-GFP IPOD with galactose for 6 hours and again chased the cells 
with this pre-existing IPOD over time in glucose-based media containing 5mM 
GdnHCl to inhibit Hsp104 activity [204]. After Hsp104 inhibition, the PrD-GFP IPOD 
did not decay at all, but retained even after 8 hours of glucose chase (Fig 29C and 
29D). This suggests that PrD-GFP aggregates are extracted by the Hsp104 
disaggregation machinery from the IPOD.   
Next, I wanted to investigate the possible fate of PrD-GFP after extraction from the 
IPOD by Hsp104. One obvious possibility was that extracted PrD-GFP is degraded 
by the proteasome, since PrD-GFP was not degraded to a significant extend by bulk 
autophagy (see Fig 27 A). For testing this, I inhibited the proteasome with MG132 
using a [PSI+] strain with the Gal-inducible PrD-GFP construct that lacks a PDR5 
gene to prevent pumping out of the proteasome inhibitor MG132. With this 
experiment, I also included as a positive control for proteasomal inhibition tGnd1-
GFP as a known substrate for proteasomal degradation [103]. In short, I grew tGnd1-
GFP expressing cells to mid-log phase and added 100 µg/ml of cycloheximide (CHX) 
to stop ongoing synthesis of tGnd1-GFP and further chased the protein for 8 hours in 
the absence and presence of proteasome inhibitor MG132 (Fig 29F, lane 2 and 3). 
After 8 hours of proteasome inhibition by MG132, tGnd1-GFP was greatly stabilized 
(Fig 29F, lane 3). Thus I repeated the PrD-GFP IPOD decay experiment as described 
below. In brief, I first induced formation of the PrD-GFP IPOD with galactose for 6 
hours in a [PSI+] Δpdr5 background strain and subsequently chased this pre-existing 
IPOD in glucose-based media (abolishment of galactose induced expression of PrD-
GFP) in the absence of the proteasome inhibitor MG132 and in the presence of 
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MG132 or GdnHCl. After 8 hours of glucose chase, the levels of PrD-GFP were 
decreased in the absence of MG132 (Fig 29E, lane 2) as compared to the amount 
before the chase (Fig 29E, lane 1), while there was a clearly reduced decrease in 
PrD-GFP levels when I inhibited the proteasome (Fig 29, lane 3). Upon proteasome 
inhibition, however, the PrD-GFP levels did not reach to the levels before the glucose 
chase ("time 0h" of glucose chase) (Fig 29E, lane 1 and lane3), suggesting that 
extracted PrD-GFP is not only degraded by the proteasome. In contrast, after 
Hsp104 inhibition with GdnHCl, the PrD-GFP levels were the same as compared to 
"time 0h" of glucose chase (Fig 29E, lane 4). This was consistent with fluorescence 
microscopy analysis as shown in Fig 29C where also no decay of the PrD-GFP IPOD 
could be observed.  
These above observations suggest that PrD-GFP can be degraded by the 
proteasome and perhaps additional cellular degradation pathways [205], but only 
after its slow and progressive extraction by Hsp104 from the IPOD. Thus 
accumulation of PrD-GFP amyloids at the IPOD might serve a temporary storage 
function when downstream cellular degradation systems are overwhelmed. Such 
temporary storage at the IPOD would sequester potentially toxic amyloids from the 
cytosol. In support of this idea, it was recently shown that non-amyloid substrates 
such as inactive proteasomes are temporally deposited at the IPOD before their 
vacuolar autophagic degradation [155].  
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FIGURE 29: PrD-GFP is slowly extracted from the IPOD by Hsp104 and progressively decays 
over time – (A) PrD-GFP was induced with galactose for 6 hours in a [PSI+] strain to allow for 
deposition of PrD-GFP at the IPOD, pelleted and resuspended in YPD for further incubation. At 
indicated times, aliquots were withdrawn, the OD600 was determined prior to fixation and fluorescence 
microscopy. (B) IPOD decay was determined for the aliquots withdrawn in (A) by plotting of the 
number of cells with aggregates as % of cells with aggregates originally present in the culture at the 
shift to YPD (compare methods for details). (C, D) Same experiment as in (A, B), but after PrD-GFP 
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induction, the cells were resuspended in YPD + 5 mM of GdnHCl (Hsp104 inhibition). (E) PrD-GFP 
IPOD was induced with galactose for 6 hours in a [PSI+] Δpdr5 background strain. Subsequently, the 
PrD-GFP IPOD was chased with glucose for 8 h. At the indicated times, the same volume of culture 
was withdrawn (compare methods in section 5.4.5. for details) and analyzed by Western Blotting with 
an antibody against GFP. PrD-GFP levels after the glucose chase in the absence of the proteasomal 
inhibitor MG132 (- MG132) and in the presence of MG132 (+MG132) or GdnHCl (+ GdnHCl) were 
compared to those before the glucose chase at "time 0h". MG132 was refreshed/replenished every 2 
hours. (F) A strain expressing tGnd1-GFP [103] as a substrate for proteasomal degradation (positive 
control for successful inhibition of the proteasome) was grown to mid-log phase and 100 µg/ml of 
cycloheximide (CHX) was added. At "time 0h", an aliquot for determination of the tGnd1-GFP levels by 
Western Blotting was withdrawn. Subsequently, the culture was split into two aliquots and was 
incubated further for 8 h without MG132 (- MG132) or with MG132 (+ MG132). Aliquots were 
withdrawn and analyzed by Western Blotting with an antibody against GFP. An anti-actin antibody 
served as loading control. Scale bar, 2 µm. 
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4.1  The involvement of vesicular transport in recruitment 
of amyloid aggregates to the IPOD 
In this thesis, I observed that cells employ a vesicular transport system to guide 
aggregates to their respective deposition sites. This is novel concept because it has 
never been reported that aggregates can associate with transport vesicles that are 
moved along actin cables to get to their destination sites.  
 
PrD-GFP amyloid aggregates and the CVT substrate preApe1 are 
recruited via a similar vesicular transport machinery to the adjacent 
sites IPOD and PAS, respectively 
In this dissertation, I explored a novel cellular recruitment machinery that is involved 
in the recruitment of different amyloid substrates to the IPOD (insoluble protein 
deposit) deposition site in S. cerevisiae. This machinery is disturbed upon impairment 
of components of the actin cable-based transport machinery such as Myo2, Cmd1 
and Tpm1/2, but also upon impairment of SNARE function (see Fig 15 and 24). The 
IPOD is in close proximity to the PAS (Phagophore Assembly Site) [56, 65] where the 
cells initiate formation of autophagosomes and CVT (Cytoplasm-to-Vacuole 
Targeting) vesicles [113, 128]. The CVT pathway is destined to deliver precursor 
hydrolases to the vacuole. Remarkably, I found that amyloid aggregates use a similar 
recruitment machinery to the IPOD as CVT substrates (preApe1) for their recruitment 
to the PAS. This recruitment machinery for CVT substrates was known to consist of 
actin cables and transport vesicles that contain the transmembrane protein Atg9. 
Therefore, these vesicles were termed Atg9 vesicles [114]. At the PAS, the vacuolar 
precursor aminopeptidase 1 (preApe1) is enwrapped into the double-membrane CVT 
vesicles that subsequently fuse with the vacuolar membrane and release their 
content into the lumen. For its recruitment to the PAS, preApe1 first oligomerizes into 
multiple dodecamers (Ape1 complex) that forms the so called CVT complex with its 
receptor Atg19 and then binds to Atg9 vesicles via the adaptor Atg11 [112-114, 116, 
127, 128]. These Atg9 vesicles, loaded with preApe1, move to the PAS along actin 
cables [114]. The actin-related protein 2/3 (Arp2/3) complex is also involved in the 
Discussion and Outlook	  
	  
	  
71	  
transport of Atg9 vesicles to the PAS [206]. Therefore, impairment of actin 
cytoskeleton by genetic mutation, inhibition of actin polymerization or conditional 
depletion of the Arp2/3 complex blocks the recruitment of both Atg9 and preApe1 to 
the PAS [179, 206]. This suggested that both Atg9 and preApe1 move to the PAS in 
a coordinated fashion and was explained by two ways:  (I) Atg9 vesicles loaded with 
the preApre1 precursor complexes move actively along actin cables or (II) these 
vesicles move to the PAS via a passive mechanism. In such a passive mechanism, 
the binding of Atg9 vesicles to the Arp2/3 complex can activate the Arp2/3 complex 
itself, which in turn induces the nucleation and elongation (synthesis) of new actin 
filaments. Such elongation of the actin filaments can physically push these vesicles 
to the PAS [114]. However, in those studies, it was unclear which factor links Atg9 
vesicles to actin cables and mediates the transport of Atg9 and preApe1 to the PAS. 
My finding shows that depletion of Myo2 blocks recruitment of preApe1 to the PAS. 
This strongly supports the hypothesis that Myo2-based active movement is crucial for 
Atg9 vesicle transport along actin cables (see Fig 30). This is also consistent with the 
known role of Myo2 in the inheritance of different organelles such as vacuolar lobes 
and post-Golgi vesicles, which are bound to Myo2 by their specific receptors and 
adaptors (for example the Vac8/17 receptor/adaptor system during vacuole 
inheritance) and then transported from the mother to daughter cells along actin 
cables [207, 208]. In addition, my findings show that depletion of the SNARE 
chaperone Sec18 [209] also disturbs preApe1 recruitment to the PAS, consistent with 
the recent finding that impairment of SNARE proteins blocks the CVT pathway and 
recruitment of CVT structural components to the PAS [182]. 
The reversible failure of PrD-GFP aggregates to be recruited to the IPOD upon 
impairment of the Myo2-based transport machinery and the co-accumulation of PrD-
GFP transport intermediates with the CVT substrate preApe1 under Myo2 depleting 
conditions led me to put forward the hypothesis that both amyloid aggregates and 
CVT substrates use a similar vesicular transport machinery for their deposition at the 
adjacent destination sites IPOD and PAS, respectively (Fig 30). From my current 
study, it remains unclear whether both substrates, PrD-GFP aggregates and 
preApe1, are loaded onto identical Atg9 transport vesicles or on different types of 
vesicles. Nevertheless, both types of substrates can be targeted to their destination 
sites independently of each other, e.g. PrD-GFP in the absence of preApe1 and vice 
versa, and both require the Myo2 motor protein to drive this transport process. I also 
observed that the additional IPOD substrates, Htt103Q-CFP, Rnq1-GFP and Ure2-
YFP [56] were not targeted to the central IPOD upon Myo2 depletion, suggesting that 
the recruitment machinery is not limited to PrD-GFP, but that amyloids in general, 
use a Myo2-based vesicular transport machinery to be deposited at the IPOD.  
I also observed that PrD-GFP transport intermediates co-localize not only with 
different CVT pathway components including preApe1, Atg9 and Atg8, but also with 
the Myo2 motor protein. Among these components, RFP-Atg8 and Myo2-3XmCherry 
showed stronger co-localization with PrD-GFP as compared to preApe1 and Atg9. 
This suggests that PrD-GFP and preApe1 may use similar, but not identical vesicles 
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for their recruitment to the respective sites, but co-accumulated at the same cellular 
location upon impairment of SNARE-mediated vesicular transport or actin-
tropomyosin based transport (see Fig 30). However, differences in the degree of co-
localization of PrD-GFP aggregates with the different components mentioned above 
must not necessarily mean a biological difference, but could potentially also be 
explained by technical reasons such as interference of the fluorescence protein tag 
added to these factors that may impair the functionality to a certain degree.  
 
The role of the actin cytoskeleton in sorting of amyloid aggregates 
during asymmetric inheritance of aggregates 
It has been reported by different groups that amyloid aggregates are associated with 
the actin cytoskeleton [210, 211]. Recently, Song and coworkers showed that 
Htt103Q aggregates partially co-localize with Myo2, Cmd1 and Sec18 during their 
asymmetric inheritance [139]. However, these aggregates were found as multiple 
punctate structures in the cytosol rather than at one central IPOD inclusion. It 
remained unclear whether these multiple punctate foci either represented transport 
intermediates of Htt103Q on transit to the IPOD, similar to those I observed here 
upon depletion of components of the actin cable-based transport machinery, or 
whether they represented IPOD-independent deposits. If the former was the case, it 
would need to be established why transport intermediates to the IPOD would 
accumulate and not reach the IPOD in the experimental conditions used in the study 
[139], because there were no particular proteins depleted that could explain the 
accumulation of transport intermediates. 
 
A putative role of endosomal vesicular transport in asymmetric 
inheritance of heat-induced aggregates 
Recently, heat-induced protein aggregates, visualized with Hsp104-GFP, were 
shown to be retained in the mother cells during asymmetric inheritance by 
“hitchhiking” on the route of ER-Golgi trafficking or late endocytosis that also employs 
Cmd1/Myo2/actin-based transport [139, 212]. However, from those studies, it 
remained unclear which transport vesicles are involved during asymmetric 
inheritance of aggregated proteins. Since Myo2 links Atg9 vesicles loaded with PrD-
GFP aggreagtes to actin cables, it is also possible that Myo2 could link an unknown 
class of vesicles to the actin cytoskeleton during asymmetric inheritance of heat-
induced protein aggregates. Thus, there might be a connection between asymmetric 
inheritance of damaged proteins [139, 146, 212] and sorting of prion aggregates to 
the IPOD site as both employ actin/Myo2-based vesicular transport.   
Subsequently, it was shown that Vac17 is also involved in asymmetric retention of 
damaged/misfolded proteins in mother cells during ageing [212]. Vac17 is a vacuolar 
adaptor protein which is involved in vacuole inheritance by attaching vacuole vesicles 
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to actin cables through its interaction with Vac8 on the one hand and to Myo2 motor 
protein on the other hand [213]. In this study, heat-induced protein aggregates 
(Hsp104-GFP substrates) were further shown to be deposited near the IPOD in a 
Myo2/Vac17-dependent manner [212]. Later, Vac17 was found to bind with Hsp104-
GFP in vitro in immunoprecipitation experiments, therefore the authors speculated 
that aggregates may hitchhike Vac17/Myo2 –based  vesicular transport routes to the 
vacuole because of the normal role of Vac17 in actin cable-dependent vacuole 
inheritance [212]. Thus, these studies would confirm the novel concept that 
aggregate sorting can employ vesicular transport. Strikingly, however,  the deletion of 
the VAC17 adaptor did not affect the inheritance of Huntingtin Htt103Q aggregates in 
this very recent study [212], suggesting that amyloids may not employ this Myo2–
Vac17–Vac8 transport complex [193] during amyloid recruitment to the IPOD. This 
could mean that different aggregates may use different vesicular transport systems 
for their recruitment to the IPOD or IPOD adjacent sites, but these issues need to be 
studied in more detail to allow for conclusive statements. It would indeed be very 
interesting to test the effect of the proteins found in the study (Vac17, Vac8, Vps1 
etc) [212] with my substrates on the one hand, and depletion of Myo2, Sec18 and 
Sec14 with their aggregate markers on the other hand.  
 
SNARE proteins function is required for vesicle-based transport of 
PrD-GFP aggregates to the IPOD 
I found evidence that PrD-GFP aggregates, during their sorting to the IPOD, are 
associated with Atg9-containing vesicles (see Fig23), which are also known to 
transport the CVT substrate, preApe1, to the PAS along actin cables [114] (see Fig7). 
Atg9 is a multispanning transmembrane protein which exists on small cytoplasmic 
vesicles termed as Atg9 vesicles [181]. Trafficking of these Atg9 vesicles from 
peripheral sites to the PAS requires several SNARE proteins such as Sso1/2, Sec9, 
Tlg2, Ykt6 and Sec22. A role for the Sec18 SNARE chaperone in Atg9 vesicular 
trafficking was also suggested [182]. Remarkably, I fished Sec18, a SNARE 
disassembly chaperone to bind with PrD fibers in vitro (see Fig13), which was found 
further to be involved in PrD-GFP recruitment to the IPOD (see Fig24C). Therefore, 
Atg9 and Sec18 SNARE-mediated vesicular transport machinery is crucial for sorting 
both substrates, PrD-GFP aggregates and preApe1to their adjacent deposition sites, 
IPOD and PAS, respectively. However, the mechanism by which these SNAREs are 
involved in the sorting of PrD-GFP aggregates to the IPOD needs to be further 
investigated.  
 
Role of Sec14 and Sec21 in sorting PrD-GFP aggregates to the IPOD 
Next to the likely involvement of the Atg9 vesicular trafficking machinery in the sorting 
of PrD-GFP to the IPOD, additional proteins involved in various steps of vesicular 
transport processes were identified to bind to immobilized PrD-GFP (see Fig13). 
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Among those, I found Sec14 and Sec21 that are involved in the formation of Golgi-
derived vesicles and their further trafficking steps [214-216]. Interestingly, the 
depletion of Sec14 and Sec21 also interfered with PrD-GFP sorting to the IPOD 
similar to the depletion of Myo2 (see Fig24). Sec14 is a phosphatidylinositol/ 
phosphatidylcholine (PI/PC) transfer protein which associates preferentially to Golgi 
membranes. It transfers phosphatidylinositol (PI) lipid from the ER to the Golgi 
complex, where PI is phosphorylated to form phosphatidylinositol-4-phosphate (PI4P) 
by the PI4P kinase, Pik1 [186, 217, 218]. It has been shown that the pool of PI4P 
lipids generated by Pik1 regulates the formation of Golgi-derived secretory vesicles 
and the subsequent transport of these vesicles to their destination sites after their 
exit/release from the Golgi [218]. Therefore, when Sec14 or Pik1 function is 
abolished, the amount of PI4P is reduced. This eventually blocks de novo formation 
of Golgi-derived secretory vesicles and downstream vesicular transport pathways. 
Remarkably, Atg9 vesicles that have also been shown to serve as membrane 
supplier for the autophagosomes/CVT vesicles [219, 220]  are also derived from the 
Golgi apparatus [219]. In line with this, it was shown that inactivation of Pik1 at the 
nonpermissive temperature (which reduces the level of PI4P) blocks the formation of 
Atg9 vesicles from the Golgi [186]. Therefore, such impairment in the Pik1 function 
also blocks the autophagy/CVT pathway indirectly because the generation of Golgi-
derived Atg9 vesicles and their movement to the PAS is reduced [186]. Since, Sec14 
functions upstream of Pik1 in the formation of PI4P lipids [217, 218], it might be 
possible that Sec14 function is also crucial for releasing of Atg9 vesicles from the 
Golgi similar to Pik1 [186]. This would plausibly explain why PrD-GFP aggregates are 
not recruited to the IPOD in the absence of Sec14.   
Besides the role of PI4P lipids on the formation of Golgi-derived Atg9 transport 
vesicles [186], PI4P also serves as a substrate for the PIP5-kinase Mss4 to generate 
PI(4,5)P2 lipids, which are required for the proper organization of the actin 
cytoskeleton [221]. In agreement with, it was shown that impaired production of PI4P 
in pik1-101 mutant cells at the permissive temperature results in less PI(4,5)P2 
generation, which causes the disruption (depolarization) of actin cables [222]. 
Therefore, upon Sec14 depletion, PI is not transported properly to Pik1 kinase for the 
generation of PI4P which then eventually reduces the levels of PI(4,5)P2 lipids and 
could affect the organization of the actin cytoskeleton. This could also account for the 
effect of Sec14 depletion on the recruitment of PrD-GFP to the IPOD. Taken 
together, since PrD-GFP aggregates are recruited to the PAS via Atg9 transport 
vesicles along actin cables, impaired function of Sec14 would disturb the sorting of 
PrD-GFP aggregates to the IPOD by two different mechanisms, both of which would 
fit in my proposed model (see Fig 30).  Future studies are required to further confirm 
the possible involvement of these two mechanisms that are linked to a Sec14-
mediated recruitment of prion aggregates to the IOPD.   	  
Sec21, a COPI coatomer protein was found to associate with Vid (vacuole import and 
degradation) vesicles to deliver inactive fructose-1,6-bisphosphatase (FBPase) into 
the vacuole for its degradation by autophagy [188]. Depletion of Sec21 also gave a 
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multiple PrD-GFP foci phenotype compared to Sec18 or Myo2 depletion, highlighting 
again that vesicular trafficking is crucial for amyloid recruitment to the IPOD. 
However, it needs to be further determined whether this effect of depletion of Sec21 
on PrD-GFP delivery to the IPOD is a direct effect or a more indirect consequence of 
impairment of upstream vesicular transport processes. 
 
4.2. Tethering of prion aggregates to the CVT vesicular 
transport machinery 
My study shed light onto a novel cellular mechanism that is involved in the 
recruitment of prion aggregates to the IPOD along actin cables. However, there are 
still key questions remaining, for example how prion aggregates are attached to the 
Atg9 transport vesicles e.g. what the linking factor is (receptor/adaptor)? Deletion of 
receptor for preApe1, Atg19 [127, 128], did not affect the targeting of PrD-GFP to the 
central IPOD, suggesting PrD-GFP is not recognized by the same receptor as 
preApe1, but may require other receptor(s) for its binding to Atg9 vesicles (Fig 30).  
In summary, however, this study nicely confirms the novel principle I discovered here, 
which is that protein aggregates can employ a vesicular transport machinery to be 
recruited to distinct deposition sites. 
 
Tethering of prion aggregates to Atg9 vesicles 
The short-lived and stress-induced protein Lsb2 was shown previously to associate 
with prion aggregates and to link them to the actin cytoskeleton during prion induction 
[211]. Lsb2 is a low abundant protein whose levels are increased in response to 
environmental stress such as heat shock, and such increased levels of Lsb2 facilitate 
de novo induction of the [PSI+] and [PIN+]/[RNQ+] prions[211]. After heat shock, 
overproduced Lsb2 binds to soluble Sup35 protein and triggers [PSI+] prion induction 
(Sup35 prion fibrillization) and subsequent association of corresponding prion 
aggregates at the cortical actin cytoskeleton. Therefore, Lsb2 seems to have a 
tethering function during de novo formation of [PSI+] by linking misfolded Sup35 
molecules to the actin cytoskeleton [211]. Although I cannot exclude a possible 
involvement of Lsb2 in tethering of PrD-GFP aggregates to the Atg9 vesicle based 
transport machinery and/or actin cables, I consider this to be less likely because my 
experiments were performed under non-stress conditions where Lsb2 levels should 
be low. In line with this, deletion of Lsb2 did not cause any effect on the IPOD 
formation (unpublished results from the Tyedmers Lab), also arguing against an 
essential role of Lsb2 in tethering of PrD-GFP aggregates to the Atg9 vesicles.  
 
Hsp104, an aggregate-remodeling and prion maintenance factor was shown to bind 
to heat-induced aggregates and to link these aggregates to actin cables during 
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asymmetric inheritance [141]. Hsp104 was also shown to associate with different 
amyloids/prions such as Sup35p PrD, Mot3 and Lsm4 [65, 203]. If Hsp104 was 
crucial for tethering the PrD-GFP transport intermediates to the actin cytoskeleton on 
transit to the IPOD, then inhibition of Hsp104 in cells harboring prion aggregates 
should impair proper sorting of prion aggregates to the IPOD. However, it was found 
that the IPOD was even increased in size upon inhibition of Hsp104 [203] rather than 
leading to multiple foci formation as I observed it here when the recruitment 
machinery was impaired. This suggests that Hsp104 is not crucial for tethering prion 
aggregates to the actin cytoskeleton during proper sorting of prion amyloids to the 
IPOD via the novel recruitment machinery discovered here. Thus the sorting of prion 
aggregates to the IPOD observed here, and the retention of aggregated proteins in 
mother cells during asymmetric inheritance, may employ different tethering 
mechanisms. 
  
An alternative mechanism of prion tethering could be mediated by direct binding of 
prions to the components of the Atg9-based vesicular transport machinery. Such 
direct binding of prion aggregates to components of the vesicular recruitment 
machinery discovered here seems possible when I consider that components of the 
endocytosis machinery (e.g. Sla1, Sla2, Pan1, Las17, Apl1, Apl3, Hof1 etc) are also 
involved in initiation of polyQ aggregation [223]. Furthermore, two endocytic 
components, Sla1 and Sla2 were shown previously to be involved in organizing and 
handling of [PSI+] aggregates [168, 169]. Sla1 and Sla2 are actin-binding proteins 
that act as adaptors and link endocytic vesicles to the cortical actin cytoskeleton 
during endocytosis [224, 225]. Interestingly, I also found Sla2 to bind with PrD fibers 
on the column during my fishing approach (see Fig13). Therefore, the role of Sla1/2 
and their interactions with amyloids needs to be studied in more detail to reveal 
whether they might be involved in sorting prion aggregates to the IPOD. 
  
Lastly, mature amyloids and prefibrillar oligomers have an intrinsic affinity for direct 
binding to lipid membranes [226]. This provides another alternative possibility for 
direct tethering of PrD-GFP aggregates to lipids present in the Atg9 transport 
vesicles. However, in such a case, it would need to be established how specificity to 
Atg9 vesicles, but not other types of membranes, is established. 
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FIGURE 30: A model for the recruitment of PrD-GFP prion aggregates to the IPOD amyloid 
deposition site in yeast – PrD-GFP prion aggregates are recruited via an unknown receptor/adaptor 
to Atg9 transport vesicles which also target the CVT complex consisting of preApe1 and its receptor 
Atg19 via its adaptor Atg11 to the Phagophore Assembly Site (PAS). PrD-GFP and preApe1 as cargo 
molecules are loaded on Atg9 vesicles and then transported via Myo2 and tropomyosin-coated actin 
cable-based transport to their adjacent destination sites, IPOD and PAS respectively. Moy2 links these 
Atg9 vesicles to the actin cytoskeleton.  
 
4.3.  PrD-GFP is turned over after extraction from the IPOD 
by the Hsp104 based disaggregation machinery  
 
I observed that PrD-GFP and CVT substrate preApe1 both use a similar vesicular 
transport machinery for their recruitment to the respective adjacent destination sites 
IPOD and PAS, respectively. At the PAS, the preApe1 substrate is enwrapped by 
double-membrane vesicle to form CVT vesicles which subsequently transport 
preApe1 into the vacuolar lumen for its maturation [127]. This raised the question if 
PrD-GFP is also deposited for the same purpose i.e. the packaging into double
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membrane autophagosomes for their autophagic degradation. This would parallel the 
autophagic turnover of aggresomes observed in mammalian cells where aggresomes 
are enwrapped into autophagosomes and fuse with lysosomes for their proteolytic 
degradation [122]. Remarkably, I did not find any positive evidence for bulk turnover 
by autophagy when PrD-GFP was overexpressed under control of the rather strong 
GPD or Gal promoters under normal, non-starvation conditions. This is consistent 
with previous electron microscopy studies where [PSI+] aggregates at the IPOD were 
never found associated with any (autophagosomal) membrane [65, 167, 227], 
suggesting that PrD-GFP aggregates are not packaged into autophagosomes at the 
PAS adjacent IPOD for their possible turnover by autophagy under these conditions, 
at least not to a significant extend that would become visible in electron microscopic 
images  [65, 167, 227] or changes in PrD-GFP protein levels.  
If the accumulation of PrD-GFP at the IPOD did not primarily serve the purpose of 
subjecting the aggregates to autophagic turnover, then another reason for PrD-GFP 
accumulation at the IPOD could be temporary storage of excess PrD-GFP when the 
capacity of downstream proteolytic machineries (UPS, autophagy, others?) involved 
in PrD-GFP degradation is not sufficient (Fig 31). This allows amyloid aggregates to 
be sequestered temporally at the IPOD to avoid possible harmful effects in the 
cytosol [228] until the Hsp104 disaggregase and downstream degradation 
machineries are available. This is consistent with a recent finding showing that the 
IPOD serves as an intermediate compartment where large molecular weight 
molecules such as inactive proteasomes [155] are deposited temporally before they 
are finally processed. After accumulation at the IPOD, amyloid aggregates can be 
extracted slowly by the Hsp104 disaggregation machinery and might afterwards be 
subjected to proteolysis by either the proteasome [71], autophagy [205] or other 
unknown degradation pathways. Therefore, revealing the fate of different amyloid 
substrates at the IPOD and the possible involvement of unknown degradation 
pathway (s) in this process could explain their deposition purpose at the IPOD site. 
Besides this, deposition of amyloid aggregates at the IPOD was also suggested to 
facilitate asymmetric aggregate inheritance [56, 65, 145, 146, 211].  
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FIGURE 31: A model for the possible fate of PrD-GFP amyloids deposited at the IPOD 
deposition site in yeast – PrD-GFP fibers after accumulation at the IPOD are extracted slowly by 
Hsp104 threading activity. This extraction leads to prion fragmentation and results in small pieces of 
PrD fibers or single unfolded PrD-GFP molecules, which are subsequently subjected to proteolysis by 
either the proteasome [71] or autophagy and/or other cellular degradation pathways. Short PrD-GFP 
fiber fragments can also act as seeds and grow to longer PrD-GFP fibers by addition of soluble PrD-
GFP molecules to their ends. 
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Outlook 
In summary, I showed that prion aggregates are targeted to the IPOD via Atg9 
vesicles along tropomyosin-coated actin cables and the Myo2 motor protein. I could 
further reveal that this is also true for preApe1 sorting to the PAS. However, it is not 
completely clear how PrD-GFP and other bona fide IPOD substrates are associated 
with such vesicles. Do these prions directly bind to Atg9 vesicles or do they require a 
specific receptor/adaptor system? Therefore, revealing a linking factor between Atg9 
transport vesicles and different IPOD substrates will shed light on this recruitment 
machinery and will help to answer the question whether it is driven directly or 
indirectly. Moreover, direct visualization of PrD-GFP foci with Atg9 vesicles in 
Myo2/Sec18 depleting conditions with Correlative Light and Electron Microscopy 
(CLEM) will support the current model. To identify an unknown linking factor (s), any 
suitable approach can be applied, such as:  (I) Testing deletion of known vesicle/PAS 
components on co-localization of PrD-GFP with PAS marker or (II) Pull-down/Co-
immunoprecipitation of both structures (HA-tagged Atg9 and PrD-GFP) in 
Myo2/Sec18 depleting conditions and finally perform a Mass Spectrometry Analysis. 
Subsequently, depletion of the identified putative linking factor (s) has to reveal if this 
disturbs the association of PrD-GFP with a PAS marker or Atg9 in vivo using 
fluorescence microscopy and/or CLEM.  
Sec18 SNARE chaperone -mediated vesicular transport and fusion is also required 
for PrD-GFP sorting to the IPOD (compare section 3.2.10). In the future, the detailed 
molecular composition of the transport vesicles and the identity of the involved 
SNARE proteins (chaperoned by Sec18) have to be revealed. Such study could 
explain why the endocytosis machinery of ER-to-Golgi trafficking can participate in 
the recruitment of amyloids to the IPOD similar to their role in autophagy [182].  
The IPOD is directly adjacent to the PAS where the cells initiate formation of CVT 
vesicles and autophagosomes [56, 65]. This raised a question if the presence of the 
PrD-GFP amyloids at IPOD interfere the autophagy or CVT pathway? Since amyloids 
are large complex structures, they could potentially inhibit many different autophagic 
processes due to its adjacent localization to the PAS. Therefore, future studies could 
to reveal the impact of an IPOD on autophagic flux or the turnover of different 
autophagic substrates such as defect mitochondria, peroxidomes, bulk cytoplasm, 
amongst others. This can be achieved by (I) looking whether mCherry-Atg8 (or 
mCherry-tagged autophagic substrates) still enter into the vacuole for autophagic 
turnover upon autophagy induction by starvation/spermidine to the same degree 
when a PrD-GFP IPOD is present in the cells or not, or (II) monitoring HA/MYC-Atg8 
processing in cells  with or without a PrD-GFP IPOD upon autophagy induction. An 
Ape1 processing assay can be monitored with similar conditions to see if the 
presence of an IPOD affects the CVT pathway. In addition, the biological significance 
of the PAS on the formation and fate of the IPOD is also not known. Therefore, if it is 
possible, the impact of abolishing PAS formation on IPOD formation should be 
studied.  
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5.1. Materials 
 
5.1.1.  Software and Equipment 
 
Computer Software 
 
Image J National Institutes of Health 
Office 2010  Microsoft Corp. 
SnapGene GSL Biotech 
Inkscape Scalable Vector Graphics (SVG) 
Excellence Olympus Soft Imaging Solutions  
Adobe Acrobat Adobe Systems Inc. 
Excel Adobe Systems Inc. 
 
 
Equipment 
 
Agarose gel chambers and trays University Hospital workshop 
Balances Mettler 
Gel documentation system Biometra  GmbH 
Centrifuges Heraeus 
Glass ware Schott 
Incubators Forma  Thermo  Scientific 
Water bath MaxQ 7000 Dinkelberg analytics 
Power supply Perkin-Elmer?, University Hospital workshop 
SDS gel chambers Biorad 
Vortex mixer  Heidolph 
Western blot chambers, semi-dry Biorad 
Magnetic stirrer MR 3001 K Heidolph 
pH meter Werner Hassa GmbH 
Spectrophotometer Eppendorf 
T-Gradient Thermocycler Biometra  GmbH  
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Mixer mill MM 400 Retsch 
French press Sim-Aminco/Bukau lab 
 
 
Microscopes 
 
Olympus CellR-PointFRAP IX81 ZMBH Imaging Facility 
Olympus CellR-PointFRAP IX81 Bukau lab 
 
Olympus xcellence PointFRAP IX81 microscope 
 
Microscope stand Olympus IX81, inverted microscope, motorized stage 
Objectives PlanC N 10x/0.25 
UPlanSApo 20x/0.75 
UPlanSApo 40x/0.95 
UPlanFL N 60x/0.90 
Apo N 60x/1.49 Oil 
UApo N 100x/1.49 Oil 
Fluorescence Lamp MT 20 illumination system with 150 W Xe or 150 W Hg/Xe arc 
burner 
Excitation Filters 387nm/11 , 427nm/10, 470nm/40, 485nm/20, 504nm/12, 
560nm/25, 572nm/35, 650nm/13 
Emission Filters Dualband CFP/YFP sbx HC filter set, 
Dualband GFP/mCherry sbx ET filter set, 
Quadband DAPI/FITC/Cy3/Cy5 sbx HC filter set 
Camera EM-CCD C9100-02 (Hamamatsu) 
Software xcellence (Olympus) 
Temperature control Incubation Chamber (ZMBH Wor kshop) 
tempcontrol 37-2 digital and heating unit (Pecon) 
Custom made heat shock stage (Olympus) Peltier element (BelektroniG) combined with water 
cooling device (innovatek), Control Unit: HAT-control 
B-20 and Software (BelektroniG) 
 
 
5.1.2.  Expendable items 
 
Cover slides Thermo Scientific Inc. 
Cover slips, 20 x 20 mm Menzel-Gläser (Thermo Scientific Inc.) 
Cuvettes Sarstedt AG & Co. 
Falcon tubes 15, 50 ml Greiner 
Petri dishes Greiner 
Microcentrifuge tubes, 1.5 ml, 2 ml Sarstedt AG & Co. 
Low protein binding microcentrifuge tubes, 1.5 ml Eppendorf 
PCR tubes, 200 µl Kisker Biotech GmbH & Co. 
PVDF membrane Millipore 
Sterile filters, 0.2 µM GE Healthcare 
Whatman paper, 3 mm Schleicher & Schuell 
Amicon Concentrators Millipore 
Costar 96-well plate Greiner 
100 Mesh copper grids (formvar/carbon coated) Electron Microscopy Sciences 
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5.1.3.  Chemicals 
If not mentioned differently, all chemicals were purchased from Roth, Sigma-Aldrich, 
Invitrogen, AppliChem or Merck.  
 
Enzymes and protease inhibitors 
Aprotinin AppliChem 
DNase I AppliChem 
Pepstatin A Pepta Nova GmbH 
Leupeptin Peptide Institute, Inc. 
Phenylmethylsulfonyl Fluoride (PMSF) Sigma-Aldrich Co. 
MyFi OptiTaq DNA Polymerase Bioline 
My Taq Red DNA polymerase Bioline 
Restr iction Enzymes NEB, Thermo Scientific Inc., Promega 
Zymolyase 100T Amsbio 
 
 
Standards and Kits 
Bio-Rad Protein Assay Dye Reagent Concentrate 
(5 x Bradford reagent) 
Bio-Rad Laboratories, Inc. 
peqGOLD Plasmid Miniprep Kit PEQLAB 
QIAquick Gel Extraction Kit QIAGEN GmbH 
GeneRuler 1 kb DNA Ladder (#SM1163) Thermo Scientific Inc. 
PageRuler Prestained Protein Ladder (# 26616) Thermo Scientific Inc 
 
 
Components for Media 
Bacto™Agar Becton, Dickinson and Company 
Bacto™Peptone Becton, Dickinson and Company 
Bacto™Tryptone Becton, Dickinson and Company 
Bacto™Yeast extract Becton, Dickinson and Company 
Difco™Yeast Nitrogen Base w/o amino acids and 
ammonium sulfate 
Becton, Dickinson and Company 
Complete Supplement Mixture (CSM) (- amino acids for drop 
out media) 
MP Biomedicals, LLC 
 
 
Antibiotics 
All listed concentrations are the final concentrations. Stock solutions were filter 
sterilized. 
Ampicillin (Amp) 100 µg/ml Sigma-Aldrich Co. 
Chloramphenicol 25 µg/ml Sigma-Aldrich Co. 
	  
	  
84	  
Cycloheximide (CHX) 100 µg/ml Serva Electrophoresis GmbH 
Hygromycin B (Hyg) 250 µg/ml InvivoGen 
Geneticin (G418) 200 µg/ml Sigma-Aldr ich Co. 
Nourseothr icin (clonNAT) 200 µg/ml Werner BioAgents 
 
 
Other Chemicals and Reagents 
Bromphenol Blue Sigma-Aldrich Co. 
ECF Substrate GE Healthcare Life Sciences 
MG132 (Z-Leu-Leu-Leu-al) Peptide Institute, Inc 
Yeastmaker™ Carrier DNA Clonetech Laboratories, Inc. 
Guanidine hydrochloride Sigma-Aldrich Co. 
Spermidine Sigma-Aldrich Co. 
Indole-3-acetic acid sodium salt (auxin) Sigma-Aldrich Co. 
Paraformaldehyde (PFA) Sigma-Aldrich Co. 
Agarose Sigma-Aldrich Co. 
D (+)-Biotin Roth 
IPTG Thermo Scientific Inc. 
Ni-NTA His-Bind Resin (# 70666) Millipore 
hyBeads Streptavidin  Beads (#311092) Hyglos GmbH 
 
 
5.1.4.  Media and Buffers 
 
All media were sterilized by filtration or autoclaving prior to usage. For the 
preparation of solid agar plates, 2% (w/v) autoclaved agar was added to the medium 
prior to pouring plates. 
 
LB (Luria-Bertani) medium   10g/l tryptone 
      5 g/l yeast extract 
      10 g/l NaCl 
 
TB (Terrific Broth) medium   12g/l tryptone 
      24 g/l yeast extract 
      16.4g/l potassium phosphate, dibasic 
      2.3g/l potassium phosphate, monobasic 
      4ml/l glycerol 
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YPD/YPG     20 g/l peptone 
      10 g/l yeast extract 
      20 g/l D-Glucose/Galactose 
 
SD (Synthetic Dropout) medium 1.7 g/l Yeast Nitrogen Base w/o amino acids and 
ammonium sulfate 
 0.7 g/l CSM mix (according to desired dropout) 
 5 g/l ammonium sulfate or 1 g/l glutamate 
2% (v/v) desired sugar, added post sterilization 
 
PBS and PBST    137 mM NaCl 
      2.7 mM KCl 
      10 mM Na2HPO4 
      2 mM NaH2PO4 
      pH was adjusted to 7.4 with HCl 
      for PBST, 0.25% (v/v) Tween-20 was added 
 
 
5.1.5.  Plasmids, Strains, Primers and Antibodies 
 
TABLE 1.: Plasmids used in this study 
 
Name Characteristic Features Source/Reference 
pH10-Sumo-PrD-TEV-Avi AmpR This study/Tyedmers lab 
pHis-Sumo-PrD-STOP  AmpR This study/Tyedmers lab 
pRS413-mCherry-Atg8 AmpR; HIS3 Nava Segev lab 
pRS414-RFP-Atg8 AmpR; TRP1 Daniel Klionsky lab 
pRS303-Ape1-mCherry AmpR; HIS3 Yoshinori Ohsumi lab 
pRS416-GFP-Atg8 AmpR; URA3 Daniel Klionsky lab 
pBS35 AmpR; hphNT1 The Yeast Resource Center 
pFA6a-kanMX4 AmpR; kanMX4 [229] 
pFA6a-hphNT1 AmpR; hphNT1 Michael Knop lab [230] 
pFA6a-natNT2 AmpR; natNT2 Michael Knop lab [230] 
pYM-N17 AmpR; hphNT1 Michael Knop lab [230] 
pNHK53 AmpR; URA3 [172] 
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pMK43_HA AmpR; kanMX4 [172] 
pMaM144 (3 x mCherry) AmpR; hphNT1 Micheal Knop lab 
pRS305 Gal RNQ1-GFP::LEU2 AmpR; LEU2 Bernd Bukau lab 
pRS305 Gal URE2-YFP::LEU2 AmpR; LEU2 Bernd Bukau lab 
pRS304 Gal 103Q-CFP::TRP1 AmpR; TRP1 Bernd Bukau lab 
pYM25 AmpR; yeGFP; hphNT1 Michael Knop lab [230] 
 
 
Yeast strains 
All strains used in this study are derivatives of 74D-694 (MATa ade1-14 his3 leu2 
trp1 ura3 [PSI+] or [psi-]) [198] that express integrated PrD-GFP under a galactose-
inducible promoter [49] (termed 74D [PSI+]-Gal-PrD-GFP) or under a constitutive 
GPD promoter with a deletion of endogenous SUP35-PrD locus [65] (termed 74D-
GPD-PrD-GFP). Yeast strains with additional genetics manipulations are shown in 
Table 2.  
 
TABLE 2.: Strains used in this study 
Name Genotype Source/Reference 
RK1 74D-694-[PSI+]-Gal-PrD-GFP::LEU2 [65] 
RK1a RK1 tpm1Δ::natNT2 This study 
RK1b RK1a-OsTIR1::URA3 This study 
RK1c RK1b-TPM2-AID ::kanMX4  This study 
RK1d RK1-OsTIR1::URA3 This study 
RK1e RK1d-MYO2-AID::kanMX4  This study 
RK1f RK1d-CMD1-AID::kanMX4  This study 
RK1g RK1d-SEC18-AID::kanMX4  This study 
RK1 atg9Δ RK1 atg9::hphNT1 This study 
RK1 atg11Δ RK1 atg11::natNT2 This study 
RK1 atg19Δ RK1 atg19:natNT2 This study 
RK1 ape1Δ RK1 ape1::kanMX4 This study 
RK1 ams1Δ RK1 ams1::kanMX4 This study 
RK1e + 
pRFP-ATG8 
RK1e + pRS414 RFP-ATG8 This study 
RK1e APE1-
mCh 
RK1e-303 APE1-mCh::HIS3 This study 
RK1e ATG9-
3xmCh 
RK1e-ATG9-3xmCh::hph NT1 This study 
RK1g + 
pmCh-ATG8 
RK1g + pRS413 mCh-ATG8  This study 
RK1g MYO2-
3xmCh 
RK1g-MYO2-3xmCh::hph NT1 This study 
RK2 74D-694-[psi-]-Gal-PrD-GFP::LEU2 [65] 
RK2a RK2-OsTIR1::URA3 This study 
RK1b RK2a-MYO2-AID::kanMX4  This study 
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RK1c RK2a-CMD1-AID::kanMX4  This study 
RK3 74D-694-ΔPrD (SUP35) [PrD-GFP+]::TRP1 [65] 
RK3 TPM1-
mCh 
RK3-TPM1-mCh::hphNT1  This study 
RK3 TPM2-
mCh 
RK3-TPM2-mCh::hphNT1  This study 
RK3 SSA1-
mCh 
RK3- SSA1-mCh::hphNT1  This study 
RK3 PUB1-
mCh 
RK3-PUB1-mCh::hphNT1  This study 
RK3 PAB1-
mCh 
RK3-PAB1-mCh::hphNT1  This study 
RK3 atg1Δ RK3 atg1Δ::natNT2 This study 
RK3 atg6Δ RK3 atg6Δ::natNT2 This study 
RK3 atg7Δ RK3 atg7Δ::natNT2 This study 
RK3 atg8Δ RK3 atg8Δ::natNT2 This study 
RK3 atg14Δ RK3 atg14Δ::natNT2 This study 
RK3 atg16Δ RK3 atg16Δ::natNT2 This study 
RK3 pep4Δ  RK3 pep4Δ::natNT2 This study 
RK4 74D-694-ΔPrD (SUP35) [prd-gfp-]::TRP1 [65] 
RK4 pep4Δ  RK4 pep4Δ::natNT2 This study 
74D 74D-694-[PSI+] [198] 
RK5a 74D-OsTIR1::URA3 This study 
RK5b RK5a-MYO2-AID::kanMX4  This study 
RK5c RK5b-GFP-preApe1::natNT2  This study 
RK5d RK5b-GFP-ATG8::natNT2 This study 
RK5e RK5a-SEC18-AID::kanMX4  This study 
RK5f RK5e-GFP-ATG8::natNT2 This study 
RK5b Rnq1-
GFP 
RK5b-305 Gal RNQ1-GFP::LEU2 This study 
RK5b Ure2-
YFP 
RK5b-305 Gal URE2-YFP::LEU2 This study 
RK5b 103Q-
CFP 
RK5b-304 Gal 103Q-CFP::TRP1 This study 
RK6 74D-305 Gal RNQ1-GFP::LEU2 This study 
RK7 74D-305 Gal URE2-YFP::LEU2 This study 
RK8 74D-304 Gal 103Q-CFP::TRP1 This study 
RK1h RK1d-SEC14-AID::kanMX4  This study 
RK1i RK1d-SEC21-AID::kanMX4 This study 
RK1j RK1d-SEC53-AID::kanMX4 This study 
tGnd1-GFP BY4741-tGnd1-GFP:: natNT2 ∆prd5 ::kanMX4 [103] 
RK1 ∆prd5   74D-694-[PSI+]-Gal-PrD-GFP::LEU2 ∆prd5::hph NT1 This study 
RK9 RK5b-304 Gal 103Q-CFP::TRP1-305 Gal URE2-
YFP::LEU2 
This study 
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TABLE 3.: Primers used in this study 
Name Sequence Source 
pH10-Sumo_P1 GTGAGCGGATAACAATTCCCCTC J. Tyedmers  
pH10-Sumo_P2 CCTTGGTTTGAATCCGACATaccaccaatctgttctctgtgagcctcaataatatcg J. Tyedmers  
PrD-GFP_P3 gaggctcacagagaacagattggtggtATGTCGGATTCAAACCAAGGCAACAATC J. Tyedmers  
PrD-GFP_P4 ggtacccgGGATCCATCGTTAACAACTTCGTCATCC J. Tyedmers  
F_Ssa1_mCherry CCTCCAGCTCCAGAGGCTGAAGGTCCAACCGTTGAAGAAGTTGATggtcgacggatccccg
gg 
  
R_Ssa1_mCherry CATTAAAAGACATTTTCGTTATTATCAATTGCCGCACCAATTGGCatcgatgaattcgagctcg   
Ssa1_Check_ORF CGATGTCGACTCTAACGG  
F_Tpm1_mCherry GCAAAGAAGGAACTGGACGAAATTGCTGCATCTCTGGAAAACTTGggtcgacggatccccg
gg 
 
R_Tpm1_mCherry CAGCGTGTTGGGGAAAAGAAAAAGAAAACAAAAAACAAAAGTAGAatcgatgaattcgagctc
g 
 
Tpm1_Check_ORF GCAATTGTCCGAGGACTCTC  
F_Tpm2_mCherry GCTCAAAAAGAATTGGACGAAATTGCTAATTCATTGGAAAATTTAggtcgacggatccccggg  
R_Tpm2_mCherry GTTTGTCGTTTGTATCTTCCGTAATTTTAGTCTTATCAATGGGAAatcgatgaattcgagctcg  
Tpm2_Check_ORF CTCGACAGTGAAGTGGAGAAG  
F_Pub1_mCherry ATGTCTGAGCAACAACAGCAACAGCAGCAACAGCAGCAACAACAAggtcgacggatccccg
gg 
 
R_Pub1_mCherry TCTTTATTCTTTCTTTTTGTTTCATTCCACTTTTCTTCATAATATatcgatgaattcgagctcg  
Pub1_Check_ORF CCGCACTTTGCCACTGAAGC  
F_Pab1_mCherry TATGAGTCTTTCAAAAAGGAGCAAGAACAACAAACTGAGCAAGCTGGTCGACGGATC
CCCGGG 
 
R_Pab1_mCherry GATGATAAGTTTGTTGAGTAGGGAAGTAGGTGATTACATAGAGCAATCGATGAATTC
GAGCTCG 
 
Pab1_Check_ORF CGGCATGCCACCTCAATTTAG  
Tpm1_F_upstr CATTGCTGTCATTCACTAATG  
Tpm1_R_downstr CAGGCACAAGTGTGAGTCC  
F_Tpm2_aid_Fusio
n 
GCTCAAAAAGAATTGGACGAAATTGCTAATTCATTGGAAAATTTAcgtacgctgcaggtcgac  
R_Tpm2_aid_Fusi
on 
GTTTGTCGTTTGTATCTTCCGTAATTTTAGTCTTATCAATGGGAA  
F_Cmd1_aid_Fusi
on 
TCAGGCGAGATCAACATTCAACAATTCGCTGCTTTGTTATCTAAAcgtacgctgcaggtcgac  
R_Cmd1_aid_Fusi
on 
ATGGTAAGGGTAAGATAGCGGGAGCAAAAAATCACAAGGATGCACatcgatgaattcgagct
cg 
 
Cmd1_Check_OR
F 
GGCTCTGATGTCTCGTCAAC  
F_Myo2_aid_Fusio
n 
AGAATAGTTGACCTTGTTGCCCAACAAGTCGTTCAAGACGGCCACcgtacgctgcaggtcga
c 
 
R_Myo2_aid_Fusio
n 
TTTTTTTAGCATTCATGTACAATTTTGTTTCTCGCGCCATCAGTTatcgatgaattcgagctcg  
Myo2_Check_ORF GGCCATCAATGCTGTGGTC  
F_Myo2_3xmCh_F
usn 
AGAATAGTTGACCTTGTTGCCCAACAAGTCGTTCAAGACGGCCACcgtacgctgcaggtcga
c 
 
R_Myo2_3xmCh_F
usn 
TTTTTTTAGCATTCATGTACAATTTTGTTTCTCGCGCCATCAGTTgcataggccactagtggatc
tg 
 
F_Atg9_3xmCh_F
usn 
TTAGGACTTGTTAAAGAGTATTACAAGAAGTCTGACGTCGGAAGAcgtacgctgcaggtcga
c 
 
R_Atg9_3xmCh_F
usn 
TTATATATATAGTTATATTGGATGATGTACACGACACAGTCTGCCgcataggccactagtggat
ctg 
 
Atg9_Check_ORF GGCCCTGGCCATAATATTTC  
F_Sec18_aid_Fusi
on 
GAAGATCCCGTGAACGAGCTTGTTGAGTTGATGACCCAATCCGCAcgtacgctgcaggtcga
c 
 
R_Sec18_aid_Fusi
on 
AGGGATAAAGAATAAAAATACAAGGACATGAAAAATTTGAAATAAatcgatgaattcgagctcg  
Sec18_Check_OR
F 
CGACAATGAGATAGCAGTTCC  
F_Sec14_aid_Fusi
on 
TATATTGGACCGGAAGGTGAAGCTCCGGAAGCCTTTTCGATGAAAcgtacgctgcaggtcga
c 
 
R_Sec14_aid_Fusi
on 
ACTCCTCTTTTCTCTCTCGAAAAAAAAATGTCTTTAAAAATAATAATCGATGAATTCGA
GCTCG 
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Sec14_Check_OR
F 
CATATGTTAGGGAAGCCTCC  
For_GFP-Atg8_N-
tagging 
TTGTAAAGTTGAGAAAATCATAATAAAATAATTACTAGAGACATGCGTACGCTGCAGG
TCGAC 
 
Rev_GFP-Atg8_N-
tagging 
CGCCTTCCTTTTTTCAAATGGATATTCAGACTTAAATGTAGACTTCATCGATGAATTCT
CTGTCG 
 
R_Atg8_ N´ 
tag_Chk_ORF 
CCTACGGTAAGGTCAGCAG  
For_GFP-Ape1_N-
tagging 
ATTGTAGAAACCTGCACAACCAACAAAATTAAGAAAAAAAGAATGCGTACGCTGCAG
GTCGAC 
 
Rev_GFP-
Ape1_N-tagging 
CTGCAGAGTTTTCTTCAATTGTTCCAGTATTTCACGTTGTTCCTCCATCGATGAATTCT
CTGTCG 
 
R_Ape1_ N´ 
tag_Chk_ORF 
GCGTCCACATGAGATCCAATG  
Ape1_F_upstr CAACTAGGGGTGATGCTG  
Ape1_R_downstr CAAGGCCCACATTGGTGTTC  
ForApe1_KO ATTGTAGAAACCTGCACAACCAACAAAATTAAGAAAAAAAGAATGCAGCTGAAGCTTC
GTACGC 
 
R_Ape1_mCherry GATAAAGAAACAGAAATCAAAAGAAATAAAAAGAGTGTGGCAAAAATCGATGAATTC
GAGCTCG 
 
Atg8_F_upstr GACAGACCCAATTGGTGATG  
Atg8_R_downstr GCATTGAACAGATCGTAATCTG  
ForPEP4 GTATTTAATCCAAATAAAATTCAAACAAAAACCAAAACTAACATGCAGCTGAAGCTTC
GTACGC 
J. Tyedmers  
RevPEP4 ATGGCAGAAAAGGATAGGGCGGAGAAGTAAGAAAAGTTTAGCTCAGCATAGGCCAC
TAGTGGATCTG 
J. Tyedmers  
ForATG1 TTTTCAAATCTCTTTTACAACACCAGACGAGAAATTAAGAAAATGCAGCTGAAGCTTC
GTACGC 
J. Tyedmers  
RevATG1 CAGGTCATTTGTACTTAATAAGAAAACCATATTATGCATCACTTAGCATAGGCCACTA
GTGGATCTG 
J. Tyedmers  
ForVPS30 CAGTCACTGTTTTCGCAAAGACTCCCAGACACGGGCATTAAAATGCAGCTGAAGCTT
CGTACGC 
J. Tyedmers  
RevVPS30 CCCTTTATCACATTTATGAAAAAATGCATTTATATGAACTACTTAGCATAGGCCACTAG
TGGATCTG 
J. Tyedmers  
ForATG7 AGTTCATTATATTTCAACAAATATAAGATAATCAAGAATAAAATGCAGCTGAAGCTTCG
TACGC 
J. Tyedmers  
RevATG7 AGTGGCACCACAATATGTACCAATGCTATTATATGCAAAATATTAGCATAGGCCACTA
GTGGATCTG 
J. Tyedmers  
ForATG8 TGTAAAGTTGAGAAAATCATAATAAAAATAATTACTAGAGACATGCAGCTGAAGCTTC
GTACGC 
J. Tyedmers  
RevATG8 CGATTTTAGATGTTAACGCTTCATTTCTTTTCATATAAAAGACTAGCATAGGCCACTA
GTGGATCTG 
J. Tyedmers  
ForATG9 TAAGAACAGCCTGAAATATCAAAATCACGGAATTATTAGGTTATGCAGCTGAAGCTTC
GTACGC 
J. Tyedmers  
RevATG9 TATATATAGTTATATTGGATGATGTACACGACACAGTCTGCCTTAGCATAGGCCACTA
GTGGATCTG 
J. Tyedmers  
ForATG11 TTGTTGTTCGGAAAGTACTTCTTTTATTTTCTTTTATACATCATGCAGCTGAAGCTTCG
TACGC 
J. Tyedmers  
RevATG11 ATAATTAAAATCTTGTCATTTGTGACAAACGTTTAGCACTGTTCAGCATAGGCCACTA
GTGGATCTG 
J. Tyedmers  
ForATG14 AAAAAGGGAAGTAAAAGTTAAAAACTAGAATCCTAGTATGACATGCAGCTGAAGCTT
CGTACGC 
J. Tyedmers  
RevATG14 ACATGCAACTTTATACACACGGCAGGAAAAAAAGTGCGCACTCTAGCATAGGCCACT
AGTGGATCTG 
J. Tyedmers  
ForATG19 GCGGCACTTGCTTCAGTAACGCCCAAAGGAGAGTTCTGGTAAATGCAGCTGAAGCT
TCGTACGC 
J. Tyedmers  
RevATG19 ATGTGAAAAGGTACTCATTGCTGTATAAAAATAGAGTTTGACCTAGCATAGGCCACTA
GTGGATCTG 
J. Tyedmers  
ForATG16_KO TGTTATTAACCTGCGCGAATCTGTATTAAGGGCGCATATTCCATGCAGCTGAAGCTT
CGTACGC 
 
RevATG16_KO TTTCTTTTGTATGCATTTTGTGACGATTTGACAACTGATGCATCAGCATAGGCCACTA
GTGGATCTG 
 
ForAms1_KO ATAGAGATTAAGGCTGCAAAAGAGTTTCAAAAATAATTAATTATGCAGCTGAAGCTTC
GTACGC 
 
RevAms1_KO TTTGGGAGTGAGTGAATGTAAAAAACAGTGAGGGAGACAAACTCAGCATAGGCCACT
AGTGGATCTG 
 
ForPDR5_KO TTAAGTTTTCGTATCCGCTCGTTCGAAAGACTTTAGACAAAAATGCAGCTGAAGCTTC  
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GTACGC 
RevPDR5_KO CATCTTGGTAAGTTTCTTTTCTTAACCAAATTCAAAATTCTATTAGCATAGGCCACTAG
TGGATCTG 
 
Kan B CAATTCAACGCGTCTGTGAG  
GFP_Check_Fowd CCAATTGGTGATGGTCCAGTC  
Rev_mCherry Cttcaagtagtcggggatgtc  
Rev_GFP CATAACCTTCTGGCATGGC  
Pep4_R_upstr CCTGCTTGATGTGGTACAAC  
Up ATG1 GGCCGAGGTTAATTCTAG  
UpVPS30/ATG6 CGCAATTTCCTTCTGGTTCGTAGGC  
UPATG7 CGAGAACACACCCGTTGAATC  
Upstr_ATG9 CGCACTCGCATCTGTCGAG  
Upstr_ATG19 GCACGCTGAGAGTATCATC  
UpATG11 CAAGTAGTAGCGGAACATCCG  
UpATG14 CTAGCAGCAAGCATTCTTGCAG  
UpATG16 CATCGTCGGCAGTGGAATTC  
Ams1_F_upstr CAAATGGGCGACCCTATTGTC  
Ams1_R_downstr CTTCCAAGGCGCAACAACTCAG  
Up_PDR5 CTACGCCGTGGTACGATATC  
5' upURA GAAGGTTAATGTGGCTGTGG  
5' inURA GTCATGCAAGGGCTCCCTATC  
REVCompTIR1 GACTTGAACGGATCCACTAGC  
 
 
TABLE 4.: Antibodies used in this study 
Antibody Dilution Source/Company 
anti-GFP (mouse) 1:1000 Roche 
anti-actin (mouse) 1: 5000 Millipore 
Anti-HA (mouse) 1: 4000 Sigma-Aldrich Co. 
HRP-linked Antibody (mouse) 1: 5000 Cell Signaling 
 
 
5.2. Molecular Biology Methods 
 
5.2.1.  Agarose gel electrophoresis 
 
1 % agarose was prepared by boiling the agarose in 0.5X TBE until completely 
melted. Ethidium bromide (10 µl of 1 % (w/v) stock solution per 100 ml) was added to 
the molten agarose and directly poured into a flat-bed tray with combs. After 
solidifying the agarose, it was transferred to the electrophoresis chamber filled with 
0.5X TBE buffer. Samples were loaded with loading dye and electrophoresis was 
carried out at 130-170 volt until the dye reached the bottom part of the gel. The gel 
was visualized under a UV transilluminator at 265 nm. If required, gel excision was 
performed at 365 nm to avoid any DNA damage. 
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5X TBE     54g/l Tris 
      27.5g/l Boric acid 
      20ml/l 0.5M EDTA (pH 8.0) 
 
6x DNA loading dye    30 % (v/v) Glycerol    
      0.25 % (w/v) Bromophenol blue   
    
 
5.2.2.  Restriction digestion of DNA 
Restriction digestions were performed to linearize the plasmids for genomic 
integration.  About 1 U of restriction enzyme/µg of DNA was used to digest the 
plasmid in a total 50 µl reaction volume. The reaction was carried out according to 
the manufacturers' instruction. 
 
5.2.3.  Purification of DNA fragments 
If required, the linearized DNA or PCR product was separated by agarose gel 
electrophoresis and excised from the gel using a sharp scalpel. The DNA was then 
extracted using QIAquick Gel Extraction Kit (Qiagen) according to the manufacturers' 
instruction.  
 
5.2.4.  Polymerase Chain Reaction (PCR) 
PCR was used to amplify a fusion cassette for yeast genomic integration or checking 
the correct genomic insertion/integration or deletion. The PCR reaction was 
performed in 50-100 µl total volume containing 0.4 µM of each primer, template DNA 
(plasmids: 25–200 ng, genomic DNA: 0.5–1 µg) and 1X My Taq Red buffer (1 mM 
dNTPs and 3 mM MgCl2). To amplify the PCR cassette for genomic integration, MyFi 
Mix was used that contained high fidelity Taq polymerase. Correct genomic 
integration and deletions were verified by a colony PCR using normal Taq 
polymerase. 
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TABLE 5.: PCR protocol 
Step Temp. Time Cycles 
Initial denaturation 95 °C 1 min  
Denaturation 
Annealing 
Extension 
95 °C 
50 °C 
72 °C 
15 s 
15 s 
30 s/kb 
 
X 33 
Final extension 72 °C 10  min  
 4 °C ∞  
 
 
Bacterial Methods 
 
5.2.5.  Construction of pHis10-Sumo-PrD-TEV-Avi and pHis10-
Sumo-PrD-STOP (Done by J. Tyedmers) 
The pHis10-Sumo-PrD-TEV-Avi construct was generated by a fusion PCR from 
“pHis10-Sumo” [231] using pH10-Sumo_P1 and pH10-Sumo_P2 primers for the 
amplification of the N-terminal His-Sumo-tag and PrD-GFP_P3 and PrD-GFP_P4 
primes for the amplification of PrD-GFP [49]. This amplification product was 
afterwards cloned into an Avi-tag (Avidity Avitag™) vector [232] to make pHis10-
Sumo-PrD-TEV-Avi construct. The pHis10-Sumo-PrD-STOP was generated from this 
pHis10sumo-PrD-TEV-Avi construct by introducing a STOP codon with a 
QuikChange PCR. 
5.2.6.  Transformation of E. coli 
An aliquot of competent E. coli cells was thawed on ice, and 1 µl (~100 ng) DNA was 
added. The mixture was incubated on ice for 10 min. A heat shock was given at 42°C 
for 1 min and immediately incubated on ice for 5 min. 1 ml of LB was added to this 
mix and allowed for the recovery by incubating at 37 °C for 1 h at 150 rpm prior to 
plating on antibiotic containing LB plates. Plates were incubated overnight at 37°C. 
 
5.2.7.  Plasmid isolation 
Plasmids were isolated from E. coli using standard peqGOLD Plasmid Miniprep Kit 
(PEQLAB) according to the manufacturers' instruction. 
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5.2.8.  Purification of 10xHis-Sumo-PrD-AviTag and 10xHis-Sumo-
PrD-STOP 
 
The two constructs 10xHis-Sumo-PrD-AviTag and 10xHis-Sumo-PrD-STOP were 
freshly transformed into E. coli BL21 (DE3) harboring a biotin ligase from an IPTG-
inducible pBirAcm plasmid (chloramphenicol resistance). BirA biotin ligase catalyzes 
the biotinylation (covalent attachment of a biotin/Avi-tag) of recombinant PrD proteins 
from AviTag™ vector once the free biotin is supplied in the media. A pre-culture was 
grown over night at 37°C. Next morning, 2% of the pre-culture was diluted into freshly 
prepared Terrific Broth (TB) containing ampicillin and chloramphenicol and grown 
until OD600 reached 0.7-0.8. During the dilution, 20mg/lit of free biotin (prepared into 
50 % ethanol) was added in the culture harboring 10xHis-Sumo-PrD-AviTag. 1 mM 
IPTG was added for 4 h to induce the expression. Cells were harvested by 
centrifugation (6000 rpm, 15 min, 4°C), resuspended in 20 ml of LWB buffer and 
disrupted by French Press (Bukau Lab). After centrifugation (12000 rpm, 45 min, 
4°C), the cleared supernatant was mixed with equilibrated 1.5 ml of Ni-NTA beads 
(Millipore) and rotated gently for 2 h at 4°C.  The beads were washed 3 times with 
LWB buffer and brought to a column, and proteins were afterwards eluted with 250 
mM imidazole in 10-15 fractions. Major eluted fractions were pooled and partially 
denatured with 2 M urea. Ulp1 protease (at 4 µg/µl) was added to remove the 
10xHis-Sumo tag and dialyzed in 3 lit of LWB buffer + 2 M urea buffer without any 
imidazole. To get rid of cleaved His-sumo tag, digested protein was again incubated 
with Ni-NTA for 1 h at 4°C and flow-through was collected. Purified PrD-AviTag and 
PrD-STOP were then concentrated with 30 kDa MWCO Amicon concentrators to get 
about 6 mg/ml of protein concentration. The concentrated proteins were brought to 
8M urea and then methanol precipitated to further concentrate by a factor of 10 and 
the pellet was resuspended in 6 M of GdnHCl prior to store at –80°C.   
 
Lysis and washing buffer (LWB)  40 mM HEPES-KOH (pH 7.4) 
      150 mM KCl 
      5 mM MgCl2   
      5 % Glycerol 
      10 mM imidazole 
      2 mM β-mercaptoethanol 
      1 mM PMSF 
      Protease inhibitors 
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Yeast Methods 
 
5.2.9.  Transformation of yeast 
Yeast transformation was performed using a standard lithium acetate (LiAc)/single-
stranded carrier DNA/ PEG method [233, 234]. For one transformation, 10 ml of 
logarithmic growth phase culture (OD600 of 0.3-0.7) in YPD was pellet by 
centrifugation (3000 rpm, RT, 5 min), washed once with sterile H2O and finally 
resuspended in 60 µl 0.1 M LiAc prior to incubation at 30°C for 15 min. This cell/ LiAc 
mix was then transferred to an eppendorf tube containing 100 µg salmon sperm ss 
DNA and 0.2-0.5 µg DNA to be transformed (plasmid, linearized plasmid or PCR 
product). 300 µl of PEG mix were added to the tube, and the transformation mixture 
was subsequently incubated at 30°C for 25-30 min on a heating block. Cells were 
heat shocked for 42°C for 20-25 min, followed by a centrifugation step at 3,000 rpm 
for 5 min. In the case of transformation was with an antibiotic resistance cassette, 
cells were resuspended in 1.5 ml of YPD and incubated for overnight at RT on a 
roller wheel prior to plating on the respective antibiotic plate. In a case of auxotrophic 
markers, transformed cells were resuspended in sterile H2O and directly plated on 
particular drop out plate. Positive clone were confirmed by colony PCR, microscopy 
and /or Western Blot after 2-3 days of incubation at 30°C.   
 
PEG mix     0.1 M LiAc 
      50% (w/v) PEG 4000 
 
 
5.2.10.  Genetic manipulation in yeast 
In yeast, genetic manipulation can be easily achieved due to homologous 
recombination. PCR cassettes with a desired tag can be created with primers 
flanking homologous sequences of gene of interest from the yeast genome. Gene 
deletions and genomic N/C-terminal tagging were performed as described before 
[230]. Alternatively, desired gene deletion cassettes were amplified by PCR using a 
genomic DNA as a template from the yeast deletion library of Tyedmers lab. C-
terminal tagging of essential genes with “aid” degron was performed as the genomic 
integration of mCherry.  
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5.2.11.  Spotting assay 
Serial dilution spotting assay was performed to check the cell viability after auxin-
induced depletion of essential proteins. Conditional “aid” mutants were grown to mid-
log phase in the absence and presence of 20mM auxin, and OD600 was adjusted to 
0.5. These cells were further 5-fold serial diluted and spotted onto YPD plates.  
Plates were incubated 30°C for 2-3 days and imaged. For Colony-forming units 
(CFU) assay, 100 µl from 10-4 and 10-5 serial dilution was spread onto YPD plates in 
triplicates and incubated at 30°C. CFUs were counted after 2 days. 
 
5.2.12.   Preparation of yeast cell lysate for Western Blotting 
Yeast cells were grown to mid-log phase. The culture with equivalent to OD600 1.0 
was centrifuged, resuspended in 500 µl of 0.2 M NaOH and incubated on ice for 15 
min. Cells were again centrifuged, and the pellet was resuspended in 100 µl of 2x 
SDS sample buffe. Samples were boiled at 95°C for 5-10 min. For analysis by SDS-
PAGE and Western Blot, generally, 10 µl protein extract was loaded. 
 
5 x SDS sample buffer   300 mM Tris/HCl (pH 6.8) 
      10 % (w/v) SDS 
      50 % Glycerol 
      25 % (w/v) β-mercaptoethanol 
      0.1 % (w/v) Bromophenol blue 
  
5.2.13.   Preparation of yeast cell lysate in a mixer mill for fishing 
approach 
50 ml of a yeast culture in logarithmic growth phase at an OD600 ~ 0.4–0.6 were 
harvested, and the pellet was transferred to 1.5 ml eppendorf tubes, resuspended in 
100 µl of fiber attachment buffer and dripped in liquid nitrogen present in a 2-ml 
round bottom eppendorf tube that contained a 7 mm stainless steel ball. After boiling 
out of the liquid nitrogen, the tubes were closed and placed in an adaptor for 2 ml 
tubes into a Retsch Mixer Mill MM 400 (Bukau Lab) and agitated twice for 2 min at 30 
Hz. The sample was cooled in liquid nitrogen in between the two rounds of agitation. 
The resulting powder of lysed cells was transferred into a 1.5 ml tube and 
resuspended in 500 µl of FAB buffer, spun at 2300 rpm for 2 min at 4°C to remove 
the cell debris. The resulting supernatant was spun down again at 14000 rpm for 30 
min to separate insoluble fraction from the soluble fraction. The soluble fraction was 
used for the fishing experiment.    
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Fiber attachment buffer (FAB)   25 mM Tris/HCl (pH 7.4) 
      150 mM KAc 
      5 mM MgAc 
      5% Glycerol 
      1 mM DTT 
      1 mM PMSF 
      Protease inhibitors 
 
 
 
5.3. Biochemical Methods 
 
5.3.1.   Bradford assay 
Standard Bradford assay was used to determine the protein concentration. The 
Bradford reagent (Bio-Rad Laboratories, Inc.) was diluted 1:5 with H2O and mixed 
with protein sample. The absorption was measured at the wavelength of λ = 595 nm 
and concentration was calculated based on BSA calibration curve.  
 
5.3.2.   SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
Proteins with different sizes were separated by denaturing SDS polyacrylamide gel 
electrophoresis (SDS-PAGE). If not mentioned, protein samples were mixed with 
sample buffer and boiled at 95°C for 5 min prior to loading onto the gel. Samples 
were run at 150-200 volt till the blue dye reached the bottom part of the gel to 
guarantee for optimal separation. 
 
SDS Running Buffer    193 mM Gycine 
      25 mM Tris 
0.1 % (w/v) SDS 
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5.3.3.   Western Blot 
Specific proteins in cell lysates were identified by Western Blot using specific 
antibodies. Protein mixture was separated by SDS-PAGE and transferred onto a 
PVDF membrane using semidry transfer method. The semidry transfer was 
performed using Trans-Blot®Turbo™system (Bio-Rad Laboratories, Inc). Before the 
transfer, the PVDF membrane was activated in methanol and equilibrated in Semidry 
Transfer Buffer. Transfer sandwich was assembled onto transfer cassette with the 
following order: 3 Whatman papers, PVDF membrane, gel and 3 Whatman papers 
followed by careful removal of air bubbles with a plastic roller. The transfer was 
performed at 25 volts for 30 min. After the transfer, the membrane was blocked in 5 
% milk powder in 1X PBST at RT for 1 hr. The membrane was incubated with primary 
antibody in 1 % milk powder in 1X PBST for overnight at 4°C. The blot was rinsed 
once with 1X PBST for 10 min. The blot was incubated with HRP-conjugated 
secondary antibody in 1 % milk powder in 1X PBST at RT for 1-2 hr. The blot was 
rinsed 3 times with 1X PBST for 10 min and incubated with an enhanced 
chemiluminescent (ECL) HRP substrate for 1 min prior to developing at AGFA Curix 
60 Film Processor (AGFA HealthCare). 
 
Semidry transfer buffer    14.4 g/l Glycine 
      3.03 g/l Tris 
      200 ml/l MeOH 
 
 
5.3.4.   In vitro formation of PrD-fibers  
 
Purified PrD-AviTag was mixed to PrD-STOP at 1:50 Molar ratio (in GdnHCl) and 
mixture was then diluted 100-fold in fiber formation buffer and rotated at 8 rpm over 
night at RT. Formed fibers were fragmented by sonication for 5 min a water bath 
sonicator (Bukau Lab). These fibers were washed twice in FAB buffer and 
equilibrated for their immobilization on streptavidin magnetic beads in my fishing 
approach.  
 
 
Fiber formation buffer    5 mM Potassium phosphate buffer (pH 7.4) 
      150 mM NaCl 
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5.3.5.   Fishing approach for the identification of amyloid binding 
proteins 
 
A 50 µl of streptavidin magnetic beads was blocked with 5 mg/ml of BSA in PBS at 
4°C over night. Subsequently, the beads were incubated with 500 µl of 5 mg/ml BSA 
in FAB buffer for 1 hour and equilibrated by washing 3 times with FAB buffer. 375 µl 
of equilibrated biotinylated PrD fibers (concentration 15 µM) were added to the beads 
and incubated for ~ 1-2 h at 4°C. Beads were gently washed 3 times with FAB buffer 
to remove unbound fibers and then incubated with 500 µl of yeast cell lysate (~2 
mg/ml protein concentration) in low binding eppendorf tubes at 4°C over night under 
gentle agitation (17 rpm) in an overhead incubator. Subsequently, the beads were 
washed 4 times with 200 µl fiber attachment buffer and proteins bound to PrD-GFP 
were eluted by boiling the beads at 95°C in 2X SDS-PAGE sample buffer (Laemmli 
buffer) for 10 min. Eluted samples were separated by SDS-PAGE and subjected for 
mass spectrometry analysis at the Core Facility to Mass Spectrometry & 
Proteomics/ZMBH, Heidelberg. 
 
 
5.4. Microscopy 
 
5.4.1.   Fixation of yeast cells for standard microscopy 
For image acquisition by fluorescence microscopy, 10 ml of culture was harvested by 
centrifugation (3500 rpm, RT, 5 min). 5 ml of the supernatant was removed, and the 
pellet was resuspended in remaining 5 ml of media. This culture then mixed with 5 ml 
of 8% PFA (paraformaldehyde) and incubated immediately for 10 min at RT. Cells 
were pelleted by centrifugation (3500 rpm, RT, 5 min) and washed once with 5 ml of 
0.1M potassium phosphate buffer (pH 6.5). Cells were pelleted by centrifugation 
(3500 rpm, RT, 5 min) and resuspended in 1ml PBS and then transferred into an 
Eppendorf tube.  After one centrifugation at max speed for 1 min, cells were 
resuspended in 15-20 µl of PBS and subjected to fluorescence microscopy.   
 
5.4.2.   Microscopy image acquisition, processing, and data 
interpretation 
The fixed cells were used for acquiring the images under the microscope. Unless 
specified differently, optical sections of 0.2 µm were acquired to image the whole cell 
volume using a widefield system (xcellence IX81Olympus, ZMBH Imaging 
Facility/Bukau Lab) and a Plan-Apochromat 100x /NA 1.45 oil immersion objective. 
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All images were acquired with a Hamamatsu ORCA-R2 camera. Acquired z-stacks 
were deconvolved with xcellence (Olympus) software using the Wiener Filter. Further 
digital image processing was performed with ImageJ by a linear adjustment of 
brightness and contrast.  
 
5.4.3.   Time-lapse microscopy 
Time-lapse microscopy was performed on agarose pads of 20 x 20 x 1 mm. These 
pads were prepared by pouring ultrapure agarose (1% w/v) in SD or YPD media 
directly onto a microscope slide. After addition of the cells onto the pad, it was 
covered with a cover slide and sealed with melted VLAP wax (1:1:1 
Vaseline:lanolin:paraffin). I acquired a stack of ~15 optical sections spaced 0.2 – 0.3 
µm apart in every 2-5 min. 
 
 
5.4.4.   Quantification of amyloid aggregates and PAS substrates 
 
In general, numbers of PrD-GFP aggregates and PAS substrates within/among the 
cells were analyzed manually. Around 100 cells were taken into account for the 
quantification. For determination of the phenotype of multiple dispersed PrD-GFP or 
PAS substrates, cells with single or multiple PrD-GFP/PAS markers were counted 
and plotted as “percentage”. The degree of co-localization of PrD-GFP aggregates 
with other proteins including preApe1, Atg8, Atg9 or Myo2 was determined by 
counting clear and distinguishable PrD-GFP fluorescent foci within the cells and was 
taken into account that how many of those distinct PrD-GFP foci co-localized at least 
partially with the corresponding other protein.  
 
 
5.4.5.   PrD-GFP decay experiments 
 
To monitor the decay of pre-existing PrD-GFP single foci (IPODs), I used cells where 
the PrD-GFP IPOD was pre-formed for 6 hours by galactose induction. The cells 
were then shifted and diluted with OD600 of 0.3 (“time point 0”) in glucose-based 
media to stop the ongoing synthesis of PrD-GFP and further incubated for up to 8 
hours at 30°C where they grew more. I withdrew samples at the indicated time 
points, measured the OD600 to monitor how often the cells had divided in the glucose-
based media, fixed the cells and counted the number of total cells as well as the 
number of cells that still had visible PrD-GFP aggregates.  
 
This was done for roughly hundred cells per 0.3 OD600 units. Finally, based upon the 
measured OD600 for the time point of interest, I calculated the number of the newly 
born cells since the beginning of glucose chase (OD at “time point 0” was 0.3) and 
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subtracted this number from the total number of cells determined. Finally, I 
determined how many of those cells present since the beginning of the decay 
experiment still had a PrD-GFP aggregate (in %). This method is based on the 
observation that the IPOD is retained in the mother cells during cell divisions [65, 
146]. 
When the amount of PrD-GFP was determined after such a decay experiment in 
glucose by Western Blotting (e.g. Fig 29E), I did not use the same number of cells for 
Western Blotting, but the same volume of culture, because the cells sometimes grew 
at different rates.  
Since new synthesis of PrD-GFP from the Gal promoter was ceased by glucose, the 
same volume of culture should contain the same amount of original PrD-GFP that 
may have been partitioned between a mother and multiple progeny or stayed in 
fewer cells when cells divided slower. For these reasons, no classical loading control 
could be included for this Western Blot.  
 
 
5.4.6.   Electron microscopy 
 
The biotin-labeled PrD amyloid fibers were confirmed by Electron Microscopy (EM) at 
BioQuant/Electron Microscopy Core Facility (EMCF), Heidelberg. A 10 µl of PrD 
fibers with 2-5 µM concentration was adsorbed onto 100-mesh activated 
formvar/carbon-coated copper grids for 2–10 min until air dry. Grids were washed 3 
times with H2O, and air dried and negatively stained with freshly prepared 2% uranyl 
acetate. Grids were again air dried for 10 min and subjected to electron microscopy 
for imaging at 50000X magnification. 
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ATP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . adenosine triphosphate 
BSA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . bovine serum albumin 
CHX . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . cycloheximide 
CVT ………………………………………….. Cytosol to vacuole targeting 
CytoQ . . . . . . . . . . . . . . . . . . . . . . . . . . . .  cytosolic protein quality control compartment 
DNA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . deoxyribonucleic acid 
dNTP . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  deoxynucleoside triphosphate 
DTT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  L,D-dithiotreitol 
DUB  ………………………………….……… Deubiquitylating enzyme 
E. coli . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Escherichia coli 
EM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  electron microscopy 
Fig ……………………………………….……. Figure 
Gal . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  galactose 
GdnHCl . . . . . . . . . . . . . . . . . . . . . . . . . . ..  guanidine hydrochloride 
GFP . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . green fluorescent protein 
Glu . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . glucose 
Hsp . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . .heat shock protein 
HSR . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . heat shock response 
INQ  ……………………………………………..intranuclear quality control compartment 
IPOD ……………………………………………insoluble protein deposit 
JUNQ …………………………………...…….. juxtanuclear quality control compartment 
kDa . . . . . . . . . . . . . . . . . . . . . . . . . … . . . . .kilo Dalton 
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LB . . . . . . . . . . . . . . . . . . . . . . . . . . . ... . . . .Luria Bertani 
LiAc . . . . . . . . . . . . . . . . . . . . . . . . . … . . . . lithium acetate 
MTOC . . . . . . . . . . . . . . . . . . . . . . . … . . . . microtubule organizing center 
OD . . . . . . . . . . . . . . . . . . . . . . . . . . … . . . . opitcal densitiy 
PAGE . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  polyacrylamide gel electrophoresis 
PBS . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . .  phosphate buffered saline 
PEG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ., polyethylene glycol 
PFA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . p-formaldehyde 
PMSF . . . . . . . . . . . . . . . . . . . . . . . . . . . .   .phenylmethylsulphonyl fluoride 
polyQ . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  polyglutamine 
PrP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  Prion Protein 
rpm . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  revolutions per minute 
RT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . room temperature 
S. cerevisiae . . . . . . . . . . . . . . . . . . . . . ...  Saccharomyces cerevisiae 
SD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  synthetic dropout 
SDS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  sodium dodecylsulfate 
sHsp . . . . . . . . . . . . . . . . . . . . . . . . . . . . .   small heat shock protein 
SPB . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  spindle pole body 
TBS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  Tris buffered saline 
Tris . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . tris(hydroxymethyl)aminomethane 
UPS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  ubiquitin-proteasome system 
VHL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  von Hippel-Lindau disease tumor suppressor 
WT …………………………………….……… Wild-type 
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A1.  Factors identified to bind to PrD (SUP35) fibers in vitro  
 
Appendix Table 1.: List of genes identified to bind to PrD (SUP35) 
fibers. A systematic and standard name and gene descriptions is given. 
Source of description is: yeastgenome.org  
	  
Systematic 
Name 
Standard 
Name 
Description    
YER165W PAB1 Poly(A) binding protein; part of the 3'-end RNA-processing complex, mediates interactions 
between the 5' cap structure and the 3' mRNA poly(A) tail, involved in control of poly(A) tail 
length, interacts with translation factor eIF-4G; stimulates, but is not required for the 
deadenylation activity of the Pan2p-Pan3p poly(A)-ribonuclease complex 
YNL016W PUB1 Poly (A)+ RNA-binding protein; abundant mRNP-component protein that binds mRNA and is 
required for stability of many mRNAs; component of glucose deprivation induced stress 
granules, involved in P-body-dependent granule assembly; protein abundance increases in 
response to DNA replication stress 
YFR031C-
A 
RPL2A Ribosomal 60S subunit protein L2A; homologous to mammalian 
ribosomal protein L2 and bacterial L2; RPL2A has a paralog, RPL2B, 
that arose from the whole genome duplication 
    
YNL178W RPS3 Protein component of the small (40S) ribosomal subunit; has apurinic/apyrimidinic (AP) 
endonuclease activity; essential for viability; nascent Rps3p is bound by specific chaperone 
Yar1p during translation; homologous to mammalian ribosomal protein S3 and bacterial S3 
YPL090C RPS6A Protein component of the small (40S) ribosomal subunit; homologous to mammalian ribosomal 
protein S6, no bacterial homolog; phosphorylated on S233 by Ypk3p in a TORC1-dependent 
manner, and on S232 in a TORC1/2-dependent manner by Ypk1/2/3p; RPS6A has a paralog, 
RPS6B, that arose from the whole genome duplication 
YML024W RPS17A Ribosomal protein 51 (rp51) of the small (40s) subunit; homologous to mammalian ribosomal 
protein S17, no bacterial homolog; RPS17A has a paralog, RPS17B, that arose from the whole 
genome duplication 
YOL123W HRP1 Subunit of cleavage factor I; cleavage factor I is a five-subunit complex required for the cleavage 
and polyadenylation of pre-mRNA 3' ends; RRM-containing heteronuclear RNA binding protein 
and hnRNPA/B family member that binds to poly (A) signal sequences; required for genome 
stability 
YJR145C RPS4a Protein component of the small (40S) ribosomal subunit; mutation affects 20S pre-rRNA 
processing; homologous to mammalian ribosomal protein S4, no bacterial homolog; RPS4A has 
a paralog, RPS4B, that arose from the whole genome duplication 
YPL131W RPL5 Ribosomal 60S subunit protein L5; nascent Rpl5p is bound by specific chaperone Syo1p during 
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translation; homologous to mammalian ribosomal protein L5 and bacterial L18; binds 5S rRNA 
and is required for 60S subunit assembly 
YLR448W RPL6B Ribosomal 60S subunit protein L6B; binds 5.8S rRNA; homologous to mammalian ribosomal 
protein L6, no bacterial homolog; RPL6B has a paralog, RPL6A, that arose from the whole 
genome duplication 
YMR242C RPL20A Ribosomal 60S subunit protein L20A; homologous to mammalian ribosomal protein L18A, no 
bacterial homolog; RPL20A has a paralog, RPL20B, that arose from the whole genome 
duplication 
YLR441C RPS1A Ribosomal protein 10 (rp10) of the small (40S) subunit; homologous to mammalian ribosomal 
protein S3A, no bacterial homolog; RPS1A has a paralog, RPS1B, that arose from the whole 
genome duplication 
YIL094C LYS12 Homo-isocitrate dehydrogenase; an NAD-linked mitochondrial enzyme required for the fourth 
step in the biosynthesis of lysine, in which homo-isocitrate is oxidatively decarboxylated to 
alpha-ketoadipate 
YDL055C PSA1 GDP-mannose pyrophosphorylase (mannose-1-phosphate guanyltransferase); synthesizes 
GDP-mannose from GTP and mannose-1-phosphate in cell wall biosynthesis; required for 
normal cell wall structure 
YOL086C ADH1 Alcohol dehydrogenase; fermentative isozyme active as homo- or heterotetramers; required for 
the reduction of acetaldehyde to ethanol, the last step in the glycolytic pathway; ADH1 has a 
paralog, ADH5, that arose from the whole genome duplication 
YOR136W IDH2 Subunit of mitochondrial NAD(+)-dependent isocitrate dehydrogenase; complex catalyzes the 
oxidation of isocitrate to alpha-ketoglutarate in the TCA cycle; phosphorylated 
YNL141W AAH1 Adenine deaminase (adenine aminohydrolase); converts adenine to hypoxanthine; involved in 
purine salvage; transcriptionally regulated by nutrient levels and growth phase; Aah1p degraded 
upon entry into quiescence via SCF and the proteasome 
YHL011C PRS3 5-phospho-ribosyl-1(alpha)-pyrophosphate synthetase; synthesizes PRPP, which is required for 
nucleotide, histidine, and tryptophan biosynthesis; one of five related enzymes, which are active 
as heteromultimeric complexes 
YNL231C PDR16 Phosphatidylinositol transfer protein (PITP); controlled by the multiple drug resistance regulator 
Pdr1p; localizes to lipid particles and microsomes; controls levels of various lipids, may regulate 
lipid synthesis; homologous to Pdr17p; protein abundance increases in response to DNA 
replication stress 
YNL037C IDH1 Subunit of mitochondrial NAD(+)-dependent isocitrate dehydrogenase; complex catalyzes the 
oxidation of isocitrate to alpha-ketoglutarate in the TCA cycle 
YER023W PRO3 Delta 1-pyrroline-5-carboxylate reductase; catalyzes the last step in proline biosynthesis  
YGR159C NSR1 Nucleolar protein that binds nuclear localization sequences; required for pre-rRNA processing 
and ribosome biogenesis; binds to single stranded telomeric DNA and mRNA; methylated by 
Hmt1p; interaction with Top1p and nucleolar localization are negatively regulated by 
polyphosphorylation 
YDL160C DHH1 Cytoplasmic DExD/H-box helicase, stimulates mRNA decapping; coordinates distinct steps in 
mRNA function and decay, interacts with both the decapping and deadenylase complexes, role 
in translational repression, mRNA decay, and processing body dynamics; may have a role in 
mRNA export; C-terminus of Dhh1p interacts with Ngr1p and promotes POR1, but not EDC1 
mRNA decay; forms cytoplasmic foci upon DNA replication stress  
YPR086W SUA7 Transcription factor TFIIB; a general transcription factor required for transcription initiation and 
start site selection by RNA polymerase II 
YEL034W HYP2 Translation elongation factor eIF-5A; required for translation of proteins containing polyproline 
stretches, including Bni1p, and this leads to a requirement for mating projection formation; 
structural homolog of bacterial EF-P; undergoes an essential hypusination modification; HYP2 
has a paralog, ANB1, that arose from the whole genome duplication; human EIF5A 
complements the inviability of the yeast hyp2 anb1 double null mutant 
YMR116C ASC1 G-protein beta subunit and guanine dissociation inhibitor for Gpa2p; ortholog of RACK1 that 
inhibits translation; core component of the small (40S) ribosomal subunit; required to prevent 
frameshifting at ribosomes stalled at repeated CGA codons; regulates P-body formation induced 
by replication stress; represses Gcn4p in the absence of amino acid starvation 
YKL110C KTI12 Protein that plays a role in modification of tRNA wobble nucleosides; protein plays role in tRNA 
wobble nucleoside modification with Elongator complex; involved in sensitivity to G1 arrest 
induced by zymocin; interacts with chromatin throughout the genome; also interacts with 
Cdc19p 
YDR432W NPL3 RNA-binding protein; promotes elongation, regulates termination, and carries poly(A) mRNA 
from nucleus to cytoplasm; represses translation initiation by binding eIF4G; required for pre-
mRNA splicing; interacts with E3 ubiquitin ligase Bre1p, linking histone ubiquitination to mRNA 
processing; may have role in telomere maintenance; dissociation from mRNAs promoted by 
Mtr10p; phosphorylated by Sky1p in cytoplasm; protein abundance increases in response to 
DNA replication stress 
YNL251C NRD1 RNA-binding subunit of Nrd1 complex; complex interacts with exosome to mediate 3'-end 
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formation of some mRNAs, snRNAs, snoRNAs, and CUTs; interacts with CTD of RNA pol II 
large subunit Rpo21p at phosphorylated Ser5 to direct transcription termination of non-
polyadenylated transcripts; H3K4 trimethylation of transcribed regions by Set1p enhances 
recruitment of Nrd1p to those sites; role in regulation of mitochondrial abundance and cell size 
YFL037W TUB2 Beta-tubulin; associates with alpha-tubulin (Tub1p and Tub3p) to form tubulin dimer, which 
polymerizes to form microtubules; mutation in human ortholog is associated with congenital 
fibrosis of the extraocular muscles (CFEOM) with polymicrogyria 
YLL001W DNM1 Dynamin-related GTPase involved in mitochondrial organization; required for mitochondrial 
fission and morphology; assembles on the cytoplasmic face of mitochondrial tubules at sites at 
which division will occur; also participates in endocytosis and regulating peroxisome abundance; 
human homolog Drp1 plays an important role in mediating maintenance of mitochondrial 
function, autophagy, and mitochondrial autophagy in the heart and cardiomyocytes 
YNL079C TPM1 Major isoform of tropomyosin; binds to and stabilizes actin cables and filaments, which direct 
polarized cell growth and the distribution of several organelles; acetylated by the NatB complex 
and acetylated form binds actin most efficiently; TPM1 has a paralog, TPM2, that arose from the 
whole genome duplication  
YIL138C TPM2 Minor isoform of tropomyosin; binds to and stabilizes actin cables and filaments, which direct 
polarized cell growth and the distribution of several organelles; appears to have distinct and also 
overlapping functions with Tpm1p; TPM2 has a paralog, TPM1, that arose from the whole 
genome duplication 
YNL243W SLA2 Adaptor protein that links actin to clathrin and endocytosis; involved in membrane cytoskeleton 
assembly and cell polarization; present in the actin cortical patch of the emerging bud tip; dimer 
in vivo 
YFR024C-
A 
LSB3 Protein containing a C-terminal SH3 domain; binds Las17p, which is a homolog of human 
Wiskott-Aldrich Syndrome protein involved in actin patch assembly and actin polymerization; 
protein abundance increases in response to DNA replication stress; LSB3 has a paralog, 
YSC84, that arose from the whole genome duplication 
YDL226C GCS1 ADP-ribosylation factor GTPase activating protein (ARF GAP); involved in ER-Golgi transport; 
required for prospore membrane formation; regulates phospholipase Spo14p; shares functional 
similarity with Glo3p; GCS1 has a paralog, SPS18, that arose from the whole genome 
duplication 
YKR048C NAP1 Histone chaperone; involved in histone exchange by removing and replacing histone H2A-H2B 
dimers or histone variant dimers from assembled nucleosomes; involved in the transport of H2A 
and H2B histones to the nucleus; required for the regulation of microtubule dynamics during 
mitosis; interacts with mitotic cyclin Clb2p; controls bud morphogenesis; phosphorylated by 
CK2; protein abundance increases in response to DNA replication stress 
YNL007C SIS1 Type II HSP40 co-chaperone that interacts with the HSP70 protein Ssa1p; shuttles between 
cytosol and nucleus; mediates delivery of misfolded proteins into the nucleus for degradation; 
involved in proteasomal degradation of misfolded cytosolic proteins; protein abundance 
increases in response to DNA replication stress; polyQ aggregates sequester Sis1p and 
interfere with clearance of misfolded proteins; similar to bacterial DnaJ proteins and mammalian 
DnaJB1 
YAL005C SSA1 ATPase involved in protein folding and NLS-directed nuclear transport; member of HSP70 
family; required for ubiquitin-dependent degradation of short-lived proteins; forms chaperone 
complex with Ydj1p; localized to nucleus, cytoplasm, cell wall; 98% identical to paralog Ssa2p 
with different functional specificity in propagation of yeast [URE3] prions, vacuolar-mediated 
degradations of gluconeogenesis enzymes; general targeting factor of Hsp104p to prion fibrils 
YLL024C SSA2 HSP70 family ATP-binding protein; involved in protein folding, vacuolar import of proteins; 
required for ubiquitin-dependent degradation of short-lived proteins; associated with chaperonin-
containing T-complex; 98% identical to paralog Ssa1p with distinct functional specificity in 
propagation of yeast [URE3] prions and vacuolar-mediated degradation of gluconeogenesis 
enzymes; binds tRNA, has role in tRNA nuclear import during starvation 
YNL064C YDJ1 Type I HSP40 co-chaperone; involved in regulation of HSP90 and HSP70 functions; acts as an 
adaptor that helps Rsp5p recognize cytosolic misfolded proteins for ubiquitylation after heat 
shock; critical for determining cell size at Start as a function of growth rate; involved in protein 
translocation across membranes; member of the DnaJ family; chimeric protein in which human 
p58IPK J domain replaces yeast Ydj1p J domain can complement yeast ydj1 mutant 
YOR007C SGT2 Glutamine-rich cytoplasmic cochaperone; serves as a scaffold bringing together Get4, Get5p, 
and other TRC complex members that are required to mediate posttranslational insertion of tail-
anchored proteins into the ER membrane; interacts with the prion domain of Sup35p; amyloid 
sensor; plays a role in targeting chaperones to prion aggregates; similar to human cochaperone 
SGT; forms cytoplasmic foci upon DNA replication stress 
YBR080C SEC18 AAA ATPase and SNARE disassembly chaperone; required for vesicular transport between ER 
and Golgi, the 'priming' step in homotypic vacuole fusion, autophagy, and protein secretion; 
releases Sec17p from SNAP complexes; has similarity to mammalian N-ethylmaleimide-
sensitive factor (NSF)  
	  
	  
118	  
YDL100C GET3 Guanine nucleotide exchange factor for Gpa1p; amplifies G protein signaling; functions as a 
chaperone under ATP-depleted oxidative stress conditions; subunit of GET complex, involved in 
ATP dependent Golgi to ER trafficking and insertion of tail-anchored (TA) proteins into ER 
membrane under non-stress conditions; binds as dimer to transmembrane domain (TMD) cargo, 
shielding TMDs from aqueous solvent; protein abundance increases under DNA replication 
stress 
YKL196C YKT6 Vesicle membrane protein (v-SNARE) with acyltransferase activity; involved in trafficking to and 
within the Golgi, endocytic trafficking to the vacuole, and vacuolar fusion; membrane localization 
due to prenylation at the carboxy-terminus; human homolog YKT6 can complement yeast ykt6 
mutant 
YCR009C RVS161 Amphiphysin-like lipid raft protein; N-BAR domain protein that interacts with Rvs167p and 
regulates polarization of the actin cytoskeleton, endocytosis, cell polarity, cell fusion and viability 
following starvation or osmotic stress 
YFL038C YPT1  Rab family GTPase; involved in the ER-to-Golgi step of the secretory pathway; complex 
formation with the Rab escort protein Mrs6p is required for prenylation of Ypt1p by type II protein 
geranylgeranyltransferase (Bet2p-Bet4p); binds to unspliced HAC1 mRNA; regulates the 
unfolded protein response (UPR) by promoting the decay of HAC1 RNA; localizes to the early 
Golgi, the transitional Golgi and ER membranes, pre-autophagosomal structures, and 
cytoplasmic vesicles  
YPL218W SAR1 ARF family GTPase; component of the COPII vesicle coat; required for transport vesicle 
formation during ER to Golgi protein transport; lowers membrane rigidity aiding vesicle 
formation; localizes to ER-mitochondrial contact sites where it enhances membrane curvature, 
thereby reducing contact size via its N-terminal amphipathic helix; regulates mitochondrial 
fission and fusion dynamics 
YFL005W SEC4 Rab family GTPase; essential for vesicle-mediated exocytic secretion and autophagy; 
associates with the exocyst component Sec15p and may regulate polarized delivery of transport 
vesicles to the exocyst at the plasma membrane 
YMR079W SEC14 Phosphatidylinositol/phosphatidylcholine transfer protein; involved in regulating PtdIns, PtdCho, 
and ceramide metabolism, products of which regulate intracellular transport and UPR; has a role 
in localization of lipid raft proteins; functionally homologous to mammalian PITPs; SEC14 has a 
paralog, YKL091C, that arose from the whole genome duplication  
YNL287W SEC21 Gamma subunit of coatomer; coatomer is a heptameric protein complex that together with Arf1p 
forms the COPI coat; involved in ER to Golgi transport of selective cargo 
YJR121W ATP2 Beta subunit of the F1 sector of mitochondrial F1F0 ATP synthase; which is a large, 
evolutionarily conserved enzyme complex required for ATP synthesis; F1 translationally 
regulates ATP6 and ATP8 expression to achieve a balanced output of ATP synthase genes 
encoded in nucleus and mitochondria; phosphorylated  
YCL064C CHA1 Catabolic L-serine (L-threonine) deaminase; catalyzes the degradation of both L-serine and L-
threonine; required to use serine or threonine as the sole nitrogen source, transcriptionally 
induced by serine and threonine 
YBR127C VMA2 Subunit B of V1 peripheral membrane domain of vacuolar H+-ATPase; electrogenic proton 
pump found throughout the endomembrane system; contains nucleotide binding sites; also 
detected in the cytoplasm; protein abundance increases in response to DNA replication stress; 
human homolog ATP6V1B1, implicated in autosomal-recessive distal renal tubular acidosis 
(RTA) with sensorineural deafness, complements yeast null mutant 
YEL051W VMA8 Subunit D of the V1 peripheral membrane domain of V-ATPase; part of the electrogenic proton 
pump found throughout the endomembrane system; plays a role in the coupling of proton 
transport and ATP hydrolysis; the V1 peripheral membrane domain of the vacuolar H+-ATPase 
(V-ATPase) has eight subunit 
YBL016W FUS3 Mitogen-activated serine/threonine protein kinase involved in mating; phosphoactivated by 
Ste7p; substrates include Ste12p, Far1p, Bni1p, Sst2p; inhibits invasive growth during mating by 
phosphorylating Tec1p, promoting its; inhibits recruitment of Ste5p, Cdc42p-mediated 
asymmetry and mating morphogenesis 
YMR095C SNO1 Protein of unconfirmed function; involved in pyridoxine metabolism; expression is induced during 
stationary phase; forms a putative glutamine amidotransferase complex with Snz1p, with Sno1p 
serving as the glutaminase 
YOR185C GSP2 GTP binding protein (mammalian Ranp homolog); involved in the maintenance of nuclear 
organization, RNA processing and transport; interacts with Kap121p, Kap123p and Pdr6p 
(karyophilin betas); not required for viability; protein abundance increases in response to DNA 
replication stress; GSP2 has a paralog, GSP1, that arose from the whole genome duplication 
YDR441C APT2 Potential adenine phosphoribosyltransferase; encodes a protein with similarity to adenine 
phosphoribosyltransferase, but artificially expressed protein exhibits no enzymatic activity; APT2 
has a paralog, APT1, that arose from the whole genome duplication  
YFL045C SEC53 Phosphomannomutase; involved in synthesis of GDP-mannose and dolichol-phosphate-
mannose; required for folding and glycosylation of secretory proteins in the ER lumen 
YCR027C RHB1 Putative Rheb-related GTPase; involved in regulating canavanine resistance and arginine 
uptake; member of the Ras superfamily of G-proteins 
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YPL226W NEW1 ATP binding cassette protein; cosediments with polysomes and is required for biogenesis of the 
small ribosomal subunit; Asn/Gln-rich rich region supports [NU+] prion formation and 
susceptibility to [PSI+] prion induction  
YPL020C ULP1 Protease that specifically cleaves Smt3p protein conjugates; required for cell cycle progression; 
associates with nucleoporins and may interact with septin rings during telophase; sequestered 
to the nucleolus under stress conditions 
YDR510W SMT3 Ubiquitin-like protein of the SUMO family; conjugated to lysine residues of target proteins; 
associates with transcriptionally active genes; regulates chromatid cohesion, chromosome 
segregation, APC-mediated proteolysis, DNA replication and septin ring dynamics; human 
homolog SUMO1 can complement yeast null mutant 
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